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1.1  Peptides: bridging the gap between small molecules 
and proteins
Two main classes of therapeutics dominate the current drug market, small 
molecules and ‘biologics’ such as proteins. While the small molecules constitute 
the low molecular weight therapeutics of typically less than 500 Da, proteins on 
the other hand are of a molecular weight greater than 10,000 Da. The molecular 
size gap between these two dominant classes offers opportunities for development 
of novel drug candidates.
 Peptides, consisting of two to hundred amino acids and ranging in molecular 
weight from around 220 Da to 12,000 Da are an important class of bioactive 
molecules of intermediate size.  (Figure 1.1) [1]. Due to their size and chemical 
 characteristics, peptides provide the advantage of generation of highly diverse 
molecules with robust and automated synthesis procedures that enables a rapid 
and efficient optimization of activity [2]. 
 Peptides do not accumulate in specific organs, can be cleaved metabolically 
and their degradation products carry no risks of toxicity which are problems that 
may be encountered for small molecule drugs [2-3]. Compared to large molecular 
weight proteins, they exhibit less immunogenicity even for non-endogenous 
structures [4] and higher tissue penetration owing to their small size. Additionally, 
the structure of peptides can be further modified for example through backbone 
modifications. Also, large-scale synthesis becomes accessible with the further 
optimization of synthesis procedures [5]. 
 Their application can be widespread from immunomodulatory stimulants to 
inhibitors of protein-protein interactions. Hence, peptides offer a vast biological 
and chemical diversity that makes them one of the most versatile classes of drugs 
to be used as hormone agonist/antagonist, radionuclide carrier, vaccines, anticancer 
drugs, drug delivery vectors and antimicrobials [6-9].  
1.2 Current peptide drugs in the market
Peptides used as therapeutics generally are either i) natural bioactive peptides 
derived from plants or animal or human or ii) genetically engineered from 
recombinant libraries or iii) chemically synthesized [3]. Currently, peptide 
therapeutics in the market constitutes both short (up to 9 amino acids) and long 
peptides (up to 50 amino acids) [2]. 
 Since the release of the first synthetic peptide drug, luteinizing hormone- 
releasing hormone (LHRH) agonist [1], many peptide-based therapeutics have 
entered the clinic like oxytocin (used in labor), calcitonin (used in osteoporosis) 
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and teriparatide (an analog of parathyroid hormone used in osteoporosis) [2]. 
Erythropoietin (for blood formation) and insulin (for the treatment of diabetes) 
remain still the strongest in the market [3]. Other peptides that are in use are 
Copaxone (an immunomodulator for multiple sclerosis), Zoladex (for breast/
prostrate cancer), Sandostatin (inhibitor of growth hormones for cancer, also used 
for treating acromegaly) and a highly derivatized peptide, Velcade, as a proteasome 
inhibitor for multiple myeloma [2]. Another peptide recently launched in the 
market for the treatment of type-2 diabetes is Exenatide [10]. Table 1.1 gives a list 
of some of the top-selling peptide drugs in the market. Due to their versatility, 
peptide drugs are nowadays used in all classes of disorders from diabetes to 
cardiovascular diseases, from erythropoiesis to cancer. According to a report from 
Lonza, most of the recent peptide drugs launched in the market are in the field of 
oncology [1]. This is because of the resistance of cancers to the routine chemo-
therapeutics and constant recurrences in patients after conventional therapies. 
Such limitations have triggered research into novel therapeutics, of which peptide 
drugs form a major part. 
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Figure 1.1  Peptides bridge the gap between small molecules and proteins. 
Due to their intermediate molecular size, peptides fill the gap between small molecule 
therapeutics and protein drugs (adapted from [1] with permission).
Increasing Molecular Weight (M.W.)
Small molecule Peptide (40-60 mer) Antibody
M.W. 180 Da M.W. 4,000-6,000 Da M.W. 150,000 Da
Chemistry Biology
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1.3 The economic scenario
The current peptide-/protein-based market constitutes more than $40 billion/year 
corresponding to 10% of the pharmaceutical market [2]. According to “Peptide 
Therapeutics Market – Global, Industry Analysis, Size, Share, Growth, Trends and 
Forecast, 2012 - 2018” the global peptide therapeutics market alone is estimated to 
reach $25.4 billion in 2018 from $14.1 billion in 2011. Another analysis by Global 
Industry Analysts in the “Protein Drugs – Global Market Report”, predicted that 
around 400 types of peptide/protein drugs are in the process of development. It is 
estimated that by 2015, the total number of peptide-based drugs launched on the 
market will exceed 80 [1].
1.4 Limitations of peptide drugs
However, despite of the potential of peptide drugs, several drawbacks severely 
limit their straightforward implementation as new drugs (Figure 1.3). Till to date, 
most of the peptide drugs are mainly produced in injectable forms. Oral delivery 
routes are still under research. Only Exenetide (used as a treatment for diabetes) 
could be made orally active but with very low bioavailability [2]. Because of the 
small size, peptides exhibit rapid renal clearance and are susceptible to protease- 
mediated degradation, both leading to short plasma half-life. Peptides themselves 
Figure 1.2   Expected disease areas where peptide drugs will be released in the 
market and their market share.
(A) Analysis of the R&D pipeline for the next-generation peptides to be launched in the 
market shows oncology to be a major area. (B) Estimated market share of the leading therapy 
classes of peptide/protein drugs by 2015 (Figure 1.2A reproduced with permission from [1], 
figure 1.2B copyrights by Laborant, [11]).
Figure 1.3   Drawbacks and their solutions in the development of peptide-based 
therapeutics.
(A) The number of peptides that enter into clinical trials from preclinical research is still 
low as compared to the initially discovered leads. (B) Bottlenecks associated with peptides 
(colored text) reduce the number of marketed peptide drugs (either in oral dosage form as 
tablets or as injectables). (C) Presently practiced strategies to overcome the drawbacks (color 
code refers to the colored text in the bottlenecks) are also listed. (Adapted from [1] with 
permission, pictorial reference from the internet is as follows: http://www.xda-developers.
com/android/potential-io-bottleneck-fix-for-the-transformer-prime/).
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to peptide/protein or small molecule drugs [16]. While PEG and dextran are already 
used in patients, HPMA and PGA are still explored in clinical trials. However, the 
majority of these polymers are not biodegradable. Polymer conjugation increases 
the hydrodynamic volume of the drugs and thus prolongs the plasma half-life by 
reducing the renal clearance [15]. Moreover, the polymer chains can shield the 
molecule from recognition by antibodies or hydrolytic enzymes. While these are 
established facts, new concepts are in development such as using polymers as 
platforms for drug delivery [15, 17], targeting to specific cell types through 
 cofunctionalization of polymer conjugates with antibodies [18] and improving 
cellular import through conjugation with CPPs [19]. Additionally, multivalency 
has been explored in polymer conjugates as a principle to improve pharmacody-
namics of a drug [20-22]. Many polymer-coupled conjugates exist in the market 
[23-27] and the number in clinical trials is increasing [28]. 
 In this thesis, we took advantage of three polymers for intracellular applications, 
two of which are approved by the FDA (i.e. dextran and PEG) and one in clinical 
trials (i.e. HPMA). Using three distinct chemical strategies these polymers were 
conjugated to a bioactive peptide and were cofunctionalized with CPPs.
1.5.2 Conjugation to Cell-Penetrating Peptides (CPPs)
In order to exert their activity, bioactive peptides have to reach their targets. While 
it may be straightforward to reach an extracellular target such as a receptor 
located in the plasma membrane of a cell, it is difficult to access intracellular 
lack membrane permeability thus restricting their application to extracellular 
targets (Figure 1.3) [2, 3, 6]. In the native form, bioactive proteins have a stable fold, 
which renders them proteolytically stable, causes their biological activity and also 
helps them to penetrate tissues [12]. However, short peptides in contrast to proteins 
have little propensity to form secondary structures that affect their stability and 
activity [13]. Hence, strategies to conformationally constrain peptides are a means 
to enhance activity and reduce proteolytic sensitivity. 
1.5 Strategies to overcome these limitations
In order to deal with the above-mentioned issues that restrict the implementation 
of peptides as drugs, several modifications have been applied to make them more 
bioavailable, stable and active (Figure 1.3). Introduction of unnatural or D-amino 
acids, conformational fixation of peptides, insertion of stable miniprotein scaffolds, 
cyclization, and chemical coupling with high molecular mass polymers are some 
approaches that have been used to improve the bioavailability and stability of 
bioactive peptides [2, 12]. Conjugation to cell-penetrating peptides (CPPs) for enhanced 
cellular uptake and liposomal or nanosomal formulations for distribution and 
controlled release are additional methodologies employed for the implementation 
of peptides as drugs.
 This thesis aims to contribute new avenues to enhance the potential of peptides 
as cancer drugs through (i) enhancing the activity of known bioactive peptides through 
chemical modification and (ii) exploring a new bioactive principle of arginine-rich 
CPPs. Within this scope, the strategies for improving peptide stability, uptake as 
well as activity will now be briefly described.
1.5.1 Conjugation to high molecular mass polymers
For any drug development process, the pharmacokinetic behavior, which describes 
the fate of the drug in an organism, is as important as its biological activity, the 
pharmacodynamics. The impact of the metabolic system on the fate of a peptide 
largely contributes to its success as a therapeutic. The pharmacokinetics can be 
modulated by conjugation of peptides or other small molecule drugs to high 
molecular weight polymers [14]. Ideally, polymers should be biodegradable or fully 
excretable, soluble, induce accumulation of the drug at the desired site of action 
and should not structurally interfere with peptide activity. Though there are 
several synthetic, natural and pseudo-synthetic polymers available, only few 
actually meet these criteria [15]. Of the successful polymers, polyethylene glycol 
(PEG), N-(2-hydroxypropyl)-methacrylamide copolymers (HPMA), dextran and 
 poly-L-glutamic acid (PGA) (Figure 1.4) are the most popular in use for conjugation 
Figure 1.4  Commonly used polymer backbones. 
Polymers in preclinical phases or in the clinic are either structures not found in nature (like 
PEG and HPMA) or are inspired by biological polymers such as polysaccharides (like dextran) 
and amino acids (like PGA). Figure adapted from [16].
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endocytic uptake efficiency for the L-enantiomers [53], an observation that questions 
the receptor independence of uptake.
 While many aspects of CPP structure and import have been investigated in 
the past two decades, there are still open questions regarding CPP-mediated 
delivery. One concerns biological responses of the cells towards the CPPs [54]. Even 
though, initially CPPs have been considered Trojan horses in the sense of acting 
only as pharmacokinetic modifiers, evidence has been presented that CPPs can 
have a pharmacodynamic activity on their own by eliciting different responses in 
cells [54, 55]. For example, CPPs can act as inhibitors of intracellular enzymes. 
Polyarginine CPPs act as potent inhibitors of protein convertases [56, 57] and of 
furin, an endoprotease [58]. However, for furin, inhibitory activity of CPPs was 
tested only at high peptide concentrations and only against recombinant purified 
enzyme. No in vivo tests were performed [58]. Some studies have also indicated an 
impact of CPPs in regulating gene expression. Altered expression of several genes 
(like p38MAPK) on addition of cationic CPPs has been documented both in vitro 
and in vivo [59, 60]. In addition, some CPPs can stabilize actin filaments [61] and 
can induce endocytosis of receptors [62]. Recently, as mentioned above, it was 
shown that arginine-rich CPPs can induce ceramide generation in the plasma 
membrane, through activation of the lysosomal enzyme acid sphingomyelinase 
[49]. Given these activities, further CPPs may be conceived that possess dual 
properties of delivery and intrinsic bioactivity. Indeed, ‘Bioportides’ have been 
identified as such CPPs [63]. Such Bioportides are predicted through QSAR 
algorithms that identify potential cell-penetrating sequences within proteins. Cyt 
C77-101, camptide and nosangiotide are Bioportides that have been successful in 
cellular entry and exhibited intracellular biological activity [63]. 
targets since the peptides have to cross the plasma membrane. As a consequence, 
intracellular delivery is a critical aspect in peptide drug development [29].
 According to Lipinski’s rule, charged molecules and molecules with hydrogen 
bond forming potential like peptides are unable to cross the plasma membrane 
due their highly hydrophilic characteristics [30]. However, in 1988 and 1991, two 
groups reported on a protein called TAT from the human immunodeficiency virus 
1 and the homeodomain of Antennapedia of Drosophila	melanogaster, that violated 
Lipinski’s rule as they were found to reach the cytoplasm upon exogenous addition 
[31, 32]. Later in 1994, the first CPP called Penetratin, was derived from the third 
helix of the homeodomain of Antennapedia as a 16-mer peptide. At that time, 
these peptides were called Protein Transduction Domain [33]. The term, Cell-Pene-
trating Peptide, dates back to 1998 when Ülo Langel’s group coined the term to 
introduce the first chimeric peptide carrier, Transportan [34]. Also in the same 
year, the minimal sequence required for TAT to exhibit cell-penetration was 
reported [35]. Now, more than two decades after their discovery, CPPs are described 
as peptides of 8-30 amino acids, either derived from proteins or based on chimeric 
sequences or generated by design. Usually, CPPs are either cationic or cationic and 
amphipathic [36-39]. Also, guanidinium groups as found in arginine offer a 
significant advantage for uptake in comparison to primary amines as in lysine 
[40]. CPPs have been successful in inducing the efficient cellular uptake of various 
cargos like peptides, proteins, oligonucleotides, polymer conjugates and nano -
particles [41]. Conjugation is either covalent or via non-covalent complexation [8, 
42, 43]. Table 1.2 shows the sequences of some popular CPPs. Two distinct uptake 
mechanisms of CPPs have been noted: endocytosis and direct transport [44]. For 
arginine-rich CPPs a concentration dependence of the uptake route has also been 
demonstrated [45]. According to the current model, endocytic uptake of CPPs 
mainly occurs through three basic steps: 1) binding to glycosaminoglycan (GAG) 
residues on the plasma membrane, 2) internalization into endosomes and 3) release 
from endosomes into the cytoplasm. The last step is an important rate-limiting 
factor in the application of CPPs. Direct uptake of CPPs has been found to be less 
dependent on the interaction with GAG [46, 47]. Contributions from our laboratory 
have indicated that the direct entry of arginine-rich CPPs at high concentrations 
is dependent on activation of a lysosomal enzyme, acid sphingomyelinase and 
formation of ceramide at the plasma membrane [48, 49]. As uptake of CPPs is 
receptor independent, they can enter a wide variety of cell lines, including primary 
cells [38]. Most CPPs are linear, however, in some cases, cyclization improves uptake 
efficiency [50]. In contrast, increasing the conformational freedom of the 
guanidinium groups has also been exploited as a strategy to improve uptake [51]. 
For a cyclic human lactoferrin-derived peptide (hLF) uptake was also dependent 
on the cyclization [52]. Interestingly, studies with L- and D-variants revealed higher 
Table 1.2  Frequently used CPPs.
Peptide Sequence Class Origin
R9 RRRRRRRRR-NH2 cationic Synthetic1
Penetratin RQIKIWFQNRRMKWKK-NH2 cationic/
amphipathic
Antennapedia 
homeodomain2
TAT (48-60) GRKKRRQRRRQC cationic HIV-TAT protein3
Transportan GWTLNSAGYLLGKINLK
ALAALAKKIL-NH2
amphipathic Galanin and 
mastoparan4
1. Proc Natl Acad Sci USA, 97 (2000) 13003-13008; Biochem Soc Trans, 35 (2007) 784-787
2. J Biol Chem, 269 (1994) 10444-10450
3. J Biol Chem, 272 (1997) 106010-106017
4. FASEB J, 12 (1998) 67-77
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1.7 Structure of the Thesis
The aim of the current thesis was to explore novel avenues to use peptides as 
cancer drugs. We employed strategies to enhance the stability as well as the 
cellular uptake of bioactive peptides and exploited CPPs as new bioactive entities 
for cancer treatment. To achieve this purpose, an apoptosis-inducing peptide was 
selected and coupled to different polymers like HPMA, dextran and PEG to enhance 
1.6  Potential of polymer- or CPP-modified peptide 
drugs in cancer treatment
Cancer is still one of the major causes of death [64]. This is due to the fact that 
conventional therapies lead to undesired side effects, chemo-resistance and 
recurrence [65]. Hence, there is still an unmet demand for the development of 
novel therapeutics. Peptides are one class of compounds being thoroughly 
investigated [7]. One group of compounds that are currently under investigation is 
the polymer-modified peptides or the CPP-peptide conjugates [4, 66]. Here, the 
advantages of such conjugates to overcome the above-mentioned problems in the 
treatment of cancer are discussed (Figure 1.5).
 Besides providing the fundamental benefits of increased stability, polymer- 
peptide and polymer-peptide-CPP conjugates potentially offer some additional 
advantages for the treatment of cancers. First, selectivity for cancer cells/tissues 
can be achieved due to the enhanced permeability and retention effect (EPR) 
[67-69]. High molecular weight anticancer agents such as polymer-drug conjugates 
were shown to specifically accumulate in tumors exhibiting hypervascularity, 
enhanced vascular permeability and poor lymphatic drainage [70]. The increase in 
vascular permeability allows the macromolecular drugs to cross the capillary 
barrier to enter the tumor where as the lack of lymphatic clearance leads to 
prolonged accumulation of the polymer conjugated drug. This effect is known as 
an EPR effect [71]. Since the EPR effect is a function of molecular size, conjugates 
within a molecular weight range of 40-800 kDa are required to exhibit such an 
effect [72]. Because of their size, peptides cannot achieve this effect on their own 
but only through conjugation to polymers. Second, polymer conjugates evade ABC 
drug transporters like P-glycoprotein in drug resistant cancers by changing the 
physico-chemical properties and uptake routes of the conjugated drug [16, 73]. 
Moreover, the plasma membrane of cancer cells is rich in microvilli and has 
increased levels of negatively charged molecules like the GAGs and anionic lipids 
like phosphatidylserine [74, 75]. Due to the presence of microvilli, the overall 
surface area of binding is increased while the negative charge enhances the 
propensity for interaction with the cationic peptides [76, 77]. Lastly, cancer cells 
express molecules on the cell surface that can be used for selective targeting [78, 
79]. Synthetic peptides can be synthesized or other types of selective binders can 
be raised against such biomarkers and can be coupled to CPP-peptide/polymer- 
peptide conjugates for specific targeting [80]. Specific targeting can also be 
achieved by designing ‘smart’ cue-sensitive polymers or conjugates [81] that utilize 
the tumor microenvironment (e.g. low pH, overexpressed receptors) [82] or by applied 
techniques like focused hyperthermia (a local increase in temperature) [83] which 
can be also be promising for treatment of deep-seated tumors [84]. 
Figure 1.5  Advantages of modified peptides as cancer therapeutics. 
Polymer-peptide or CPP-peptide or combined conjugates coupled to targeting moieties can 
be used to bypass multidrug resistance, to enhance accumulation by the EPR effect and to 
achieve specific targeting of cancer cells. The presence of microvilli and of a high density of 
negative charges like in GAGs and anionic lipids present on the plasma membrane of cancer 
cells promotes the interaction of the conjugates with the cancer cells. Using cues from the 
tumor microenvironment, stimuli-responsive conjugates can also provide advantages for 
selective targeting.
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the synthesis of phosphites to yield bis-phosphoramidate-linked polymer- peptide 
conjugates. The branched bis-phosphoramidate-PEG-peptide-conjugates showed an 
enhanced stability in cell lysate with a 57-fold increase in half-life when only two 
medium-sized PEG 2000 chains were attached. Most importantly, when introduced 
into cells by electroporation, the PEG-modified BH3-peptides displayed a homogeneous 
intracellular distribution and a specific intracellular apoptosis-inducing activity 
when compared to the non-modified derivatives, demonstrating that PEGylation 
can also benefit the intracellular application of peptides.
 Chapter 5 elucidates in detail the effect of multivalency of R9 coupled to a 
flexible linear dextran scaffold. Increased avidity through multivalency was 
hypothesized to potentiate molecular phenomena that may escape detection if 
only a monovalent counterpart is used. Through multivalency we hoped to mimic 
the arrangement of R9 at the membrane at high local peptide concentrations. At a 
peptide concentration of 20 μM, the multivalent conjugate showed a sphingomye-
linase-dependent direct cytoplasmic uptake similar to the one of free R9; however, 
this uptake was accompanied by an increased membrane disturbance and cellular 
toxicity. Toxicity was also noted for cells expressing low levels of GAGs indicating 
that the toxicity induced by the conjugate was independent of the interaction with 
negatively charged oligosaccharides. In erythrocytes, exposure to the multivalent 
linear geometry of R9 induced the formation of cell aggregates and flipping of 
membrane lipids but showed little membrane lysis. In conclusion, the results 
suggest that multivalency of R9 increases the capacity to interact with the plasma 
membrane and the observed membrane perturbation is a function of the cellular 
response to peptide binding.
 In Chapter 6, we demonstrate that the ceramide-inducing capacity of arginine- 
rich CPPs can be exploited to sensitize ovarian cancer cells to the chemotherapeutic 
agent Paclitaxel when the drug and the peptide are added together as separate 
entities without any covalent coupling. Ceramide is an important pro-apoptotic 
lipid. With siRNA silencing, we proved that ceramide generation via acid sphingo-
myelinase activation is the primary cause for this sensitizing effect. Furthermore, 
we also showed that the sensitization effect is restricted to proliferating cancer cells 
like ovarian or cervical cancers and is absent in normal and quiescent fibroblasts. 
 The thesis ends in Chapter 7 summarizing the conclusions from chapters 2 to 
6. It provides an outlook on polymer/CPP-based applications and gives an overview 
of the current clinical status of the peptide/polymer-based drugs in cancer. Lastly, 
it concludes with the contribution of this thesis to the field.
the proteolytic stability while a cationic CPP, nona-arginine (R9), was conjugated 
to the peptide-polymer conjugates to induce import (Chapter 2 to 4). These 
approaches involved a modular design of the HPMA and dextran-peptide-CPP 
conjugates and multivalency. Site-specific modification with branched PEGs was 
also evaluated. To better understand the functional impact of the coupling of CPPs 
to a flexible polymer scaffold, also the cellular import and toxicity of a dextran 
polymer carrying multiple R9 CPPs was investigated (Chapter 5). Finally, the 
potential of arginine-rich CPPs to induce cellular ceramide formation was 
exploited as a principle to enhance the activity of cytostatic drugs (Chapter 6). 
 Chapter 2 demonstrates that cofunctionalization of an HPMA polymer with 
nona-arginine and an apoptosis-inducing Bid-BH3 peptide greatly increases the 
apoptosis-enhancing activity. The Bid-BH3 peptide corresponding to the BH3 
domain of the pro-apoptotic Bid protein was coupled to a thioester-activated HPMA 
of 28.5 kDa via native chemical ligation in a simple one-pot synthesis. Cellular 
delivery was mediated either via electroporation or by conjugation to R9. 
Independent of the mode of import, the HPMA-coupled Bid-BH3 peptide showed a 
higher activity than the free peptide. Induction of activity of the effector caspase 
caspase-3 was used as a functional readout for apoptosis. Fluorescence correlation 
spectroscopy measurements to study stability revealed a strongly enhanced 
half-live of the HPMA coupled Bid-BH3 peptide in comparison to the free peptide, 
both, inside cells and in crude cell lysates. This led to the conclusion that protection 
from proteolysis accounted for the enhanced activity of the polymer-coupled 
Bid-BH3 peptide.
 In Chapter 3, we extended this study by exploring the multivalent presentation 
of the Bid-BH3 peptide as a concept to enhance the apoptosis-inducing potential of 
this molecule in cancer cells. Bid-BH3 interacts with the pro-apoptotic multidomain 
protein Bax. When activated, Bax forms oligomers in the mitochondrial membrane 
triggering apoptosis. We hypothesized that a multivalent presentation of the 
Bid-BH3 peptide would lead to stronger binding to Bcl-xL or Bax, potentiating 
apoptosis compared to the monovalent free peptide at the same peptide concentration. 
To investigate the impact of multivalency, different numbers of the Bid-BH3 peptide 
were coupled to a linear dextran scaffold. To assess activity, the conjugates and 
also the free peptides were either directly introduced into the cytoplasm via elec-
troporation or by incubation of cells with peptides and conjugates coupled to R9. 
Independent of the mode of delivery multivalency enhanced the apoptotic activity. 
 In Chapter 4, we probed the impact of small to medium-sized phosphorami-
date-linked oligo- and polyethylene glycol chains on the stabilization of the 
BH3-peptide against proteolysis in cell lysates as well as on the intracellular activity. 
PEG-chains were attached to azido-containing peptides by the chemoselective 
Staudinger-phosphite reaction, thereby employing inexpensive linear PEG alcohols for 
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2.1 Introduction
The chemical nature of peptides provides a nearly infinite diversity in structure, 
accessible by highly robust and parallel synthesis protocols [1]. Therefore, peptides 
provide a highly valuable repertoire of molecular interactors, both in basic and 
applied biomedical research [2]. In the past years, numerous peptides have been 
approved as drugs [3-5]. Nevertheless, the intracellular applicability of peptides is 
still limited. One major drawback of peptides is their short cytoplasmic half-life. 
Major investments have been made to increase the stability of peptides. Terminal 
capping by acetylation (N-terminus) and amidation (C-terminus) is the most 
straightforward modification for increasing the resistance of a peptide to serum 
proteases [6]. The incorporation of non-native amino acids such as D-amino acids 
[7, 8], beta-amino acids [9, 10] or backbone modifications such as N-methylation [11] 
has been presented as possible solutions. However, these approaches do not only 
render the synthesis more time-consuming and expensive, they also require a 
careful revalidation of the structure-activity relationship of the molecule [12].
 An alternative approach that is well established in order to extend the plasma 
half-life of small molecule drugs in the bloodstream and to prevent liver accumulation 
is the conjugation of the drugs to high-molecular weight polymers [13, 14]. In this 
context the HPMA copolymer has been widely used [15-17]. For peptides, coupling 
to dendrimers has yielded a protection from proteolytic breakdown [18].
 In a previous study, we have shown that coupling of peptides containing an 
N-terminal cysteine residue to thioester-preactivated HPMA polymers is a convenient 
and robust method for production of polymer-coupled peptides via native chemical 
ligation [19-21]. Conjugates containing an apoptosis-enhancing peptide, loaded 
into cells by electroporation had a greatly increased biological activity in comparison 
to the free peptide. Correspondingly, bifunctional conjugates containing the 
apoptosis- enhancing peptide and nona-arginine (R9) as a cell-penetrating peptide 
(CPP) [22, 23] showed a higher biological activity than the free bioactive peptide 
extended by the CPP.
 Differences in import efficiency, retention time inside the cell and stabilization 
from proteolytic breakdown were considered as the basis for these observations. 
However, the structure of the bioactive peptide compromised a determination of 
the molecular mechanism. The peptide required free and unmodified seven 
N-terminal amino acids for bioactivity and could therefore only be linked to the 
polymer via a cysteine residue coupled to a C-terminal lysine side chain. Therefore, 
a fluorescence-based assessment of proteolytic cleavage of the polymer-coupled 
peptide was not possible. Ideally, a peptide used for the analysis of proteolytic 
stability should be coupled to the polymer via its N-terminus and carry a fluorescent 
reporter group at its C-terminus.
Abstract
Here, we demonstrate that coupling to N-hydroxypropyl methacrylamide (HPMA) 
copolymer greatly enhances the activity of apoptosis-inducing peptides inside 
cells. Peptides corresponding to the BH3 domain of Bid were coupled to a thio-
ester-activated HPMA (28.5 kDa) via native chemical ligation in a simple one-pot 
synthesis. Peptides and polymer conjugates were introduced into cells either by 
electroporation or by conjugation to the cell-penetrating peptide nona-arginine. 
The molecular basis of the increased activity was elucidated in detail. Loading 
efficiency and intracellular residence time were assessed by confocal microscopy. 
Fluorescence correlation spectroscopy was employed as a separation-free analytical 
technique to determine proteolytic degradation in crude cell lysates. HPMA conjugation 
strongly increased the half-life of the peptides in crude cell lysates and inside cells, 
revealing proteolytic protection as the basis for higher activity.
Abbreviations 
CPP, cell-penetrating peptide; DMSO, dimethyl sulfoxide; FCS, fluorescence correlation 
spectroscopy; fpm, fluorescence per molecule; HPMA, N-hydroxypropyl metha cryl-
amide; rfpm, relative fpm.
Keywords 
HPMA, fluorescence correlation spectroscopy, apoptosis, half-life, stability, polymer- 
coupled peptides.
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2.2 Materials and Methods
2.2.1 Reagents 
Preactivated hydroxypropyl methacrylamide copolymer N-methacrylateglycylglycine 
p-nitrophenyl ester (poly-(HPMA-co-methacrylate-Gly-Gly-p-nitrophenyl ester)) with an 
average molecular weight (MW) of 28.5 kDa (Mw/Mn: 1.32) and a total nitrophenol 
content of 8.28 mol % was purchased from Polymer Laboratories (Shropshire, Great 
Britain). On the basis of the specifications provided by the manufacturer, 12.5 
reactive groups were estimated per molecule. Peptides were purchased from EMC 
microcollections (Tübingen, Germany). The other chemicals for synthesis were 
supplied by Fluka (Deisenhofen, Germany), PD-10 columns by GE Healthcare (Uppsala, 
Sweden). Cell culture media were purchased from PAN biotech (Aidenbach, Germany). 
The electroporation kit Cell Line Nucleofector Kit V was provided by AMAXA (Cologne, 
Germany). Alexa-647-labeled Annexin-V was supplied by Invitrogen (Karlsruhe, 
Germany).
2.2.2 Peptide synthesis 
Peptides were synthesized by automated solid-phase peptide synthesis using Fmoc/
tBu chemistry. Fluorescein-labeled peptides with a C-terminal fluorophore were 
synthesized on preloaded carboxyfluorescein-labeled lysyl-Rink amide resin ((Flu-
o(Trt))-Lys-Rink) [32], unlabeled peptides on Rink amide resin. N-terminal labeling 
proceeded as described previously [32]. The peptides were purified by preparative 
RP-HPLC (Grom-SIL 120 ODS-4 HE, 125ł 20 mm, C18 column, 5 μm particle diameter; 
Grom, Herrenberg, Germany). Purity was determined by analytical RP-HPLC 
(Grom-SIL 120 ODS-4 HE, 100 ł 2 mm, C18 column, 5 μm particle diameter; Grom), 
identity was validated via electrospray mass spectrometry with an LCQ Advantage 
Max mass spectrometer (Thermo Fisher Scientific, Waltham, USA). Concentrations 
were determined by UV/Vis spectroscopy of peptides and conjugates diluted 
1000-fold in Tris/HCl buffer pH 8.8 assuming an extinction coefficient for 
fluorescein E492 = 78 000 L/(mol ł cm).
2.2.3 Synthesis of HPMA-peptide conjugates 
Poly(HPMA-comethacrylate-Gly-Gly-p-nitrophenylester) (4 mg) was dissolved in 
anhydrous benzylmercaptan (50 μL) and anhydrous dimethyl sulfoxide (DMSO; 
200 μL). After 15 min, peptide was dissolved in this solution (5.6 mM corresponding 
to a 10-fold excess over polymer and 0.8 excess over reactive groups, respectively) 
and incubated for 30 min at 20°C. After addition of thiophenol (50 μL) and 
incubation for 16 h at 20°C, phosphate buffer (100 mM) and guanidinium chloride 
(6 M), pH 7.5 (200 μL), were added and the mixture was incubated for 72 h at 20°C. 
Finally, the reaction mixture was diluted with PBS (700 μL) and purified twice with 
 Here, we therefore selected a Bid-derived BH3 peptide as a model peptide 
[24-26]. This peptide has a length of 22 amino acids and does not require a free 
amino terminus for biological activity. Coupling to the polymer occurred straight-
forward via an N-terminal cysteine residue. A fluorescein label was attached to a 
C-terminal lysine residue. Therefore, in contrast to our previous choice, this peptide 
was ideally suited to detect proteolytic cleavage off the polymer and release of 
C-terminal low molecular weight fluorescein-labeled fragments. The BH3 peptide 
can directly induce apoptosis by interacting with the multidomain proapoptotic 
Bcl-2 family protein Bax. Bax forms homo-oligomers at the mitochondrial 
membrane and triggers the release of cytochrome c and other proapoptotic factors 
[25, 27, 28]. The induction of mitochondrial apoptosis by the Bid BH3-peptide, 
conjugated to the cell-penetrating peptide d-octa-arginine was shown before [29]. 
 In order to eliminate the complex CPP-mediated import kinetics, involving 
endosomal release [30], first the free peptides and the conjugates were introduced 
into the cell via electroporation and the bioactivity of both was investigated. The 
free peptide was N-terminally capped by labeling with fluorescein and C-terminally 
blocked by amidation. Again the polymer-coupled peptide exhibited a greatly 
increased activity in Jurkat T cell leukemia cells and in Hela cells. 
 Import efficiency and intracellular distribution were analyzed by confocal 
laser scanning microscopy and flow cytometry. The intracellular retention was 
addressed by time-lapse microscopy in combination with quantitative image 
analysis. Subsequently, the proteolytic stability was compared by incubation of 
conjugate and peptide with crude cell lysate. The latter experiment was performed 
by fluorescence correlation spectroscopy (FCS) [31]. This fluorescence-based analytical 
technique provides information about the average number and size of fluorescently 
labeled molecules that diffuse through a sub-femtoliter confocal detection volume. 
The method is separation-free. Therefore, less than one picomole referring to a few 
nanograms of the labeled construct was required per measurement. 
 For the HPMA-peptide conjugate the import efficiency was reduced and the 
intracellular retention of fluorescence did not widely differ between HPMA-conjugate 
and free peptide. However, the stability against cytosolic proteases was tremendously 
increased. Finally, we demonstrate that a bifunctional HPMA-peptide conjugate, 
containing R9 as a cell-penetrating peptide next to the functional BH3 peptide 
induced apoptosis in a specific and concentration-dependent manner. Together, 
the results demonstrate a generalization of our HPMA-based approach and provide 
a mechanistic basis for the advantages of this approach. 
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binding buffer was added and the samples were analyzed by flow cytometry with 
a FACSCalibur System (BD Biosciences, San Jose, USA).
 For microscopy, using an LSM510 confocal microscope (Carl Zeiss, Jena, 
Germany), Alexa-647-labeled Annexin-V was excited with a 633 nm helium-neon 
laser and fluorescence detected using an LP 650 long pass filter.
 Caspase activity was measured in HeLa and Jurkat cells electroporated with 
peptides or polymers as described above. Furthermore, cell-penetrating constructs 
were tested on Jurkat cells. 106 Jurkat E6.1 cells were incubated with increasing 
concentrations of free BH3-R9 / mBH3-R9 peptide and R9-HPMA-BH3 / R9-HPMA-mBH3 
conjugates for 6 h at 37ºC. Cells were washed once with ice-cold PBS, lysed in lysis 
buffer (20 mM Tris/HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, pH 7.7) 
supplemented with protease inhibitor cocktail tablets (Roche Diagnostics, Mannheim, 
Germany) for 30 min on ice. The protein content in lysates was determined using 
a commercially available Bradford protein assay kit (Bio Rad Laboratories, 
München, Germany). An equivalent of 20 μg protein for each sample was diluted in 
caspase activity buffer (20 mM HEPES,10 mM dithiothreitol, 10% glycerol, 100 mM 
NaCl, pH 7.5). Fluorogenic caspase-3 substrate (Ac-DEVD-AMC, Calbiochem, Bad 
Soden, Germany) was added to the samples to a final concentration of 2 μM. 
Fluorescence was detected in a Synergy 2 single-channel microplate reader (BioTek 
Instruments, Inc., Winooski, USA) was analyzed immediately after substrate 
addition and after 3 h incubation at 37ºC.
2.2.7 Analysis of peptide release 
5 x 105 electroporated Jurkat E6.1 cells were incubated in 200 μL phenol red-free 
RPMI medium for 10 min at 37°C until they had settled on the bottom of a 8-well 
chambered coverglass (Nunc, Rochester, USA). Subsequently, the cells were 
analyzed by confocal laser scanning microscopy using a Leica SP5 confocal 
microscope equipped with an HCX PL APO 63x N.A. 1.2 water immersion lens 
(Leica Microsystems, Mannheim, Germany). The cells were incubated at 37°C and 
5 % CO2 in a cell culture incubator and at certain time intervals confocal images 
were taken by laser scanning microscopy. The microscopy stage was housed in an 
incubator box maintained at 37°C.
2.2.8 Image analysis 
For intracellular quantification of fluorescence, the confocal microscopy images 
were analyzed using the program Image J 1.41. The images were smoothed with a 
low pass filter and converted into a black and white mask with a threshold that 
was adjusted to include all cells. Adjacent cells were separated with a watershed 
operation. This binary mask was used for segmentation of the original image. 
Mean fluorescence intensity of the cells was then calculated.
a PD-10 column followed by lyophilization. Absorption was detected at 215 nm 
(peptide bonds), 280 nm (aromatics), and 492 nm (fluorescein). For the bifunctional 
conjugates either BH3 or mBH3, and nona-arginine were conjugated to the HPMA 
polymer in a ratio of 10:10:1 (cargo:nona-arginine:HPMA).
2.2.4 Determination of stoichiometry by FCS 
The determination of stoichiometry proceeded as described previously [20] using 
FCS. FCS measurements were performed in 384-well plates (175 μm, low-base 
design, MMI, Eching, Germany). A solution of 25 nM HPMA-peptide conjugate was 
incubated in PBS-buffer containing 40 U/mL proteinase K for 1.5 h at RT. During 
this incubation, autocorrelation measurements using a TCS SP5 fluorescence 
correlation spectroscope equipped with an HCX PL APO 63x N.A. 1.2 water 
immersion lens (Leica Microsystems, Mannheim, Germany) were performed in 
regular intervals until the diffusional autocorrelation time and the amplitude of 
the autocorrelation function had reached a minimum. After digestion, the number 
of particles and the fluorescence per molecule (fpm), calculated by dividing the 
total background-corrected fluorescence by the number of molecules, of intact and 
completely digested samples were compared. The ratio of the number of particles 
after and before digestions represents the stoichiometry of peptides per polymer.
2.2.5 Electroporation 
106 Jurkat E6.1 cells were resuspended in 100 μL Nucleofector Solution V (Lonza 
Cologne, Cologne, Germany) and the respective free peptide or HPMA-peptide 
conjugate was added into the electroporation cuvette (Lonza Cologne) in the 
desired concentration. Electroporation was performed in a Nucleofector (Lonza 
Cologne) using the electroporation method X-001 according to the recommendations 
of the manufacturer. Subsequently, 900 μL RPMI medium was added carefully and 
the cells were incubated for 5 min at RT, followed by washing of the cell suspension 
in medium by centrifugation. Hela cells were electroporated in a total volume 
of 500 ml at a density of 107 cells/mL using a 10 ms pulse of 300 V (Fischer 
Electroporator, Heidelberg). Cells were then resuspended in fresh medium and 
incubated for 6 h at 37°C.
2.2.6 Bioactivity of conjugates 
For the testing of the activity of electroporated conjugates by Annexin-V staining, 
the electroporated cells were washed, transferred to a 24-well tissue culture plate 
with flat bottom (Sarstedt, Nümbrecht, Germany) and incubated for 20 h in RPMI 
medium. Subsequently, the cells were washed in cold PBS and incubated in 100 μL 
Annexin-binding buffer (10 mM HEPES, 140 mM NaCl and 2.5 mM CaCl2, pH 7.4) 
containing 5 μL Annexin-V Alexa Fluor 647 for 15 min on ice. 400 μL Annexin- 
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2.3 Results
2.3.1  Synthesis and analytical characterization of HPMA-peptide 
conjugates 
Following our previously published procedure [20], the BH3 peptide, containing an 
uncapped N-terminal cysteine residue was coupled to an active ester-activated 
HPMA polymer by native chemical ligation. A conjugate containing only fluorescein- 
labeled cysteine-lysyl moeities and a conjugate carrying a mutated BH3 peptide, in 
which three residues were replaced for alanines, were employed as negative 
controls. The positions of the first and second alanine exchanges correspond to 
conserved amino acids. These mutations had been implemented into negative 
controls before [29]. We had decided to introduce one more mutation as the double 
mutant had shown residual activity in preliminary experiments. For the 
determination of coupling efficiency the number of fluorescent particles before 
and after digestion of the HPMA-peptide conjugate with 40 U/mL proteinase K (2 U 
in 50 mL) was determined by fluorescence correlation spectroscopy. Digestion led to 
a decrease of the amplitude of the autocorrelation function, corresponding to an 
increase in the number of fluorescent particles. The release of the fluorescent 
reporter group from the scaffold was also reflected by the shift in the diffusional 
autocorrelation. Completion of the reaction was confirmed by observing the 
reaction over time. The stoichiometry of peptide loading was derived from 
calculating the number of particles before and after digestion. On average each 
polymer carried two peptides (Table 2.1). Assuming a Poissonian distribution of 
coupling efficiency, at an average coupling ratio of 2 about 27% of the conjugates 
carried only 1 peptide, 59% of the polymers carried two or more peptides and 14% of the 
polymers had remained unfunctionalized. Fluorescence correlation spectroscopy 
also revealed the molecular brightness per molecule (fpm – fluor escence per 
molecule), calculated by dividing the total background-corrected fluorescence of a 
sample by the number of molecules. As before, even though the polymer on average 
carried two fluorophore per molecule, the molecular brightness was the same for 
the polymers and for the free peptide (Table 2.1). This observation is very likely due 
to quenching of fluorescence.
2.3.2 Bioactivity of electroporated conjugates
Cellular import by electroporation of functional conjugates lacking a cell-pene-
trating moiety was chosen to elucidate whether coupling to the polymer affected 
the activity per peptide. In electroporation cells are briefly exposed to a strong 
electric field that transiently introduces pores into the plasma membrane [33]. 
Electroporation is a powerful method to introduce molecules directly into the 
cytoplasm of cells. For our analyses of intracellular activity, electroporation 
2.2.9 Proteolytic stability in cell lysate 
For preparation of HeLa cell lysate, 4 x 106 cells were harvested by treatment with 
trypsin and EDTA and washed with medium and PBS. For Jurkat cells, 5 x 107 cells 
were washed with PBS. Cells were resuspended in 1 mL PBS containing 1% (v/v) 
Triton-X-100 and lysed for 45 min on ice. Subsequently, the cell membranes were 
removed by centrifugation (20,000 x g for 20 min at 4°C). The supernatant was split 
into two aliquots of 500 μL, each, into which either 2 μM HPMA-BH3 conjugate or 
the free BH3 peptide were added. The concentration of the cell suspension was 
adjusted so that the degradation of the peptide and conjugate could be followed 
over several hours. The samples were incubated at 37°C. At the indicated times 
samples of 5 μL were taken, mixed with 95 μL protease inhibitor cocktail (Complete, 
Roche Diagnostics, Mannheim, Germany) and frozen. Finally, the frozen samples 
were thawed, 1000 μL Tris buffer (100 mM Tris-HCl, pH 8.8) was added and aliquots 
of 50 μL were transferred into a 384-well plate (175 μm, low-base design, MMI). Au-
tocorrelation measurements were performed using a TCS SP5 fluorescence 
correlation spectroscope equipped with an HCX PL APO 63x N.A. 1.2 water 
immersion lens. The fractions of intact and degraded polymer or peptide were 
derived from two-component fits of the autocorrelation function. The diffusional 
autocorrelation times for the high-molecular weight component were fixed to 
values determined for the intact conjugate or peptide. The diffusional autocorrela-
tion time for the low molecular weight component was fixed to the one of a fully 
degraded sample. After 24 h a high concentration of 800 U/mL proteinase K (160 U 
in 200 μL) was added in order to validate the general sensitivity of the conjugates 
to protease degradation.
2.2.10 Peptide stability in living cells 
106 Jurkat E6.1 were electroporated with 30 μM solutions of free BH3 peptide and 
HPMA-BH3 conjugate. The cells were washed by centrifugation (340 x g, 5 min) and 
incubated for 2 h at 37°C and 5% CO2. Subsequently, the cells were lysed by 
resuspension in 25 μL PBS containing 1% (v/v) Triton-X-100 for 45 min on ice. The 
cell membranes were removed by centrifugation (20,000 x g for 20 min at 4°C). The 
supernatant was frozen at -20°C. Finally, the samples were thawed and analyzed 
by FCS as described above. In order to determine the autocorrelation time τD of the 
intact polymer/peptide 20 nM of the molecules were mixed with cell lysate of 
untreated Jurkat E6.1 cells.
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therefore circumvented the complications of endosomal uptake, breakdown and 
release associated with CPP-mediated cellular import [30, 34]. After washing by 
centrifugation, Jurkat E6.1 or HeLa cells were incubated for 6 h to allow the 
induction of apoptosis. Apoptosis induction was assessed by measuring caspase-3 
activity. As a further assay for induction of apoptosis, Jurkat E6.1 cells were 
incubated with Annexin-V Alexa Fluor 647. Annexin-V binds to the phospholipid 
phosphatidylserine on the cell surface, which is externalized to the outer leaflet of 
the plasma membrane during apoptosis. An increase in caspase-3 activity was 
observed for the HPMA-BH3 conjugates in Jurkat E6.1 and HeLa cells (Figure 2.1A-B). 
As the indicated concentrations represent peptide concentrations, this result 
demonstrates that the specific activity of the peptides was increased considerably 
due to the conjugation of the peptides to polymers. Annexin-V confirmed that only 
the HPMA-BH3 conjugate initiated apoptosis in a concentration-dependent manner, 
but not the mutant HPMA-mBH3 or the cysteine-containing HPMA construct (Figure 
2.1C-E).
 We then aimed to resolve the molecular basis of the different activities. Next 
to a mere difference in electroporation efficiency of the polymer and the free 
peptide, differences in intracellular residence time or stabilization from proteolytic 
breakdown were considered.
2.3.3 Quantification of electroporation efficiency 
In a first step, we compared the electroporation efficiency of the conjugates and 
the free peptides. To this end, 30 mM of the free BH3 peptide and the HPMA-BH3 
conjugate were electroporated into Jurkat E6.1 cells. The intracellular fluorescence 
was quantified by flow cytometry and observed by confocal laser scanning 
microscopy 1 h after electroporation. All electroporated cells were positive for Ta
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Scheme 2.1  Synthesis of a HPMA-BH3 conjugate. 
(a) DMSO (anhydrous), benzylmercaptane; (b) DMSO (anhydrous), thiophenol; (c) DMSO, 
thiophenol, phosphate buffer (100 mM), guanidiniumchloride (6 M, pH 7.5). Amino acids are 
represented in single letter code and printed in italics.
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fluorescence. The fluorescence of cells loaded with the free BH3 peptide was 
approximately 4-fold higher than that of cells loaded with the HPMA-BH3 conjugate 
(Figure 2.2). Considering that (i) the polymer carried on average two BH3 peptides 
per polymer and (ii) both the free BH3 peptide and the HPMA-BH3 conjugate had 
the same molecular brightness, irrespective of the fact that the polymer carried on 
average two peptides, this finding indicated that in case of the free peptide about 
twice as many peptides were inside the cells than in the case of the polymer-cou-
pled peptides.
2.3.4 Determination of intracellular retention
The induction of apoptosis was determined 6 and 20 h after electroporation. We 
therefore reasoned that the higher biological activity could be explained by a 
longer residence time of the higher molecular weight conjugates. For a comparison 
of residence times, Jurkat E6.1 cells were electroporated with 30 mM solutions of 
the peptides and conjugates. The cells were washed and observed by confocal laser 
scanning microscopy over time in a chase experiment (Figure 2.3). Subsequently, 
the images were analyzed by digital image analysis and the average brightness of 
the cells was calculated (Figure 2.4). 
 The fluorescence residence time of the unbound BH3 peptide had a half-life of 
5.8 ± 1.8 h, the one for the free mBH3 peptide 5.0 ± 1.1 h, the HPMA-BH3 conjugate 
10.6 ± 7.4 h and the HPMA-mBH3 conjugate 4.4 ± 1.7 h. In contrast, the free 
fluorescein molecules had an intracellular half-life of less than 0.5 h. For the HP-
MA-conjugates larger errors were found repeatedly due to the lower intensity of 
cellular fluor- escence that also precluded an observation over longer times. The 
intracellular distribution did not change significantly over time (Figure 2.5). In all 
cases, fluor- escence remained homogeneously distributed inside the cytoplasm 
demonstrating that no sequestration into intracellular structures occurred. These 
results indicate that rapid cellular exit of the free peptide cannot be the reason for 
the increased activity of HPMA-conjugated peptides. 
2.3.5. Peptide stability in cell lysate 
Having excluded differences in loading and rapid cellular exit of the free peptide 
as the source for the increased biological activity, we therefore addressed the 
sensitivity to proteolytic breakdown of the free and the HPMA-conjugated peptide. 
Intracellular fluorescence may as well result from biologically inactive fragments 
that are retained within the cells. Therefore, the comparable intracellular 
residence times do not necessarily provide information on the presence of 
biologically active molecules. HPMA-BH3 conjugate and free BH3 peptide were 
incubated with crude HeLa or Jurkat E6.1 cell lysate as a source of proteolytic 
activity. The concentrations of the lysates were adjusted so that the degradation of 
Figure 2.1  Apoptosis induction by HPMA-peptide conjugates and free peptides. 
Jurkat or HeLa cells were electroporated with the free apoptosis-inducing BH3 peptide, the 
mutated mBH3 peptide or the respective polymer-conjugated peptides HPMA-BH3 and 
HPMA-mBH3 at the indicated concentrations. (A, B) Determination of caspase-3 activity in 
(A) Jurkat cells and (B) HeLa cells lysed 6 h after electroporation with free peptides and 
HPMA-peptide conjugates. Error bars indicate the standard deviation from two independent 
experiments. The concentrations relate to the number of bioactive peptides. (C-E) Apoptosis 
detection by Annexin-V staining. After electroporation, the cells were washed and incubated 
in FCS-containing medium for 20 h with HPMA-peptide conjugates. Subsequently, cells were 
stained with Alexa-647-labeled Annexin-V. (C) Flow cytometry histograms of Jurkat cells 
electroporated with various concentrations of HPMA-BH3 and stained with Alexa-647- 
labeled Annexin-V. (D) Microscopy image of Annexin-V-stained cells, electroporated with 40 
mM HPMA-BH3, 20 h after incubation. (E) Annexin-V positive cells represented as the 
normalized fraction of Annexin-V positive cells for the indicated concentrations of the 
HPMA-peptide constructs. The error bar shows the standard error of three independent 
experiments.
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 The complete degradation of both, free peptide and conjugate upon treatment 
with proteinase K confirmed that both molecules could be in principle digested by 
proteases. The results revealed that the HPMA conjugation stabilizes the peptide 
from being proteolytically digested in cell lysate. Given the very similar loading 
efficiencies and the absence of a rapid cellular exit of the free peptide, protection 
from proteolytic breakdown should therefore be the explanation for the higher 
biological activity. This result also indicates that for the free peptide intracellular 
retention of fluorescence does not correlate with stability. The results suggest that 
proteolytic fragments are formed that are retained within the cell.
peptide and conjugate could be followed over several hours. The samples were 
incubated at 37°C for 24 h. At certain times aliquots were extracted. Degradation 
was assessed by fluorescence correlation spectroscopy. In a representative 
experiment the autocorrelation time τD for the intact HPMA-BH3 conjugate was 93 
ms, for the undigested free BH3 peptide 51 ms and for the digested samples 35 ms. 
By fixing these values, the fractions of intact and degraded polymer/peptide were 
derived from two component fits to the autocorrelation functions. With the 
selected concentration of cell lysate, the HPMA-BH3 conjugate showed a half-life of 
> 10 h whereas the unbound free BH3 peptide showed a half-life of only 1.1 ± 0.1 h 
(Figure 2.6). 
Figure 2.2   Electroporation efficiency of free peptides and HPMA-peptide 
conjugates. 
Jurkat E6.1 cells were electroporated with (A) medium 30 mM of (B) free BH3 peptide or (C) HPMA-BH3. The 
concentration of conjugate relates to the number of peptide moieties. Subsequently, the living cells were 
washed with medium and observed by (A-C) confocal laser scanning microscopy 1 h after electropora-
tion. The scale bar in the microscopy images represents 50 mm; (D-E) corresponding flow cytometry 
histograms and (G) medians of intracellular fluorescein intensities.
Figure 2.3   Release of cellular fluorescence after electroporation of free peptides 
and HPMA-peptide conjugates. 
Jurkat E6.1 cells were electroporated with 30 μM of free peptides and HPMA-peptide conjugates or 
fluorescein. The concentration of conjugate relates to the number of peptide moieties. Subsequently, the 
cells were washed twice with medium, seeded into an 8-well chambered coverglass and incubated at 
37°C. In certain time intervals confocal images were taken by laser scanning microscopy. The scale bar 
represents 50 μm.
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shown for cell lysate above also in living cells the HPMA conjugated peptides are 
more stable.
2.3.6. Peptide stability in cells 
In order to directly address differences in proteolytic degradation inside cells, 
Jurkat E6.1 cells were electroporated with 30 mM solutions of free BH3 peptide and 
HPMA-BH3. Following a 2-h incubation at 37°C cells were lysed and cell lysates 
analyzed by FCS. The autocorrelation times τD of the intact polymer and peptide 
were determined by adding these molecules to cell lysates of untreated cells. In a 
representative experiment the τD for the intact HPMA-BH3 conjugate was 97 ms, 
for the undigested BH3 peptide 57 ms and for the digested samples 25 ms. By fixing 
these values, the fractions of intact and degraded polymer/peptide were derived 
from two component fits to the autocorrelation functions. After an incubation 
time of 2 h the free BH3 peptide was nearly fully degraded, as only 6% of the 
peptide was intact, whereas 68% of the HPMA-BH3 was still intact (Figure 2.7). As 
Figure 2.4   Analysis of release kinetics. 
The confocal images generated by laser scanning microscopy (Fig. 3) were analyzed by quantitative 
image analysis. (A) Superposition of all curves (the intensity at the beginning of the experiment was set 
to 100%), (B) free BH3 peptide, (C) free mBH3 peptide, (D) HPMA-BH3 conjugate, (E) HPMA-mBH3 conjugate 
and (F) fluorescein. The data were fitted with a first order exponential decay.
Figure 2.5   Intracellular distribution of fluorescence at different time points 
after electroporation. 
Jurkat E6.1 cells electroporated with (A) the free BH3 peptide, (B) the HPMA-BH3 conjugate, (C) the free 
mBH3 peptide, (D) the HPMA-mBH3 conjugate and (F) fluorescein were observed (A-E) 30 min after electro-
poration and (F-J) 6 h after electroporation. The scale bar represents 20 μm.
Figure 2.6   Proteolytic stability of HPMA-BH3 and the free BH3 peptide in crude 
cell lysates of (A) Hela and (B) Jurkat E6.1 cells. 
Cell lysate was generated by lysis of cells in Triton-X-100. The cell lysate was mixed with 2 μM HPMA-BH3 
conjugate or free BH3 peptide and the samples were incubated at 37°C. The concentration is related to 
the number of peptide moieties. After certain time points samples were extracted and frozen. After 24 h 
proteinase K was added to the samples in order to confirm the general sensitivity to proteases. The 
fractions of intact conjugate (filled squares) and peptide (blank circles) were determined by fluorescence 
correlation spectroscopy and derived from two-component fits of the autocorrelation functions. 
Half-lifes were derived from first-order exponential fits. Each panel shows the results of a representative 
experiment for either cell line.
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 The conjugate effectively induced apoptosis in Jurkat cells in a concentration- 
dependent manner as measured by caspase-3 activation, while the conjugate 
functionalized with the mutated peptide did not (Figure 2.8). The R9-HPMA-BH3 
conjugate was more effective in inducing apoptosis than the free R9-BH3 peptide, 
consistent with the results for the electroporated peptides. The mutant free 
R9-conjugated mBH3 peptide also induced some apoptosis, albeit less reproducibly 
and to a lesser extent than the R9-HPMA-BH3 conjugate. 
2.4 Discussion
Our previous analyses had shown that coupling of peptides to an HPMA polymer by 
native chemical ligation yielded bioactive conjugates by a modular design [20]. These 
initial analyses had already indicated that the polymer-coupled peptides had a 
higher activity per peptide moiety. Differences in cellular loading efficiency, in 
retention inside the cell as well as in peptide stability were considered as the 
molecular basis for this observation. However, the bioactive peptide, derived from 
the proapoptotic protein Smac [35], that we had selected, was not accessible to an 
elucidation of these questions. For this peptide a free amino terminus was required 
for activity. Therefore, coupling to the polymer occurred via a cysteine residue 
coupled to a lysine side chain at the C-terminus of the peptide. Here, we selected an 
apoptosis-inducing peptide derived from the proapoptotic Bid protein that could be 
coupled to the polymer via the N-terminus in a straightforward manner. Coupling 
efficiencies for this longer peptide were in the same range as those reported before, 
confirming the general usefulness and robustness of this synthesis procedure.
 Using this peptide we demonstrate an increase in the activity per peptide 
moiety that is very likely due to a protection from proteolytic degradation. Given 
the faster degradation of the free peptide one could also expect a faster release of 
degradation products from the cells. However, cellular retention times of 
fluorescence were not markedly different for the free peptides and for conjugates. 
We explain this observation by the generation of fluorescein-containing fragments 
that were still efficiently retained within the cells. We have indications from other 
experiments that negatively charged peptides are retained more strongly inside a 
cell than positively charged or neutral ones. The two N-terminal amino acid 
residues glutamic acid and aspartic acid are negatively charged. 
 For the HPMA-conjugated peptide the activity was increased considerably per 
peptide moiety. The HPMA-mBH3 conjugate and the fluorescein-conjugated polymer 
did not show any activity. This finding confirmed that induction of caspase-3 
activity and phosphatidylserine exposure were not due to electroporation or to a 
toxic effect by the polymer itself.
2.3.7. Biological activity of a bifunctional cell-penetrating conjugate 
Finally, we addressed whether cofunctionalization of the HPMA polymer with a 
cell-penetrating moiety would yield a bioactive conjugate to induce apoptosis by 
CPP-mediated cell entry. The modular assembly of CPP and BH3 peptide as independent 
building blocks on the polymer backbone constitutes a clear advantage over the 
synthesis of one long cell-penetrating BH3-R9 peptide. 
Figure 2.7   Proteolytic stability of HPMA-BH3 and the free BH3 peptide in living 
Jurkat E6.1 cells. 
The conjugate/peptide was electroporated into cells. After incubation cell lysate was generated and 
measured by FCS. Whereas the (A) diffusion time τD of the free BH3 peptide decreased significantly upon 
incubation in cells, the (B) τD of the HPMA-BH3 decreased only slightly. The shifts in diffusional auto-
correlation times between the intact conjugate or peptide (solid lines) and the incubated samples (dashed 
lines) are indicated by arrows.
Figure 2.8   Apoptosis induction by R9-HPMA-BH3.  
Jurkat cells were incubated with conjugates for 6 h at 37 °C. Titration of cells with HPMA-R9 conjugates 
and peptide-R9 conjugates and determination of caspase-3- activity. Concentrations of the polymer 
conjugates in the medium were adjusted to the same concentration with respect to the functional peptide. 
For the HPMA conjugates and the free peptides, the normalized mean and mean error of two and four 
independent experiments is shown.
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 In contrast to the HPMA-BH3 conjugate, the free BH3 peptide did not show any 
activity, in spite of the higher electroporation efficiency. For this free peptide, in 
vitro assays had shown that concentrations of 10 mM and more were required to 
induce formation of Bax oligomers [36]. Only for a membrane-targeted analog [28] 
or a peptide with a stabilized a-helix [27] were activities at lower concentrations 
observed. We therefore conclude that due to the rapid proteolytic breakdown of 
the free peptide concentrations required for activity were not reached. 
 A conjugate of this peptide to the CPP d-octa-arginine had shown apoptosis 
inducing activity in a number of cancer cells [29] at concentrations of 20 mM and 
higher. These concentrations were higher than the ones used for the cell-penetrating 
conjugate in our experiments. 
 While our studies focused on the intracellular pharmacokinetics of the free 
peptides and HPMA-peptide conjugates, it is nevertheless interesting to note that 
the HPMA-BH3 conjugate was active in spite of its lower electroporation efficiency. 
It is tempting to speculate that next to the proteolytic stabilization, the multi - 
valency of this conjugate may contribute to this observation. This multivalency 
should enable the simultaneous interaction with at least two Bax molecules. In 
nature and also in the generation of synthetic binders, multivalency is a highly 
powerful principle for increasing the interaction of low-affinity binders [37, 38]. 
 Finally, the HPMA-based strategy also proved its potential as a modular synthesis 
approach for the combination of different functionalities. Synthesis of a single 31 
amino acid peptide containing the BH3 domain and the nona-arginine CPP is a 
major challenge and we repeatedly obtained this peptide only with low purities and 
yields. Fusion of peptide fragments by native chemical ligation requires synthesis of 
a C-terminal thioester, which is also not straightforward in Fmoc peptide chemistry. 
Separate synthesis of the functional BH3 peptide and the CPP and incorporation into 
the polymer therefore constitutes a major synthetic advantage. 
 For the cell-penetrating R9-HPMA-BH3 conjugate the same higher activity was 
observed in comparison to the free peptide as was observed for the molecules that 
were loaded by electroporation. 
 In summary, our results provide a powerful methodological approach to 
address the pharmacokinetics of peptides and polymer conjugates in intracellular 
applications. Fluorescence correlation spectroscopy was employed as an analytical 
method to determine proteolytic degradation in microliter volumes of crude cell 
lysates in a separation-free manner. The analyses demonstrate that conjugation of 
peptides to the HPMA polymer confers significant protection from proteolytic 
degradation. Together with the robust, modular synthesis procedure, these results 
further underline the usefulness of the HPMA-based strategy to increase the 
functionality of peptides in intracellular applications in fundamental and applied 
biomedical research. 
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3.1 Introduction
Intracellular protein-protein interactions (PPIs) are essential for the transmission 
of information within and between living cells [1]. While numerous protein- 
protein interactions have been predicted by proteome-wide interaction screens 
such as yeast-two-hybrid systems [2], such methods are prone to produce high 
numbers of false positives and the functional relevance of many of the postulated 
protein-protein interactions remains unclear. Therefore, chemical tools to 
specifically disrupt and modulate protein-protein interactions are in high demand. 
While in some examples peptides corresponding to parts of the native interaction 
domains can effectively modulate PPIs, in other cases, they fail to do so due to a 
lack of activity. Multivalency is a biologically relevant mechanism for converting 
low-affinity binding into high-affinity interactions found ubiquitously in nature 
[3, 4]. Consequently, multivalent arrangements of peptides should be able to 
potentiate the biological activity by increasing the local ligand concentration and 
by targeting proteins which present multivalent binding sites, e.g. by incorporation 
in membranes [5-7]. Therefore, the development of a flexible synthetic access to 
multivalent and structurally defined peptide-oligosaccharide conjugates (“peptide- 
dextrans”) were investigated [8]. Ideally, such a material was expected to increase the 
biological potency of a multivalently conjugated peptide relative to a monovalent 
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Figure 3.1   Design principles for bioactive BH3 peptides. 
(A) Helical BH3 peptides (red) bind to Bcl-xl proteins (blue) in the outer mitochondrial membrane 
replacing the Bax protein (green) or (B) directly interact with Bax. Oligomerization of Bax leads to the 
formation of membrane pores and the release of cytochrome c into the cytosol triggering the activation 
of caspases and resulting in apoptosis.
membraneBid-BH3cytoplasm
plasma membrane
inactive Bax
activated Bax
of Bid-BH3 on a dextran
scaffold
A B
Apoptosis at low peptide concentrations
Activation of multiple Bax
Release of cytochrome C
Mitochondrial
inner membrane
space
Inactive Bax
Apoptosis
multivalent presentation
outer mitochondrial
58 | Chapter 3 Multivalency boosts peptide activity | 59
2-position of glucose as revealed by HMQC-HMBC NMR-analysis of 2 (Figure S3.2, 
S3.3). Loading of 2-CED was varied in a range between 6 and 25 carboxyethyl (CE) 
groups per dextran molecule and was quantified by 1H NMR spectroscopy (Figure 3.2).
free peptide at the same peptide concentration, if the targeted PPI indeed was 
accessible to multivalent binding.
 To test this hypothesis, the activity of multivalent Bid-BH3-dextrans was 
investigated. Bid-BH3 is a pro-apoptotic peptide, derived from the apoptosis- 
activating Bid protein [9, 10]. Expression of the Bid-protein is stimulated by binding 
of the tetrameric oncoprotein p53 to damaged DNA and leads to the induction of 
apoptosis via the interaction of the BH3 helix with anti-apoptotic Bcl-proteins [11, 
12]. Mutation of the p53 gene which is found in >95% of all tumors to be responsible 
for the shut-down of apoptosis in cancer cells and thus constitute a crucial switch 
towards the survival of cancer cells [13-15]. Therefore, the re-stimulation of the 
pro-apoptotic pathway downstream of p53 leads to the efficient reversion of cancer 
cell survival and might have the potential to kill cancer cells with mutated p53 
selectively. The Bid-BH3 peptide has been found to interact with the anti-apoptotic 
Bcl-proteins Bcl-xl, Bcl-2, and Bclw but also the proapoptotic Bax protein in mito -
chondrial membranes, interactions which have been characterized functionally 
as well as structurally (Figure 3.1) [16-18].
 Apoptosis is triggered by induction of Bax oligomers in the mitochondrial 
membrane. While Bid-BH3 peptides bind to Bcl-xl in homogeneous, cell-free 
in-vitro systems with affinities at high nM to μM concentrations, no stimulation of 
apoptosis has been found for the free peptide in cells [19]. Only upon peptide 
lipidation or conformational fixation of the BH3 helix by hydrocarbon staples 
induction of apoptosis was observed [11, 20]. Also small molecules have been 
developed as BH3 analogs and are in clinical trials to date [21]. Since activation of 
Bax involves formation of a multimeric complex, we ask here whether multivalency 
may be useful to increase activity. 
3.2 Results and Discussion 
For the synthesis of peptide-oligosaccharide conjugates dextran (a(16)-linked oligo- 
D-glucose) was selected as a well-characterized, biocompatible polymer which we 
have demonstrated recently as an efficient carrier in intracellular applications [22]. 
Dextran 1 displayed an average molecular weight of 10 kDa and a polydispersity 
index of 1.58 (Scheme 3.1). 
 Thus, an average dextran molecule 1 was constructed of 62 glucose monomers 
and spanned a distance of 25 nm in its extended conformation corresponding to 
the size of 8 globular proteins of 24 kDa. Dextran 1 was alkylated with acrylamide and 
the amides were hydrolyzed yielding 2-carboxyethyl dextran (2-CED) 2 which was 
isolated by precipitation followed by dialysis [22, 23]. Using the reported optimized 
reaction conditions, carboxyethylation was found to be entirely selective for the 
Scheme 3.1   Synthesis of peptide dextrans 8a-i. 
a) acryl amide, 1N NaOH, 30-50 °C, 0.1 N HCl, b) N-(2-aminoethyl)-maleimide 5, EDC, pH 6.5, c) cysteinyl-
peptide 7, TCEP, pH 6.5.
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ethanol for 16 h. Obtained peptide dextrans 8a-i were analyzed after precipitation 
and dialysis by gel permeation chromatography, NMR, and quantitative amino 
acid analysis. Fluorescence correlation spectroscopy was employed in order to 
verify the polymer attachment of the fluorescein dye. No traces of free, unattached 
fluoresceinyl peptides were detected in the polymer product. Coupling efficiencies 
correlated directly with peptide concentration and provided oligosaccharides 
with 3 to 7 peptide copies; relative stoichiometries of peptides on the polymer 
reflected the stoichiometry in the reaction mixture with no significant effect of 
peptide sequences and lengths. 
 In order to investigate the intracellular multivalency effect of the 22-mer 
Bid-BH3 peptide and to substantiate the findings with all necessary control 
experiments, nine peptide dextrans 8a-i and four free peptides 9-12 were designed 
and synthesized (Table 3.1). Multivalent peptide dextrans 8c,d,e,h, and i were 
produced as low-valent (divalent) and dextrans 8a,b,f, and g as high-valent 
(pentavalent) derivatives in order to dissect the multivalency effect from the effect 
of oligosaccharide attachment alone. In addition, two routes of administration 
were investigated, delivery by an oscillating electric field, denominated as electro-
poration (or nucleofection), and endosomal delivery using a cell-penetrating peptide. 
Peptide dextrans 8a-d were prepared without attachment of a cell-penetrating 
Results were confirmed by colorimetric titration of polymer 2. All subsequent 
experiments were conducted employing 2-CED 2 with a loading of 1.2 mmol/g 
polymer (13 CE groups per dextran molecule). For the ligation with unprotected 
peptides carboxy groups of polymers were condensed either with ethyl glycine 
thioester 3 and N-ethyl-N´-3-dimethylamino-propyl carbodiimide (EDC) furnishing 
polymer 4 for native chemical ligation or with EDC and 2-(aminoethyl)-maleimide 
5 yielding polymer 6 for maleimide-thiol couplings (Scheme 3.1). 
 In both cases the complete amidation of the carboxyethyl groups could be 
confirmed by NMR spectroscopy of the polymer (Figures S3.4 and S3.5). Activated 
dextrans 4 and 6 (each at 1 mM with 13 mM activated carboxylates) were tested in 
both ligation protocols with N-cysteinylated R9-peptide 7 at concentrations of 5 
and 7 mM. The efficiency of the maleimide couplings was found to be superior 
compared to native chemical ligation (max. yield of 75% vs. 30%, see Tables S3.4, 
S3.5). Thus, maleimide couplings at pH 6.5 were preferred for all subsequent 
ligation reactions. Polymer 6 was loaded with mixtures of one to three different 
N-cysteinyl-peptides yielding nine different peptide dextrans 8a-i in one step 
(Table 3.1). Cysteinyl-peptides were applied in 1.5-2 fold excess to the desired degree 
of substitution. Remaining maleimide groups were deactivated using 2-mercapto-
Table 3.1  Composition of tested peptide dextrans 8a-i and peptides (9-12).
# Structure Name
8a Dextran 6 with 5 C-BH3[a] and 1 C-Fluo[b] Dex-5B
8b Dextran 6 with 5 C-mBH3[c] and 1 C-Fluo Dex-5mB
8c Dextran 6 with 2 C-BH3 and 1 C-Fluo Dex-2B
8d Dextran 6 with 2 C-mBH3 and 1 C-Fluo Dex-2mB
8e Dextran 6 with 2 CR9[d] and 1 C-Fluo Dex-2R
8f Dextran 6 with 5 C-BH3-Fluo and 2 CR9 Dex-5B-2R
8g Dextran 6 with 5 C-mBH3-Fluo and 2 CR9 Dex-5mB-2R
8h Dextran 6 with 2 C-BH3-Fluo and 2 C-R9 Dex-2B-2R
8i Dextran 6 with 2 C-mBH3-Fluo and 2 C-R9 Dex-2mB-2R
9 Fluo-BH3 BH3
10 Fluo-mBH3 mBH3
11 Fluo-BH3-R9 BH3-R9
12 Fluo-mBH3-R9 mBH3-R9
[a] BH3: EDIIRNIARHLAQVGDSMDRSI-NH2; [b] C-Fluo: CK(N-fluoresceinyl-carboxy); [c] mBH3: EDIIRNIAR-
HAAQVGASADRSI-NH2; [d] R9: RRRRRRRRR-NH2
Figure 3.2   Overlay of HMBC (red) and HMQC (black). 
Spectra showed that signals of CE-methylene groups 1´  correlated only with the signals of the glucose 
units in position 2, but not in position 3 or 4.
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addition of Trypan Blue and Propidium Iodide, dyes, which do not enter healthy 
and early apoptotic cells. 
 After this initial demonstration of the conjugate´ s activity, we investigated 
the impact of multivalency on the induction of apoptosis using conjugates with 
different numbers of BH3 peptides per polymers. For a reliable quantification of 
apoptosis induction, the activity of the protease caspase-3 was measured [27]. This 
specific enzyme was selected as a biomarker, as in every apoptotic process, caspase-3 
peptide and were delivered by nucleofection, thereby challenging the possibility 
that CPP-delivery was required for multivalent enhancement. Dextrans 8e-i were 
synthesized with two copies of the N-cysteinylated cell-penetrating peptide (CPP) 
nona-arginine in order enable delivery via endosomal uptake. For this group of 
polymers, peptide dextran 8e, carrying only two copies of the CPP, served as a 
control to exclude that the CPP alone was sufficient to induce apoptosis. 
 Peptide dextrans 8a,c,f,h were obtained from the maleimide-dextran 6 by 
coupling with the N-cysteinyl derivative of the native 22-mer BH3 peptide (C-BH3), 
whereas 8b,d,g,i were ligated with the N-cysteinyl derivative of the mutated, 
inactive control peptide mBH3 (C-mBH3) in order to prove that the observed effect 
was specific to the BH3 sequence. mBH3 peptide was rendered inactive by three 
alanine mutations in positions 12, 17, and 19, which have been described as 
essential for the interaction with Bcl-xl protein [16]. For fluorescence labeling, either 
N-cysteinyl-lysinyl-5(6)-carboxyfluorescein was used in the coupling mixture, or 
fluoresceinyl-lysine was added C-terminally to both the BH3 and mBH3 peptides 
[24]. Finally, non-conjugated, “free” peptides were prepared for comparison, namely 
the 23-mer Fluo-BH3 9 with an N-terminal lysinyl-N-e-fluoresceinyl-carboxy residue, 
the mutated derivative Fluo-mBH3 10, and the two C-terminal nona-arginine 
conjugates, 11 and 12, both being 32mer peptides.
 Preparation of all free peptides (9-12) and the ligated peptides (C-BH3 and 
C-mBH3) required the careful optimization of the synthesis protocols in order to 
obtain products of sufficient quality and without deletion sequences. Efficient 
synthesis of the BH3 sequence required the employment of the pseudodipeptide 
building blocks Asp-Ser(ΨMe,MePro) and Ala-Ser(ΨMe,MePro) in position 17 and 
18 of the 23mers C-BH3 C-mBH3, FluoBH3 (9), FluomBH3 (10), as well as in the 
32mers Fluo-BH3-R9 and Fluo-mBH3-R9 (11,12) [25]. 
 The apoptosis-inducing activity of peptide dextrans 8a-i (Table 3.1) was 
investigated at Jurkat E6.1 cells, an established lymphoma cell line (Figures 3.3, 
3.5). Peptide dextrans 8a-d were imported into Jurkat E6.1 cells by nucleofection, a 
gentle way of electroporation, in which the plasma membrane is temporarily 
permeabilized by an externally applied electric field. Peptide dextrans 8e-i were 
imported into cells by covalently attached nona-arginine, an established cell-pen-
etrating peptide [26]. After loading of cells with peptide dextrans at various 
concentrations the cellular distribution of peptide dextrans was evaluated by 
confocal laser scanning microscopy (Figure 3.3) and uptake was quantified 
employing flow cytometry. First, apoptotic cells were visualized by addition of 
Annexin-V labeled with the fluorescent dye Alexa Fluor 647 to cells after washing. 
Annexin-V is a protein binding specifically to the membrane phospholipid phos-
phatidylserine (PS) which is externalized to the outer leaflet of the plasma 
membrane in early apoptosis. Integrity of the plasma membrane was validated by 
Figure 3.3   Induction of apoptosis by the pentavalent BH3 peptide dextran 8a  
(10 μM total peptide concentration) after 8 h in cells of the human 
cell line Jurkat E6.1. 
8a was transferred into the cells by nucleofection, a mild form of electroporation. 8a and the mutated 
pentavalent control peptide dextran 8b were homogeneously distributed in the cells as indicated by 
staining with the fluorescein label (left column). Only 8a led to the membrane staining of cells with 
Annexin-V (purple) characteristic for cells in early apoptosis. At the same time Trypan blue staining (red) 
was detectable only outside of living cells for both 8a and 8b, indicative for intact, not yet permeabilized 
outer cell membranes.
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polymer architecture. In the next step, the same set of experiments was conducted 
with peptide dextrans 8f-i delivered by the attachment of two copies of nona- 
arginine via endosomal uptake without nucleofection. Dextran 8e labeled with 
is the central effector protease, which is activated by a pro-apoptotic signal – like 
the presence of BH3 peptides – and then leads to the proteolytic degradation of the 
cell. Notably, caspase-3 is activated only during apoptosis, but not in other processes 
leading to cell death such as necrosis. Caspase-3 activation by peptide-dextrans 
without nona-arginine was determined following to nucleofection of cells with 
peptide dextrans or with free peptides. After washing with buffer, cells were 
incubated for 6 h at 37°C and lyzed. The protein content of the cell lysate was 
determined by the Bradford assay and equal amounts of protein (30 μg) for each 
sample were incubated with a fluorogenic substrate of caspase-3 (Ac-DEVD-AMC = 
N-(N-acetyl-aspartyl-glutamyl-valinyl-aspartyl)-7-amino-5-methyl coumarin) [27] in 
a 96 well plate and analyzed in a fluorescence spectrometer. Fluorescence was 
recorded after 3 h and the activity of caspase-3 was compared after subtraction of 
the initial fluorescence (Figure 3.5A). 
 While no significant induction of apoptosis was observed either for the 
monovalent BH3 peptide 9 or the monovalent mutated BH3 (mBH3) 10, and the 
mutated BH3-dextran conjugates 8b,d, a considerable, concentration-dependent 
induction of apoptosis was recorded for the bi- and pentavalent BH3 peptide dextrans 
8a,c at identical overall peptide concentrations of 10 μM. Very remarkably, the 
bivalent Dex-2B 8c increased the caspase activity by a factor of 12, whereas 
caspase-3 activity in cells treated with the pentavalent Dex-5B 8a was raised even 
21-fold, demonstrating a clear multivalency effect for the pentavalent peptide 
Figure 3.4   Cellular uptake of peptide dextrans 8f,g (10 μM total BH3-peptide 
concentration) after 30 min in Jurkat E6.1 cells. 
The green fluorescent dextran was homogeneously distributed in the cells. The absence of propidium 
iodide staining in the cells showed their good viability.
Figure 3.5   Induction of apoptosis by Bid-BH3-containing peptide dextrans in 
Jurkat E6.1 cells. 
(A) Activation of caspase-3 in nucleofected cells, (B) with CPP-mediated delivery of peptide dextrans. 
Error bars reflect S.E. of three independent sets of experiments.
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loaded, multivalent peptide dextrans was designed and synthesized in order to 
investigate the multivalency effect for the BH3 peptide in living cells. BH3 peptide 
dextrans were delivered to the interior of cells either by nucleofection or via the 
attachment of two copies of N-cysteinyl-nona-arginine as cell-penetrating peptides. 
The obtained multivalent peptide dextrans displayed specific biological activity in 
the induction of apoptosis. Independent of the mode of cellular import and of the 
protection against proteolytic degradation exerted by the polymer, this activity 
was significantly potentiated by multivalent presentation of the peptides. To our 
knowledge this is the first example of a multivalency effect proven with synthetic 
peptide constructs for an intracellular protein target. The demonstrated methodology 
should enable the investigation of homo- and hetero-multivalency effects for other 
PPIs in cells as well. The flexible access to peptide dextrans should pave the way to 
further biological applications of these novel materials.
3.4 Experimental Section
3.4.1 Materials 
All chemicals for synthesis were purchased from Sigma Aldrich (Germany) and 
used without further purification. Annexin-V Assay Kit was obtained from 
Invitrogen (Karlsruhe, Germany), resins for SPPS from Rapp Polymere (Tübingen, 
Germany), PD-10 columns from Sigma Aldrich (Germany) and cell culture medium 
from PAN biotech (Aidenbach, Germany). Automated peptide synthesis was 
performed at an Activo P11 (Cambridge, England) synthesizer. Cell Line 
Nucleofector Kit was purchased from AMAXA (Cologne, Germany). 1H and 13C 
NMR measurements were performed on a Bruker AVANCETM 300 MHz 
spectrometer. 2D NMR measurements were performed on a Bruker AVANCETM 
600 MHz spectrometer. UV spectra were obtained with a JASCO V-550 UV/Vis 
spectrometer. Amino acid analysis was performed by Genaxxon Bioscience GmbH 
(Ulm, Germany).
3.4.2 2-Carboxyethyl dextran (2-CED) 2 
Dextran (5 g, 0.5 mmol, MW 10 kDa, PDI =1.58) was dissolved in a 1 N NaOH solution 
(50 mL). Acryl amide (0.9 g, 12.5 mmol) was added and stirred at 30°C. After 24 h 
the reaction temperature was increased to 50°C and stirred for additional 24 h. 
The solution was neutralized the oligosaccharide products were precipitated with 
methanol; solvents were removed after centrifugation (4000 x rpm, 5 min). After 
washing of precipitate with methanol the precipitate was dried. The white solid 
was dissolved in water (25 mL) and dialyzed (benzoylated dialysis tubing, pore size: 
2000 NMWCO, Sigma Aldrich) twice with 0.1 N HCl (10 L) and water (2 x 10 L) over 
N-cysteinyl-nona-arginine amide and N-cysteinylfluorescein amide as well as dextrans 
8f-i functionalized with N-cysteinyl nona-arginine amide and fluorescently labeled 
Cys-BH3(Fluo) showed good uptake into cells with two copies of the cell-penetrating 
peptide and no signs of toxicity within the tested concentration range. After 
washing, the integrity of the cell membranes was indicated by the complete 
exclusion of propidium iodide from the interior of cells. Confocal laser scanning 
microscopy revealed a homogeneous distribution of fluorescein fluorescence in 
the cells (Figure 3.4, Figure S3.3). No induction of apoptosis was observed at up to 
10 μM total peptide concentration by the monomeric, R9-conjugated peptides 11 
and 12 or by the dextran-conjugated R9 with mutated BH3-dextrans (8g,i, Figure 
3.5B).
 In contrast, apoptosis was induced efficiently by multivalent BH3-carrying 
peptide dextrans 8f,h. At 10 μM overall BH3-peptide concentration the bivalent 
BH3-peptide dextran Dex-2B-2R 8h induced caspase-3 to a seven-fold level of 
activity. For comparison, the pentavalent BH3-peptide dextran Dex-5B-2R 8f 
increased the caspase-3 activity even 17-fold at the same overall BH3-peptide 
concentration corresponding to a dextran concentration of 2 μM, demonstrating 
again that the degree of multivalency had a strong positive impact on activity. 
While the seven-fold activity enhancement for the divalent peptide polymer, 8h, 
can be attributed partially to the protection from proteolytic degradation exerted 
by the polymer [19], the additional amplification observed for the pentavalent 
architecture, 8f, can only result from the multivalency of the construct. Therefore, 
comparison of the biological activities of differentially loaded peptide dextrans 8a, 
8c, 8f, and 8h proved conclusively a strong multivalency effect for the intracellular 
interactions of BH3 peptides. Furthermore, it could be confirmed from the 
conducted control experiments that the observed effect can be contributed to 
specific interactions of the BH3 peptides as neither the nona-arginine nor the 
mutated BH3 peptides had an effect on the biological activities. 
3.3 Conclusion
In summary, the presented results demonstrate the efficient and modular 
synthesis of multivalent and multifunctional peptide dextrans. For the purpose, a 
protocol for selective carboxyethylation of dextran in the 2-hydroxy position has 
been developed which was employed for the diverse derivatization of dextran over 
a broad concentration range between 6 to 25 carboxyethyl groups per 10 kDa 
dextran. The biocompatible CE-dextran carriers were activated either as maleimides 
or as thioesters and were ligated with mixtures of N-terminally cysteinylated 
peptides in a single step. Using this method a small collection of differentially 
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3.4.5  S-Ethyl-thiocarbonyl-ethyl amidoethyl dextran  
(Thioester dextran) 4 
2 (0.2 g, 0.02 mmol) and 3 (0.23 g, 1.49 mmol) were dissolved in water (1 mL). After 
adjusting the pH value of 6.5 with sodium bicarbonate, EDC (0.14 g, 0.74 mmol) was 
added. After 1 h (0.14 g, 0.74 mmol) EDC was added again and the solution was 
stirred over night. The product was precipitated with MeOH and washed several 
times with MeOH. The precipitate was dissolved in water (2.5 mL) and purified on 
a PD-10 column. After lyophilization a white solid was obtained as product (0.19 g, 
77%). 1H-NMR (D2O, 300 MHz): δ = 1.17 (t, 3 H, J = 7.4, SCH2CH3), 2.59 (t, 2 H, J = 5.4, 
CH2COSEt), 2.86 (q, 2 H, J = 7.4, SCH2CH3), 3.3-4.1 (m, C(2-6) H-dextran, OCH2CH2CO), 
4.92 (s, anomeric H unsubst.), 4.9-5.3 (m, anomeric H) ppm; 13C-NMR (D2O, 75 MHz): 
δ = 13.32 (SCH2CH3), 22.50 (SCH2CH3), 35.49 (CH2CONH), 48.70 (NHCH2CO), 59.95 
(C(6)), 64.97 (OCH2CH2CO), 68.98 (C(5)), 69.64 (C(3)), 70.87 (C(2)), 72.87 (C(4)), 97.16 
(C(1)), 174.14 (CONHCH2), 200.97 (COSEt) ppm.
3.4.6 Maleimidoethyl amidoethyl dextran (Maleimide dextran) 6 
2 (0.2 g, 0.02 mmol) with 13 carboxy groups (0.26 mmol) and 5 (0.69 g, 2.69 mmol) 
were dissolved in water (1 mL). A pH of 6.5-7 was adjusted and EDC (0.26 g, 1.35 
mmol) added. After 1 h EDC (0.26 g, 1.35 mmol) was added again and the solution 
was allowed to stir for 4 h. The mixture was precipitated with methanol. The 
precipitate was washed with methanol and DMF. The solid was dissolved in water 
(2.5 mL) and purified over Sephadex® G-25. Lyophilization led to product as a white 
solid (yield: 0.19 g, 82%). Quantification of maleimide groups per dextran was 
performed using 1H NMR spectroscopy (Figure S3.4). It could be proven that under 
the used conditions all carboxy groups on the dextran reacted to the corresponding 
maleimidoethyl amide groups. 1H NMR (D2O, 300 MHz): δ = 2.48 (t, 2 H, J = 4.7, 
CH2CH2CO), 3.3-4.1 (m, CH2CH2CO, H (glucose units)), 4.98, -5.3 (m, anomeric H), 
6.89 (s, 2 H, COCHCHCO) ppm; 13C NMR (D2O, 75 MHz): δ= 36.38 (CH2CONH), 37.12 
(NHCH2CH2NH2), 39.97 (NHCH2CH2N), 65.35 (C(6)H2), 65.58 (C(OCH2CH2CONH), 
67.94 (C(4) Glucose), 71.41 (C(5) Glucose), 72.57 (C(3)H Glucose), 74.68 (C(2) Glucose), 
98.71 (C(1) Glucose), 179.29 (CONH), 181.82 (CH2CONH) ppm.
3.4.7 Peptide synthesis (7, 9, 10, 11, 12) 
Peptides were synthesized manually or by automated Fmoc-SPPS on TentaGel S 
Ram amide (0.2 mmol/g) resins. Fluorescein labeled peptides were synthesized 
using preloaded Nα-carboxyfluorescein-lysinyl amide TentaGel R Ram resin. To 
avoid aspartimide formation, Fmoc-groups were cleaved using 20% piperidine and 
0.1 N acetic acid solution in DMF. To decrease impurities by sequence termination 
pseudo prolines were used. For the synthesis of BH3-peptides Asp17-Ser18 were 
substituted by Asp-Ser(ΨMe,MePro) and Ala17-Ser18 were substituted by Ala-Ser 
24 h. The loading with carboxyethyl groups was quantified by 1H NMR spectroscopy 
and confirmed by titration against 0.1 N NaOH as described below. Positions of the 
CE-substitution were determined by using HMBC-HMQC NMR spectroscopy as 
described below. Substitution was found selectively in the 2-position under both 
conditions described (see also Figures 3.2 and S3.2). After lyophilization a white 
powder was obtained in a yield of 4 g (72%, 13 carboxyethyl groups per dextran). 1H 
NMR (D2O, 300 MHz): δ= 2.65 (t, 2 H, CH2COOH), 3.25-4.1 (m, CH2CH2COOH, C(2-6)
H (glucose units)), 4.93 - 5.30 (m, 1 H, C(1)H) ppm; 13C NMR (D2O, 75 MHz): δ= 34.20 
(CH2COOH), 65.03 (OCH2CH2COOH), 69.03 (C(4) glucose unit), 69.67 (C(2) glucose 
unit), 70.89 (C(4) glucose unit), 72.89(C(3) glucose unit), 97.18 (C(1) glucose unit, 
175.39 (CH2COOH) ppm. CE-Substitution of dextran was varied by using different 
concentrations of acryl amide in the reaction mixture. Under the reported 
conditions about 50% of the employed acrylamide was attached to the polymer 
(Table S3.1). With 5 g (0.5 mmol) dextran 25, 12.5, and 6.25 mmol of acrylamide 
yielded a loading of 25, 13, and 6 carboxyethyl groups per polymer, respectively. 
CE-groups per dextran were quantified using titration with 0.1 NaOH and phenol-
phthalein as indicator (S3, Table S3.2).
3.4.3 Glycine thioethyl ester hydrochloride 3 
15 (23.1 g, 105.3 mmol) was stirred in 4 N HCl in dioxane (10 mL) for 90 min. The 
mixture was concentrated in vacuo and the product precipitated in cold Et2O. The 
precipitate was filtered, washed with Et2O and dried to provide the product as 
white solid; (yield: 15.34 g, 96%). 1H-NMR (D2O, 300MHz): δ = 1.22 (t, 3 H, J = 7.4 Hz, 
SCH2CH3), 2.98 (q, 2 H, J = 7.4 Hz, SCH2CH3), 4.11 (s, 2H, CH2COSEt) ppm; 13C-NMR 
(D2O, 75 MHz): δ = 13.3 (SCH2CH3), 23.08 (SCH2CH3), 46.63 (CH2COSEt), 194.92 
(COSEt) ppm; HRMS (ESI-TOF): m/z calculated for C4H9NOS: 120.0478 [M+H]+. Found 
120.0476 [M+H]+.
3.4.4 N-(2-Aminoethyl)maleimide (5) 
14 (4.6 g, 19.2 mmol) was dissolved in DCM (35 mL) at 0°C. To this solution, TFA (27 
mL) was added and stirred 1 h while being allowed to reach room temperature. 
The mixture was concentrated and precipitated with cold Et2O (50 mL). Trituration 
with cold Et2O (3 x 50 mL) followed by evaporation of remaining solvent provided 
a white solid as product (yield: 2.5 g, 93%). 1H NMR (CDCl3, 300 MHz): δ = 3.18 (t, 2 
H, J = 5.8 Hz, NH3+CH2CH2), 3.79 (t, 2 H, J = 5.8 Hz, NH3+CH2CH2N), 6.86 (s, 2 H, 
COCH2CH2CON) ppm; 13C NMR (CDCl3, 75 MHz): δ = 34.92 (NH3+CH2CH2), 38.28 
(NH3+CH2CH2), 134.6 (COCH2CH2CO), 172.53 (COCH2CH2CO) ppm; HRMS (ESI-TOF): 
m/z calculated for C6H8N2O2: 141.0659 [M+H]+. Found 141.0662 [M+H]+.
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solvent was removed under reduced pressure chromatography of the dark brown 
oily residue over silica gel (EtOAc/hexane 1:1) gave the product as a white solid 
(yield: 3.7 g, 48.1%). 1H NMR (CDCl3, 300 MHz): δ = 1.4 (s, 9 H, CCH3), 3.34 (q, 2 H, J = 
4.9 Hz, CH2CH2NHBoc), 3.66 (t, 2 H, J = 5.1 Hz, CH2CH2NHBoc), 4.74 (br s, 1 H, 
NHBoc), 6.71 (s, 2 H, CHCHCON) ppm; 13C NMR (CDCl3, 75 MHz): δ = 27.83 (CCH3), 
37.5 (CH2CH2NHBoc), 38.91 (CH2CH2NHBoc) 79.07 (CCH3), 133.96 (CHCHCON), 
155.46 (NHCOO), 170.34 (CONCO) ppm; HRMS (ESI-TOF): m/z calculated for 
C11H16N2O4: 241.1183 [M+H]+. Found 241.1188 [M+H]+.
3.4.11 N-tert-Butoxycarbonyl-glycine thioethyl ester 15 
N-Boc-glycine (24.7 g, 141.5 mmol) and carbonyldiimidazole (25 g, 154.2 mmol) 
were stirred in dry THF (125 mL) at 20°C under a nitrogen atmosphere for 30 min. 
Mercaptoethanol (31.39 mL, 424.3 mmol) was added and the mixture was stirred 
over night. After addition of 4 N NaOH (250 mL), the solution was rapidly extracted 
with DCM (3 x 150 mL). The organic phase was dried over MgSO4, evaporated and 
redissolved in ethyl acetate. The solution was filtered over silica gel and the solvent 
removed under reduced pressure to provide pure product as yellowish oil; (yield: 
23 g, 75%). 1H NMR (D2O, 300 MHz): δ= 1.23 (t, 3 H, J = 7.2 Hz, SCH2CH3), 1.44 (s, 9 H, 
OC(CH3)3), 2.89 (q, 2 H, J = 7.2, SCH2CH3), 4.00 (s, 2 H, NHCH2COSEt), 5.19 (br s NHBoc) 
ppm; 13C NMR (D2O, 75 MHz): 14.03 (SCH2CH3), 22.47 (SCH2CH3), 27.80 (C(CH3)3)), 
49.86 (CH2NHBoc), 79.76 (C(CH3)3), 155.04 (NHCOOC), 197.82 (COSEt) ppm; HRMS 
(ESI-TOF): m/z calculated for C9H17NO3S: 220.1002 [M+H]+. Found 220.1004 [M+H]+.
3.4.12  Synthesis of nona-arginine dextran conjugates using 
maleimide thiol coupling 16, 17 
6 (10 mg, 1 μmol) loaded with 12 maleimide groups (12 μmol) was dissolved in MES 
buffer (1 mL, pH 6.5). After degassing, cysteinyl nona-arginine amide 7 (6 mg, 5 
μmol) was added under nitrogen atmosphere. The pH value was checked and the 
mixture stirred for 16 h. The solution was concentrated and the product 
precipitated with MeOH. After several washing steps with MeOH and DMF the 
solid was dissolved in water (2.5 mL) and purified twice using PD-10 columns. After 
lyophilization the resulting conjugate was obtained as a white powder. Results of 
amino acid analysis showed how much peptide per polymer was coupled (S3, Table 
S3.4: 8 mg, 68%, 3 R9 groups per dextran).
3.4.13  Synthesis of nona-arginine dextran conjugates using native 
chemical ligation 18, 19 
Thioester dextran 4 (10 mg, 1 μmol) loaded with 12 thioester groups (12 μmol) was 
dissolved in phosphate buffer (1 mL, 100 mM KH2PO4/ Na2PO4 pH 7.4). After 
degassing, cysteinyl nona-arginine amide 7 (6 mg, 5 μmol), TCEP (9 mg, 50 eq.) and 
(ΨMe,MePro)[28]. Purification was performed by preparative RP HPLC. Peptides 
were identified by LCMS, HRMS and Maldi TOF.
3.4.8  General procedure for synthesis of dextran-peptide conjugates 
(8a-g) 
6 (5 mg, 0.4 μmol) with 13 maleimide groups was dissolved in an MES buffer (1 mL, 
pH 6.5). After degassing, cysteinyl BH3(Fluo)-peptide (7 mg, 2 μmol for 8f and 3 mg, 
1 μmol for 8h) and cysteinyl nona-arginine amide 7 (2 mg, 1 μmol) were added 
under a nitrogen atmosphere. The pH value was checked and the mixture stirred 
for 16 h. The solution was concentrated and the product precipitated with MeOH. 
After several washing steps with MeOH and DMF the solid was dissolved in water 
(2.5 mL) and purified twice using PD-10 columns. The produced conjugate was 
obtained after lyophilization. Purity of the conjugates was checked using fluorescence 
correlation spectroscopy (FCS). Results of amino acid analysis showed how much 
peptide per polymer was coupled (S3, Table S3.3 (8f: 7 mg, 60%, 5 BH3(Fluo)- and 2 
R9 groups per dextran)). Cellular uptake was shown in Jurkat E6.1 cells. Viability 
of cells was checked with propidium iodide (also S3, Figure S3.6).
3.4.9 N-(tert-Butoxycarbonyl)-1,2-diaminoethane 13 
To an ice-cold solution of 1,2-diaminoethane (27 mL, 400 mmol) in CHCl3 (400 mL) 
was added drop wise a solution of Boc-anhydride (8.7 g, 40 mmol) in CHCl3 (200 mL) 
over 3 h. After complete addition, the mixture was stirred at 0°C for 30 min and 
afterwards allowed to warm to room temperature overnight. The solvent was 
removed under reduced pressure and the residue dissolved in 3 N Na2CO3 (300 mL) 
solution. The mixture was extracted with CHCl3 (3 x 200 mL), the organic phase 
dried over MgSO4 and evaporated to provide the product as a colorless oil (yield: 6.4 
g, 98%). 1H NMR (300 MHz, CDCl3): δ = 1.35 (s, 9 H, CCH3), 2.69 (t, 2 H, CH2NHBoc), 
3.07 (q, 2 H, CH2CH2NHBoc), 5.11 (br s, 1 H, NHBoc) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 27.87 (CCH3), 41.36 (H2NCH2CH2), 42.93 (CH2NHBoc), 78.52 (CCH3), 155.73 
(NHCOO) ppm; HRMS (ESI-TOF): m/z calculated for C7H16N2O2: 161.1285 [M+H]+. 
Found 161.1285 g/mol [M+H]+.
3.4.10 N-(2-((tert-Butoxycarbonyl)aminoethyl)maleimide 14 
Mono-protected N-Boc-ethylenediamine 13 (5.1 g, 31.9 mmol) and Et3N (6.6 mL, 
47.79 mmol) were dissolved in Et2O (60 mL) at 0°C. Maleic anhydride (3.1 g, 31.9 
mmol) in 60 mL Et2O was added drop wise and the reaction mixture was stirred 
for 4 h while being allowed to reach room temperature. After concentrating the 
solution the residue was dissolved in acetone (150 mL). Et3N (8.8 mL, 63.7 mmol) 
was added and the mixture was heated to reflux. Acetic anhydride (4.5 mL, 
47.8 mmol) was added and the solution was heated to reflux for 20 h. After the 
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3.4.17 Electroporation 
106 Jurkat E6.1 cells were resuspended in Nucleofector Solution V (100 μL). Peptide 
or peptide polymer was added in the respective concentration and the solution 
was pipetted into LONZA nucleofection cuvettes. Nucleofection was performed in 
an AMAXA Nucleofector using program X-001 in accordance with the recommen-
dations of the manufacturer. Following nucleofection 900 μL medium were added 
carefully and the cells incubated for 5 min at RT. Subsequently cells were washed 
and resuspended in fresh medium.
3.4.18 Annexin-V Assay 
Electroporated Jurkat E6.1 cells were washed with medium, transferred to a 
24-well tissue culture plate and incubated for 14 h in RPMI medium. The cells were 
washed in cold PBS buffer and incubated for 15 min with 5 μL AnnexinV Alexa 
Fluor 647 in 95 μL Annexin-binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM 
CaCl2, pH 7.4) on ice. Following the Annexin-binding buffer (400 μL) was added to 
each sample. Analysis was performed by flow cytometry on a FACS Calibur System 
(Becton Dickinson, Heidelberg). Using nucleofection for peptide delivery, no 
stimulation of apoptosis was observed in the Annexin-V assay either by BH3-peptide 
9, mBH3-peptide 10, or by the peptide polymer 8c with 5 copies of mBH3 (Dex-5mB). 
In contrast, polymer 8a with 5 copies of BH3 (Dex-5B) showed significant apoptosis 
after 8 h, respectively, in confocal laser scanning microscopy and in flow cytometry 
66% of all cells at an overall peptide concentrations of 2.5 μM, corresponding to a 
polymer concentration of 0.5 μM. At a polymer concentration of 5 μM ca. 75% of all 
cells went into apoptosis (S3, Figure S3.8B).
3.4.19 Caspase-3 assay 
106 Jurkat E6.1 cells were incubated with peptide or peptide dextran conjugate at 
the respective concentration for 6 h. After washing with ice-cold PBS buffer, the 
cells were spun down at 1900 x rpm for 5 min and pellets were resuspended in 
lysis buffer (20 mM Tris/HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 protease 
inhibitor cocktail tablet (Roche Diagnostics Mannheim, Germany) per 50 μL buffer, 
pH 7.7). After 30 min cooling on ice, the lysate was separated from the remaining 
solid by centrifugation and protein content estimated by commercially available 
Bradford Protein Assay Kit (Bio-Rad Laboratories Munich, Germany). 30 μg protein 
aliquots of each sample were diluted in caspase activity buffer (20 mM HEPES, 100 
mM NaCl, 10 mM dithiothreitol, 10% glycerol, pH 7.5). Finally, fluorogenic caspase-3 
substrate (Ac-DEVD-AMC) was added to a concentration of 2 μM. Cleavage efficiency 
of active caspase-3 in solution was measured immediately after addition of the 
substrate and after 3 h at 37°C by measuring fluorescence increase using a Synergy 
2 single channel microplate reader (BioTek Instruments, Winooski, USA).
4-mercaptophenyl acetic acid (5 mg, 32 eq.) were added under a nitrogen atmosphere. 
The pH value was checked and the mixture stirred for 16 h. The solution was 
concentrated and the product precipitated with MeOH. After several washing steps 
with MeOH and DMF the solid was dissolved in 2.5 mL water and purified twice 
using PD-10 columns. Resulting conjugate was obtained after lyophilization. 
Results of amino acid analysis showed how much peptide per polymer was coupled 
(S3, Table S3.5: 8 mg, 73%, 1.2 R9 groups per dextran).
3.4.14 Comparison of both ligation methods 
To compare NCL and maleimide thiol coupling 4 and 6 were reacted with different 
amounts of cysteinyl nona-arginine amide. Polymers were worked up as previously 
described and analyzed using amino acid analysis. Under optimized conditions 
25% of the available cysteinyl peptides were coupled to S-Ethyl-thiocarbonyl-ethyl 
dextran using NCL. In contrast to that 75% of the available cysteinyl peptides were 
coupled on 4 using maleimide thiol coupling. Advantages and disadvantages of 
both ligation methods are summarized in S3, Table S3.6.
3.4.15 Laser scanning microscopy 
Jurkat E6.1 cells seeded in 8 chambered cover slips were incubated with peptides 
or peptide dextrans, dissolved in HEPES buffer, for 30 min at 37°C under a LSM-510 
or LSM 710 laser scanning microscope (Carl Zeiss, Jena, Germany) equipped with a 
63 water objective. Immediately after adding the substance, pictures were recorded 
every 60 sec for 30 min. Cells were washed to removed the peptide solution and 
with HEPES buffer, TrypanBlue was added to prove the viability of treated cells 
and their membrane integrity. 
3.4.16 Fluorescence correlation spectroscopy 
FCS measurements were performed at room temperature on an LSM 510-ConfoCor 
2 system and on an LSM 710-ConforCor 3 system (Carl Zeiss MicroImaging, Jena). 
Fluorescent BH3-peptides, BH3-dextrans 8f-i respective mixtures of unreactive 
CED 2 and fluorescent BH3-peptides were dissolved in water at a concentration of 
10-8 mol/L. Each solution on cover slips (50 μL per sample) were fixed in a 
measurement chamber. An argon ion laser (488 nm) was used for excitation of 
fluorescein. Calculations of the autocorrelation function as well as fitting of the 
autocorrelation function were performed using ZEN 2009 software. Correlation 
functions accounting for free diffusion in three dimensions were fitted for one 
component and yielded diffusional autocorrelation times of particles through the 
confocal volume (S3, Figure S3.7). In two component fittings, it could be shown 
that the investigated peptide polymers (e.g. 8f) contained no free peptides.
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S3.3 Quantification of CE-groups per dextran using titration
CED was weighted in and dissolved in water. As indicator a phenolphthalein 
solution (0.1% in EtOH) was employed and the CED solution was titrated against 0.1 
N NaOH (Table S3.2). The number of CE-groups per anhydro glucose unit (AHG) 
(Table S3.1) was calculated using formula (1).
S3 Supporting Information
S3.1 Materials All chemicals for synthesis were purchased from Sigma Aldrich 
(Germany) and used without further purification. Annexin-V Assay Kit was 
obtained from Invitrogen (Karlsruhe, Germany), resins for SPPS from Rapp 
Polymere (Tübingen, Germany), PD-10 columns from Sigma Aldrich (Germany) 
and cell culture medium from PAN biotech (Aidenbach, Germany). Automated 
peptide synthesis was performed at an Activo P11 (Cambridge, England) synthesizer. 
Cell Line Nucleofector Kit was purchased from AMAXA (Cologne, Germany). 1H 
and 13C NMR measurements were performed on a Bruker AVANCETM 300 MHz 
spectrometer. 2D NMR measurements were performed on a Bruker AVANCETM 
600 MHz spectrometer. UV spectra were obtained with a JASCO V-550 UV/Vis 
spectrometer. Amino acid analysis was performed by Genaxxon Bioscience GmbH 
(Ulm, Germany).
S3.2 2-Carboxyethyl dextran (CED) (2) Dextran (5 g, 0.5 mmol, MW 10 kDa, PDI 
=1.58) was dissolved in a 1 N NaOH solution (50 mL). Acryl amide (0.9 g, 12.5 mmol) 
was added and stirred at 30 °C. After 24 h the reaction temperature was increased 
to 50 °C and stirred for additional 24 h. The solution was neutralized the oligosac-
charide products were precipitated with methanol, solvents were removed after 
centrifugation (4000 x rpm, 5 min). After washing of precipitate with methanol 
the precipitate was dried. The white solid was dissolved in water (25 mL) and 
dialyzed (benzoylated dialysis tubing, pore size: 2000 NMWCO, Sigma Aldrich) 
twice with 0.1 N HCl (10 L) and water (2 x 10 L) over 24 h. The loading with 
carboxyethyl groups was quantified by 1H NMR spectroscopy and confirmed by 
titration against 0.1 N NaOH as described below. Positions of the CE-substitution 
were determined by using HMBC-HMQC NMR spectroscopy as described below. 
Substitution was found selectively in the 2-position under both conditions 
described (S3, Figures S3.2 and S3.3). After lyophilization a white powder was 
obtained in a yield of 4 g (72%, 13 carboxyethyl groups per dextran).
1H NMR (D2O, 300 MHz): δ= 2.65 (t, 2 H, CH2COOH), 3.25-4.1 (m, CH2CH2COOH, 
C(2-6)H (glucose units)), 4.93 - 5.30 (m, 1 H, C(1)H) ppm; 13C NMR (D2O, 75 MHz): δ= 
34.20 (CH2COOH), 65.03 (OCH2CH2COOH), 69.03 (C(4) glucose unit), 69.67 (C(2) 
glucose unit), 70.89 (C(4) glucose unit), 72.89(C(3) glucose unit), 97.18 (C(1) glucose 
unit, 175.39 (CH2COOH) ppm;
The degree of substitution could be changed by varying the acrylamide 
concentration of the solution. It could be shown that under used conditions about 
50% of the employed acrylamide was bound to the polymer (Table S3.1). 
Table S3.1   Correlation between employed acrylamide concentration and the 
degree of loading.
Starting material CE-groups /
dextran
bound CE groups /
applied acrylamiden (acrylamide)
[mmol]
n (dextran)
[mmol]
acrylamide /
dextran
25 0.5 50 25 0.5
12.5 0.5 25 13 0.52
6.25 0.5 12.5 6 0.48
Table S3.2   Results of titration experiments.
m(CED) [g] Consumption of 
0.1 M NaOH [mL]
n(CE):n(AHG)
0.266 3.150 0.210
0.259 3.050 0.209
0.339 4.000 0.209
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S3.5 Determination of the substituted positions in the polymer Using HMQC 
NMR spectroscopy the preferred position for the substitution could be detected. 
Signals of substituted glucose units were compared to the signals of unsubstituted 
ones. The largest signal shift could be detected at position 2 of the pyranose rings 
(Figure S3.2). 
S3.6 Glycine thioethyl ester hydrochloride (3) 15 (23.1 g, 105.3 mmol) was stirred 
in 4 N HCl in dioxane (10 mL) for 90 min. The mixture was concentrated in vacuo 
and the product precipitated in cold Et2O. The precipitate was filtered, washed 
with Et2O and dried to provide the product as white solid; (yield: 15.34 g, 96%).
1H-NMR (D2O, 300MHz): δ = 1.22 (t, 3 H, J = 7.4 Hz, SCH2CH3), 2.98 (q, 2 H, J = 7.4 Hz, 
SCH2CH3), 4.11 (s, 2H, CH2COSEt) ppm; 13C-NMR (D2O, 75 MHz): δ = 13.3 (SCH2CH3), 
23.08 (SCH2CH3), 46.63 (CH2COSEt), 194.92 (COSEt) ppm; HRMS (ESI-TOF): m/z 
calculated for C4H9NOS: 120.0478 [M+H]+. Found 120.0476 [M+H]+.
S3.7 S-Ethyl-thiocarbonyl-ethyl amidoethyl dextran (Thioester dextran) (4) 2 (0.2 
g, 0.02 mmol) and 3 (0.23 g, 1.49 mmol) were dissolved in water (1 mL). After 
adjusting the pH value of 6.5 with sodium bicarbonate, EDC (0.14 g, 0.74 mmol) was 
added. After 1 h (0.14 g, 0.74 mmol) EDC was added again and the solution was 
S3.4 Quantification of CE-groups per dextran using 1H NMR spectroscopy In 
Figure S3.1 the quantification of CE groups per polymer using 1H NMR spectroscopy 
is depicted. The integral over the signals of anomeric protons (red) corresponds to 
the number of glucose units per polymer. Thus, the integral over the signal of 
CE-methylene groups (blue) can be used to calculate the degree of substitution.
Figure S3.1   Quantification of carboxyethyl groups using 1H NMR spectroscopy. 
Dextran (10 kDa) contains an average of 62 glucose units with 62 anomeric C(1)H protons (red). 
The number of carboxyethyl groups per polymer results from the relation of the integrals (blue: protons 
of CE methylene groups).
CE-groups / Dextran
CE-groups / Dextran9312
2
8525 .. =
HDO
Figure S3.2   HMQC-NMR spectra of 2. 
Overlay of HMBC (red) and HMQC (black) spectra showed that only signals of CE-methylene groups 
2´ correlated with the signals of the glucose units in position 2, but not in position 3 or 4 (Figure S3.3).
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1H NMR (CDCl3, 300 MHz): δ = 3.18 (t, 2 H, J = 5.8 Hz, NH3+CH2CH2), 3.79 (t, 2 H, J = 
5.8 Hz, NH3+CH2CH2N), 6.86 (s, 2 H, COCH2CH2CON) ppm; 13C NMR (CDCl3, 75 
MHz): δ = 34.92 (NH3+CH2CH2), 38.28 (NH3+CH2CH2), 134.6 (COCH2CH2CO), 172.53 
(COCH2CH2CO) ppm; HRMS (ESI-TOF): m/z calculated for C6H8N2O2: 141.0659 
[M+H]+. Found 141.0662 [M+H]+.
S3.9 Maleimidoethyl amidoethyl dextran (Maleimide dextran) (6) 2 (0.2 g, 0.02 
mmol) with 13 carboxy groups (0.26 mmol) and 5 (0.69 g, 2.69 mmol) were dissolved 
in water (1 mL). A pH of 6.5-7 was adjusted and EDC (0.26 g, 1.35 mmol) added. After 
1 h EDC (0.26 g, 1.35 mmol) was added again and the solution was allowed to stir 
for 4 h. The mixture was precipitated with methanol. The precipitate was washed 
with methanol and DMF. The solid was dissolved in water (2.5 mL) and purified 
over Sephadex® G-25. Lyophilization led to product as a white solid (yield: 0.19 g, 
82%). Quantification of maleimide groups per dextran was performed using 1H 
NMR spectroscopy (Figure S3.4, S3.5). It could be proven that under the used 
conditions all carboxy groups on the dextran reacted to the corresponding 
maleimidoethyl amide groups.
stirred over night. The product was precipitated with MeOH and washed several 
times with MeOH. The precipitate was dissolved in water (2.5 mL) and purified on 
a PD-10 column. After lyophilization a white solid was obtained as product (0.19 g, 
77%).
1H-NMR (D2O, 300 MHz): δ = 1.17 (t, 3 H, J = 7.4, SCH2CH3), 2.59 (t, 2 H, J = 5.4, 
CH2COSEt), 2.86 (q, 2 H, J = 7.4, SCH2CH3), 3.3-4.1 (m, C(2-6) H-dextran, OCH2CH2CO), 
4.92 (s, anomeric H unsubst.), 4.9-5.3 (m, anomeric H) ppm; 13C-NMR (D2O, 75 MHz): 
δ = 13.32 (SCH2CH3), 22.50 (SCH2CH3), 35.49 (CH2CONH), 48.70 (NHCH2CO), 59.95 
(C(6)), 64.97 (OCH2CH2CO), 68.98 (C(5)), 69.64 (C(3)), 70.87 (C(2)), 72.87 (C(4)), 97.16 
(C(1)), 174.14 (CONHCH2), 200.97 (COSEt) ppm;
S3.8 N-(2-Aminoethyl)maleimide (5) 14 (4.6 g, 19.2 mmol) was dissolved in DCM (35 
mL) at 0°C. To this solution, TFA (27 mL) was added and stirred 1 h while being 
allowed to reach room temperature. The mixture was concentrated and 
precipitated with cold Et2O (50 mL). Trituration with cold Et2O (3 x 50 mL) followed 
by evaporation of remaining solvent provided a white solid as product (yield: 2.5 g, 
93%).
Figure S3.3   HMBC (red) and HMQC (black) NMR spectra of 2.
C(2)H subst. 
C(1´)H 
C(1´)H2-C(2)H subst. 
C(1´)H2-C(2)H subst 
C(6) 
unsubst.
C(4)H unsubst. 
C(2)H unsubst. 
Figure S3.4   Quantification of reactive thioester groups per dextran on 4 using 
1H NMR spectroscopy. 
The integral over the signal of thioester-methylene protons (red) is equal to that over the signal of CE-methylene 
protons (blue). Therefore it could be proven, that all carboxy groups had reacted quantitatively.
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1H NMR (D2O, 300 MHz): δ = 2.48 (t, 2 H, J = 4.7, CH2CH2COOH), 3.3-4.1 (m, 
CH2CH2COOH, H (glucose units)), 4.98, -5.3 (m, anomeric H), 6.89 (s, 2 H, COCHCHCO) 
ppm; 13C NMR (D2O, 75 MHz): δ= 36.38 (CH2CONH), 37.12 (NHCH2CH2NH2), 39.97 
(NHCH2CH2N), 65.35 (C(6)H2), 65.58 (C(OCH2CH2CONH), 67.94 (C(4) Glucose), 71.41 
(C(5) Glucose), 72.57 (C(3)H Glucose), 74.68 (C(2) Glucose), 98.71 (C(1) Glucose), 179.29 
(CONH), 181.82 (CH2CONH) ppm;
S3.10 Peptide synthesis (7, 9, 10, 11, 12) Peptides were synthesized manually or by 
automated Fmoc-SPPS on TentaGel S Ram amide (0.2 mmol/g) resins. Fluorescein 
labeled peptides were synthesized using preloaded Nα-carboxyfluorescein-lysinyl 
amide TentaGel R Ram resin. To avoid aspartimide formation, Fmoc-groups were 
cleaved using 20% piperidine and 0.1 N acetic acid solution in DMF. To decrease 
impurities by sequence termination pseudo prolines were used. For the synthesis 
of BH3-peptides Asp17-Ser18 were substituted by Asp-Ser(ΨMe,MePro) and Ala17-Ser18 
were substituted by Ala-Ser(ΨMe,MePro) [S1]. Purification was performed by 
preparative RP HPLC. Peptides were identified by LCMS, HRMS and Maldi TOF.
S3.11 General procedure for synthesis of dextran-peptide conjugates (8a-g) 6 
(5 mg, 0.4 μmol) with 13 maleimide groups was dissolved in an MES buffer (1 mL, 
pH 6.5). After degassing, cysteinyl BH3(Fluo)-peptide (7 mg, 2 μmol for 8f and 3 mg, 
1 μmol for 8h) and cysteinyl nona-arginine amide 7 (2 mg, 1 μmol) were added 
under a nitrogen atmosphere. The pH value was checked and the mixture stirred 
for 16 h. The solution was concentrated and the product precipitated with MeOH. 
After several washing steps with MeOH and DMF the solid was dissolved in water 
(2.5 mL) and purified twice using PD-10 columns. The produced conjugate was 
obtained after lyophilization. Purity of the conjugates was checked using 
fluorescence correlation spectroscopy (FCS). Results of amino acid analysis showed 
how much peptide per polymer was coupled (see Table S3.3 (8f: 7 mg, 60%, 5 
BH3(Fluo)- and 2 R9 groups per dextran)). Cellular uptake was shown in Jurkat E6.1 
cells. Viability of cells was checked with Propidium iodide (Figure S3.6)
S3.12 N-(tert-Butoxycarbonyl)-ethyl-1,2-diamine (13) To an ice-cold solution of 1,2-
diaminoethane (27 mL, 400 mmol) in CHCl3 (400 mL) was added drop wise a 
solution of Boc-anhydride (8.7 g, 40 mmol) in CHCl3 (200 mL) over 3 h. After 
complete addition, the mixture was stirred at 0°C for 30 min and afterwards 
allowed to warm to room temperature overnight. The solvent was removed under 
Figure S3.5   Quantification of reactive maleimide groups per dextran on 
polymer 6 using 1H NMR spectroscopy. 
The integral over the signal of maleimide protons (red) is equal to that over the signal of CE-methylene protons (blue). 
Therefore it could be proven, that all carboxy groups had reacted.
!
Figure S3.6   Cellular uptake of 8f,g (10 μM total BH3-peptide concentration) after 
30 min in Jurkat E6.1 cells. 
Green fluorescent dextran was homogeneously distributed in the cells. The absence of propidium iodide staining 
in the cells showed their good viability.
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reduced pressure and the residue dissolved in 3 N Na2CO3 (300 mL) solution. The 
mixture was extracted with CHCl3 (3 x 200 mL), the organic phase dried over 
MgSO4 and evaporated to provide the product as a colorless oil (yield: 6.4 g, 98%).
1H NMR (300 MHz, CDCl3): δ = 1.35 (s, 9 H, CCH3), 2.69 (t, 2 H, CH2NHBoc), 3.07 (q, 2 
H, CH2CH2NHBoc), 5.11 (br s, 1 H, NHBoc) ppm; 13C NMR (75 MHz, CDCl3): δ = 27.87 
(CCH3), 41.36 (H2NCH2CH2), 42.93 (CH2NHBoc), 78.52 (CCH3), 155.73 (NHCOO) ppm;
HRMS (ESI-TOF): m/z calculated for C7H16N2O2: 161.1285 [M+H]+. Found 161.1285 g/
mol [M+H]+.
S3.13 1-(N-tert-Butoxycarbonyl)-2-aminoethyl) maleimide (14) Mono-protected 
N-Boc-ethyl-1,2-diamine 13 (5.1 g, 31.9 mmol) and Et3N (6.6 mL, 47.79 mmol) were 
dissolved in Et2O (60 mL) at 0°C. Maleic anhydride (3.1 g, 31.9 mmol) in 60 mL Et2O 
was added drop wise and the reaction mixture was stirred for 4 h while being 
allowed to reach room temperature. After concentrating the solution the residue 
was dissolved in acetone (150 mL). Et3N (8.8 mL, 63.7 mmol) was added and the 
mixture was heated to reflux. Acetic anhydride (4.5 mL, 47.8 mmol) was added and 
the solution was heated to reflux for 20 h. After the solvent was removed under 
reduced pressure chromatography of the dark brown oily residue over silica gel 
(EtOAc/hexane 1:1) gave the product as a white solid (yield: 3.7 g, 48.1%).
1H NMR (CDCl3, 300 MHz): δ = 1.4 (s, 9 H, CCH3), 3.34 (q, 2 H, J = 4.9 Hz, CH2CH2NHBoc), 
3.66 (t, 2 H, J = 5.1 Hz, CH2CH2NHBoc), 4.74 (br s, 1 H, NHBoc), 6.71 (s, 2 H, CHCHCON) 
ppm; 13C NMR (CDCl3, 75 MHz): δ = 27.83 (CCH3), 37.5 (CH2CH2NHBoc), 38.91 
(CH2CH2NHBoc) 79.07 (CCH3), 133.96 (CHCHCON), 155.46 (NHCOO), 170.34 (CONCO) 
ppm; HRMS (ESI-TOF): m/z calculated for C11H16N2O4: 241.1183 [M+H]+. Found 
241.1188 [M+H]+.
S3.14 N-tert-Butoxycarbonyl-glycine ethyl-thioester (15) N-Boc-glycine (24.7 g, 
141.5 mmol) and carbonyldiimidazole (25 g, 154.2 mmol) were stirred in dry THF 
(125 mL) at 20°C under a nitrogen atmosphere for 30 min. Mercaptoethanol (31.39 
mL, 424.3 mmol) was added and the mixture was stirred over night. After addition 
of 4 N NaOH (250 mL), the solution was rapidly extracted with DCM (3 x 150 mL). 
The organic phase was dried over MgSO4, evaporated and redissolved in ethyl 
acetate. The solution was filtered over silica gel and the solvent removed under 
reduced pressure to provide pure product as yellowish oil; (yield: 23 g, 75%).
1H NMR (D2O, 300 MHz): δ= 1.23 (t, 3 H, J = 7.2 Hz, SCH2CH3), 1.44 (s, 9 H, OC(CH3)3), 
2.89 (q, 2 H, J = 7.2, SCH2CH3), 4.00 (s, 2 H, NHCH2COSEt), 5.19 (br s NHBoc) ppm; 
13C NMR (D2O, 75 MHz): 14.03 (SCH2CH3), 22.47 (SCH2CH3), 27.80 (C(CH3)3)), 49.86 
(CH2NHBoc), 79.76 (C(CH3)3), 155.04 (NHCOOC), 197.82 (COSEt) ppm; HRMS (ESI-TOF): 
m/z calculated for C9H17NO3S: 220.1002 [M+H]+. Found 220.1004 [M+H]+.
S3.15 Synthesis of nona-arginine dextran conjugates using maleimide thiol 
coupling (16, 17) 6 (10 mg, 1 μmol) loaded with 12 maleimide groups (12 μmol) was 
dissolved in MES buffer (1 mL, pH 6.5). After degassing, cysteinyl nona-arginine 
amide 7 (6 mg, 5 μmol) was added under nitrogen atmosphere. The pH value was 
checked and the mixture stirred for 16 h. The solution was concentrated and the 
product precipitated with MeOH. After several washing steps with MeOH and DMF 
the solid was dissolved in water (2.5 mL) and purified twice using PD-10 columns. 
After lyophilization the resulting conjugate was obtained as a white powder. 
Results of amino acid analysis showed how much peptide per polymer was coupled 
(see Table S3.4: 8 mg, 68%, 3 R9 groups per dextran).
S3.16 Synthesis of nona-arginine dextran conjugates using native chemical 
ligation (18, 19) Thioester dextran 4 (10 mg, 1 μmol) loaded with 12 thioester 
groups (12 μmol) was dissolved in phosphate buffer (1 mL, 100 mM KH2PO4/ Na2PO4 
pH 7.4). After degassing, cysteinyl nona-arginine amide 7 (6 mg, 5 μmol), TCEP (9 
mg, 50 eq.) and 4-mercaptophenyl acetic acid (5 mg, 32 eq.) were added under a 
nitrogen atmosphere. The pH value was checked and the mixture stirred for 16 h. 
The solution was concentrated and the product precipitated with MeOH. After 
Table S3.3   Results of amino acid analysis for 8a-i.
Compound
#
Name Concentration / mg  
peptide polymer [nmol]
Composition of 
peptide polymers
Cys-BH3-
peptide
Cys-R9 
peptide
dextran BH3-
groups  
per  
dextran
R9-groups 
per  
dextran
8a Dex-5B* 211 - 45 4.7 -
8b Dex-5mB* 231 - 43 5.3 -
8c Dex-2B* 124 - 68 1.9 -
8d Dex-2mB* 149 - 63 2.1 -
8e Dex-2R* - 151 77 - 1.9
8f Dex-5B-2R 175 58 37 4.7 1.6
8g Dex-5mB-2R 182 72 35 5.2 2.1
8h Dex-2B-2R 117 83 51 2.3 1.6
8i Dex-2mB-2R 103 112 53 1.9 2.1
*dextran loaded with peptides and N-cysteinyl-lysinyl-5(6)-carboxyfluorescein (H2N-CK(Fluo)-CONH2)
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S3.19 Fluorescence Correlation Spectroscopy FCS measurements were performed 
at room temperature on an LSM 510-ConfoCor 2 system and on an LSM 
710-ConforCor 3 system (Carl Zeiss MicroImaging, Jena). Fluorescent BH3-peptides, 
BH3-dextrans 8f-i respective mixtures of unreactive CED 2 and fluorescent 
BH3-peptides were dissolved in water at a concentration of 10-8 mol/L. Each solution 
on cover slips (50 μL per sample) were fixed in a measurement chamber. An argon 
ion laser (488 nm) was used for excitation of fluorescein. Calculations of the auto-
correlation function as well as fitting of the autocorrelation function were 
performed using ZEN 2009 software. Correlation functions accounting for free 
diffusion in three dimensions were fitted for one component and yielded 
diffusional autocorrelation times of particles through the confocal volume (Figure 
S3.7). In two component fittings, it could be shown that the investigated peptide 
polymers (e.g. 8f) contained no free peptides. 
S3.20 Electroporation 106 Jurkat E6.1 cells were resuspended in Nucleofector 
Solution V (100 μL). Peptide or peptide polymer was added in the respective 
concentration and the solution was pipetted into LONZA nucleofection cuvettes. 
Nucleofection was performed in an AMAXA Nucleofector using program X-001 in 
accordance with the recommendations of the manufacturer. Following 
nucleofection 900 μL medium were added carefully and the cells incubated for 5 
min at RT. Subsequently cells were washed and resuspended in fresh medium.
S3.21 Annexin-V Assay Electroporated Jurkat E6.1 cells were washed with medium, 
transferred to a 24-well tissue culture plate and incubated for 14 h in RPMI 
medium. The cells were washed in cold PBS buffer and incubated for 15 min with 
5 μL AnnexinV Alexa Fluor 647 in 95 μL Annexin-binding buffer (10 mM HEPES, 
140 mM NaCl, 2.5 mM CaCl2, pH 7.4) on ice. Following the Annexin-binding buffer 
(400 μL) was added to each sample. Analysis was performed by flow cytometry on a 
FACS Calibur System (Becton Dickinson, Heidelberg). Using nucleofection for 
peptide delivery, no stimulation of apoptosis was observed in the Annexin-V assay 
several washing steps with MeOH and DMF the solid was dissolved in 2.5 mL water 
and purified twice using PD-10 columns. Resulting conjugate was obtained after 
lyophilization. Results of amino acid analysis showed how much peptide per 
polymer was coupled (see Table S3.5: 8 mg, 73%, 1.2 R9 groups per dextran).
S3.17 Comparison of both ligation methods To compare native chemical ligation 
(NCL) and maleimide thiol coupling 4 and 6 were reacted with different amounts 
of cysteinyl nona-arginine amide. Polymers were worked up as previously described 
and analyzed using amino acid analysis. Under optimized conditions 25% of the 
available cysteinyl peptides were coupled to S-Ethyl-thiocarbonyl-ethyl dextran 
using NCL. In contrast to that 75% of the available cysteinyl peptides were coupled 
on 4 using maleimide thiol coupling. Advantages and disadvantages of both 
ligation methods are summarized in Table S3.6.
S3.18 Laser scanning microscopy  Jurkat E6.1 cells seeded in chambered cover 
slips were incubated with peptides or peptide dextrans, dissolved in HEPES buffer, 
for 30 min at 37°C under a LSM-510 or LSM 710 laser scanning microscope (Carl 
Zeiss, Jena, Germany) equipped with a 63 water objective. Immediately after 
adding the substance, pictures were recorded every 60 sec for 30 min. After 
removing peptide solution and washing cells with HEPES buffer, propidium iodide 
was added to prove the viability of treated cells and their membrane integrity. 
Table S3.4   Results of amino acid analysis for nona-arginine dextran prepared 
from 6.
weighed sample Loading Coupling results
Compound # c(Maleimide dextran) 
[mM]
c(R9 peptide)
[mM]
CR9/polymer CR9/polymer
16 1 5 3.1 62 %
17 1 7 5.2 75 %
Table S3.5   Results of amino acid analysis for nona-arginine dextran prepared 
from 4.
weighted sample Loading Coupling results
Compound # c(Thioester dextran) 
[mM]
c(R9 Peptide)
[mM]
CR9/polymer CR9/polymer
18 1 5 1.2 25 %
19 1 7 2.1 30 %
Table S3.6   Comparison of NCL and maleimide thiol coupling.
Native Chemical Ligation (NCL) Maleimide Thiol coupling
Amide formation Thioether formation
pH 7.2-7.4 pH 5.5-7 
Reducing agents necessary (e.g. TCEP) No reducing agents necessary
Favored for coupling of peptides containing 
more than 1 N-terminal cysteine 
Favored for coupling of peptides containing 
only 1 thiol group.
Coupling efficiency ~25% Coupling efficiency ~75%
88 | Chapter 3 Multivalency boosts peptide activity | 89
either by BH3-peptide 9, mBH3-peptide 10, or by the peptide polymer 8c with 5 
copies of mBH3 (Dex-5mB). In contrast, polymer 8a with 5 copies of BH3 (Dex-5B) 
showed significant apoptosis after 8 h, respectively, in confocal laser scanning 
microscopy and in flow cytometry 66% of all cells at an overall peptide concentrations 
of 2.5 μM, corresponding to a polymer concentration of 0.5 μM. At a polymer 
concentration of 5 μM ca. 75% of all cells went into apoptosis (Figure S3.8B). 
S3.22 Caspase-3 assay 106 Jurkat E6.1 cells were incubated with peptide or 
conjugate in the respective concentration for 6 h. After washing with ice-cold PBS 
buffer, the cells were spun down at 1900 rpm for 5 min and pellets resuspended in 
lysis buffer (20 mM Tris/HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 protease 
inhibitor cocktail tablet (Roche Diagnostics Mannheim, Germany) per 50 mL 
buffer, pH 7.7). After 30 min cooling on ice, the lysate was separated from the 
remaining solid by centrifugation and protein content estimated by commercially 
available Bradford Protein Assay Kit (Bio-Rad Laboratories Munich, Germany). 30 
μg protein aliquots of each sample were diluted in caspase activity buffer (20 mM 
HEPES, 100 mM NaCl, 10 mM dithiothreitol, 10% glycerol, pH 7.5). Finally, 
fluorogenic caspase-3 substrate (Ac-DEVD-AMC) was added to a concentration of 2 
μM. Cleavage efficiency of active caspase-3 in solution was measured immediately 
after addition of the substrate and after 3 h at 37°C by measuring fluorescence 
increase using a Synergy 2 single channel microplate reader (BioTek Instruments, 
Winooski, USA).
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Figure S3.7   Fits of autocorrelation functions of fluorescent BH3-peptide 9, 
BH3-dextran 8f and respective mixtures of CED 2 and 9.
Figure S3.8   Quantification of fluorescein fluorescence in Jurkat E6.1 cells 
immediately after elelctroporation (A) and quantification of 
apoptosis by measuring Annexin-V staining in nucleofected Jurkat 
E6.1 cells after 8 h (B).
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4.1 Introduction
Peptide and protein-based drugs have become important therapeutic agents, 
however, short circulating half-life due to clearance in the kidney, antigenicity 
and proteolysis present serious obstacles in their application [1]. An established 
strategy to overcome these problems is the attachment of polyethylene glycol (PEG) 
to proteins, which shields the protein surface from proteases and from inducing 
an adaptive immune response [2-4]. In this context, it has been shown that 
branched PEGs protect far better than linear PEGs of the same molar mass due to 
the so-called “umbrella effect” [5, 6]. If the molecular weight of the PEG is about 30 
kDa or higher, renal clearance is dramatically decreased [7]. Similarly, also other 
polymeric materials like poly(N-(2-hyroxypropyl)methacrylamide) (HPMA) [8] or 
even biopolymers themselves, e.g. random coils consisting of proline, alanine and 
serine residues (PASylation) [9], have been used for stabilization, shielding and 
solubilization of biopolymers. In addition to the modification of biopolymers, the 
benefits of PEGylation have also been exploited in the design of various drug 
delivery vehicles [10, 11].
 Currently, many protein PEGylation strategies address nucleophilic side 
chains of canonical amino acids, i. e. amine or thiol groups that are reacted with 
electrophilic PEG-derivatives [12]. However, due to lack of site-specificity of these 
approaches the biological activity of the proteins can be decreased; also, the 
identification of the PEGylation-site and -extend of the protein conjugates is 
challenging [13]. As an alternative, site-specific PEGylation strategies mostly rely 
on the expression of proteins containing non-canonical amino acids. These carry 
reactive handles that can be PEGylated chemoselectively, most commonly used 
areketones [14], alkynes [15, 16] and azides [14, 15, 17]. In our own laboratory, we 
have contributed to these methods by reaction of a p-azido-phenylalanine (Pap) 
containing protein in a Staudinger-phosphite reaction with PEG-phosphites, 
which proceeded in excellent yields and chemoselectivity [18-21]. The Stauding-
er-phosphite PEGylation strategy has the advantage that inexpensive linear 
PEG-monomethyl ethers can be used for the synthesis of symmetric PEG-phosphites, 
which lead after the chemoselective Staudinger reaction to a promising PEG 
branching point by simultaneous attachment of two PEG-chains to the protein via 
a phosphoramidate linkage (Figure 4.1).
 In the current paper we first intend to probe the impact of phosphoramidate- 
linked PEG-chains on the stability of biologically active peptides in cell lysates. 
Furthermore, we address the rarely investigated intracellular distribution and 
finally the biological activity of the PEGylated peptides in an intracellular 
environment, proposing that the branching point ensures significantly increased 
peptide stability with small to medium-sized PEG chains while maintaining 
Abstract
PEG intracellularly! Although long known to enhance residence half-life of 
peptides in serum and lysates, the effect of PEGylation on biological probes in cells 
has received only limited attention. In this study, we show that phosphorami-
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as well as high apoptotic activity after introduction into cells.
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cellular peptide distribution by confocal microscopy. The phosphoramidate- 
branched PEG chains were positioned at the N-terminus of the peptides, which 
contained two PEG monomethylether-chains consisting of either 4 (in the BH3 or 
mBH3 PEG200 peptide, for nomenclature see Figure 4.1), 15 (in (m)BH3 PEG750) or 
45 (in (m)BH3 PEG2000) ethylene glycol units (polymeric distribution, averages are 
given). A dimethyl-phosphoramidate unit served as an unPEGylated control 
peptide ((m)BH3 unPEGylated), to which no stabilizing polymer was coupled.
4.2 Results and Discussion
Fluorescent peptides with an N-terminal Pap residue were synthesized on a car-
boxyfluorescein-lysine containing Rink amide resin [31] by standard Fmoc-based 
SPPS (Scheme S4.1). Subsequent Staudinger-phosphite PEGylation with readily 
available PEG-phosphites (see S4) is possible by employing as substrates either a 
protected aryl-azido-BH3-peptide on the solid support or an unprotected peptide 
in solution. First, we focused on the Staudinger-phosphite reaction on the solid 
support (Scheme 4.1A left), because an excess of the PEG-phosphites as well as the 
PEG-alcohol that is formed during the reaction can be washed away directly [32]. 
Unfortunately, despite various efforts of optimization, the occurrence of several 
truncated peptidic side products during SPPS led to an inseparable mixture of 
modified peptides after the Staudinger-phosphite PEGylation on the solid support, 
which is caused by the broad retention time of the PEGylated molecules (Scheme 
4.1B). To overcome this problem, we decided to take advantage of the chemoselec-
tivity of the Staudinger-phosphite reaction and performed the PEGylation after 
the azido-containing peptides had been cleaved from the resin and purified by 
HPLC (Scheme 4.1A right). To our delight we found that the reaction proceeded 
very smoothly in 100 mM TRIS Buffer at a pH of 8.4 with 30 equivalents of phosphite 
added in three portions, delivering a raw product which could easily be purified 
by preparative HPLC (Scheme 4.1C). Although this synthetic route still requires an 
additional final purification step, we were able to obtain pure PEG-phosphorami-
date modified peptides as verified by LC-HRMS (see S4).
 Highly PEGylated probes have previously been reported to form aggregates or 
micelle-like structures [33] which may strongly influence the in vivo activity of any 
biologically active molecule. In light of the subsequent cellular experiments, we 
first investigated the behavior of the PEG-peptide conjugates in solution. For this 
purpose, we employed dynamic light scattering (DLS) that enables the determination 
of the hydrodynamic radius to probe whether the conjugates formed aggregates. 
At a concentration of 1 mM in PBS, all conjugates were present at monomers, 
demonstrating that all tested BH3 peptides have no tendency to aggregate (see S4).
peptide function in cells. Specifically, we decided to apply the Staudinger-phosphite 
PEGylation strategy to the modification of a synthetically challenging proapoptotic 
peptide. Our 22-amino acid model peptide was derived from the BH3-interacting 
domain of the pro-apoptotic protein Bid, for which the measurement of caspase-3 
activity serves as the functional read out for induction of controlled cell death [22]. 
Caspase-3 is an effector caspase, activated during the early phase of apoptosis [23]. 
Bid, the ‘activator’ proapoptotic BH3-only Bcl-2 protein can directly interact with 
Bax, a multidomain proapoptotic Bcl-2 effector protein to form Bax homo-oligomers 
in the outer mitochondrial membrane inducing release of cytochrome C and 
subsequent activation of caspases [24, 25]. We have previously used Bid-BH3 
peptides to investigate the impact of conjugated linear HPMA scaffolds [22] and 
multivalency [26] on intracellular activity. Both studies demonstrated that inside 
the cell, the free peptide does not show activity. Other studies employed 
conformational constraints [27] or membrane anchoring [28] as principles to yield 
activity. In addition, linear PEGylated BH3-peptides have previously been used in 
combination with cancer cell-directing hormones and drugs to induce apoptosis 
in cancer cells [29, 30]. Given the general requirement for activity-enhancing 
peptide modifications, this peptide therefore provides a highly interesting test 
case for assessing the impact of PEGylation on intracellular peptide activity.
 The BH3 peptide as well as a mutated non-active analog (mBH3) carried a 
 carboxyfluorescein fluorophore at the C-terminus (Figure 4.1) to allow the analysis 
of peptide degradation by fluorescence correlation spectroscopy (FCS) and intra- 
Figure 4.1   Structure and nomenclature of PEGylated phosphoramidate-linked 
BH3 peptide conjugates used in this study.
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 Next we probed the stability of the PEGylated and unPEGylated peptides 
against proteolytic cleavage upon incubation in crude cell lysate, which was 
determined by fluorescence correlation spectroscopy (FCS) [34]. FCS derives 
information on the concentration and diffusion behavior of molecules from the 
analysis of temporal fluctuations of fluorescence resulting from diffusion of 
particles through a subfemtoliter confocal detection volume.
 PEGylation by the Staudinger-phosphite reaction was found to dramatically 
increase the proteolytic half-life of the peptide (Figure 4.2a and 4.2b). There was a 
positive correlation between PEG chain length and increase in stability (Figure 
4.2b). In comparison to the unPEGylated control peptide, BH3 PEG200, BH3 PEG750 
and BH3 PEG2000 showed increases in half-life by factors of 1.5, 11, and 57. Addition 
of a high concentration of proteinase K resulted in a complete degradation of the 
PEGylated BH3 conjugates (Figure 4.2a and S4) demonstrating that PEGylation 
inhibits, but not completely impedes accessibility of the peptide to proteases. 
Differences observed between the wild type and the mutant conjugates were 
within the limits of significance (Table S4.1 and S4.2).
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Figure 4.2   Proteolytic stability for the unPEGylated and PEGylated peptides. 
a) Representative proteolytic degradation experiment using 2 μM peptides incubated with crude cell lysates of Jurkat 
E6.1 cells and analysis using FCS. b) Fold increase in average relative half-life and S.D. of the unPEGylated BH3 peptide 
and the PEGylated conjugates of 3 independent experiments.
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h and also, after 6.5 h the major part of the fluorescence was still homogenously 
distributed (Figure 4.3); only with BH3 PEG2000 there was some heterogeneity in 
the nuclear distribution after 6.5 h. We also observed a considerably higher 
intracellular retention of BH3 PEG2000 compared to the unPEGylated or BH3 
PEG750 peptides, in which fluorescence of the latter two peptides showed similar 
intracellular residence times (Figure 4.3, unadjusted 6.5h; Figure S4.3). Previously, 
we have observed for BH3 peptides coupled to an HPMA polymer, that an increase 
in proteolytic stability was not reflected by a prolonged intracellular residence 
time of fluorescence [22]. Since we observed such a correlation for several different 
peptides, this finding indicates that for the unPEGylated BH3-peptide a proteolytic 
fragment is formed that does not readily cross the plasma membrane [34].
 Next, we addressed the effect of a stabilizing PEG-phosphoramidate modification 
on the intracellular activity of the BH3 peptide. For this experiment, we focused 
on the BH3 peptides with the smallest PEG chains that showed sufficient stability, 
since PEG modifications can be associated with loss of activity of the conjugated 
proteins [36]. Consequently, we chose the BH3 PEG750 peptide, which displayed a 
considerable stabilization in cell lysates.
 After electroporation with BH3 PEG750 as well as the mutated counterpart 
(mBH3), cells were incubated for 6 h, and apoptosis-inducing activity was measured 
by a caspase-3 assay. Electroporation experiments were performed with 100 as 
well as 300 μM peptide solutions. Additionally, 0.5 μM staurosporine acted as a 
positive control for caspase-3 activation in Jurkat cells. Our studies demonstrated 
that only BH3 PEG750 showed a concentration-dependent significant and specific 
increase of caspase-3 activity in comparison to mock electroporated cells (Figure 
4.4a, Tables S4.3-S4.5). In contrast, introduction of the unPEGylated BH3 peptide 
led only to a slight increase in caspase-3 activation relative to the mock cells; 
however, this increase was non-specific at the lower concentration, since the same 
level of activity was also observed for the mBH3 unPEGylated. Specific activity 
could only be seen for the unPEGylated BH3 peptide at concentrations as high as 
300 μM (Figure 4.4a). In light of the high peptide concentrations one should note 
explicitly that for molecules of the size used in this study, only a minor fraction is 
delivered into the cytoplasm. Concentrations inside the cell will therefore be 
much lower than in the electroporation cuvette (for example, for peptides of 20 
amino acids in length, intracellular peptide concentrations were less than a fifth 
of those in the electroporation cuvette, see Ref. 34).
 Finally, we compared intracellular activity induced by BH3 PEG750 and BH3 
PEG2000 delivered at a concentration of 100 μM. Interestingly, in spite of the longer 
intracellular retention time of fluorescence, PEG2000 did not confer a higher 
activity (Figure 4.4b).
The next step in our study addressed the intracellular distribution of phosphora-
midate PEGylated peptides, especially, since long-chain PEGs are known to induce 
membrane fusion [35]. Based on the increased stability in cell lysate, we focused on 
the BH3 PEG750 and BH3 PEG2000 conjugates. Cellular delivery was facilitated by 
electroporation, in which a short electric pulse leads to the transient formation of 
pores in the plasma membrane that act as a size filter. To investigate the 
time-dependent intracellular peptide distribution, Jurkat cells were electroporated 
with 100 μM of BH3 PEG750, BH3 PEG2000, unPEGylated BH3 or just fluorescein as 
a control and monitored periodically for 6.5 h using live-cell confocal microscopy 
(Figure 4.3). To our delight, 30 min after electroporation all of the probed peptide 
conjugates showed a homogenous distribution throughout the cytoplasm and 
nucleus comparable to free fluorescein. As observed previously [22] fluorescein 
exited the cells in less than an hour. In contrast, both the unPEGylated BH3 and 
the PEGylated counterparts showed a homogenous distribution throughout the first 5 
Figure 4.3   Time-dependent intracellular distribution of unPEGylated BH3 and 
conjugates. 
Jurkat E6.1 cells were electroporated with 100 μM of a) fluorescein or b) unPEGylated BH3 c) BH3 PEG750 or d) BH3 
PEG2000 and time-chased confocal microscopy images were recorded over 6.5 h at the indicated time points. Scale 
bar corresponds to 10 μm. Each time point represents images with same scale bar. Brightness and contrast 
parameters were adjusted to visualize the localization of the peptides for 6.5 h. Unadjusted panel refers to images 
showing cell-associated intensity without brightness/contrast adjustments.
a)
b)
c)
d)
30 min 1.5 h 2.5 h 6.5 h
incubation time unadjusted
6.5 h
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4.3 Conclusions
In summary, we have successfully probed the impact of small to medium-sized 
oligo- and polyethylene glycol chains on the stabilization against proteolysis in 
cell lysates and the intracellular activity of apoptosis-inducing BH3-peptides. Phos-
phoramidate-linked PEGylated BH3-peptides were obtained by the chemoselective 
Staudinger-phosphite reaction in solution resulting in a more than 57 fold increase 
in the half-life of the peptide in Jurkat cell lysate when two only medium-sized PEG 
2000 chains (n=45) were attached. Subsequently, we probed the intracellular 
proapoptotic activity of the PEGylated BH3 peptides. For BH3 PEG750 it could be 
demonstrated that N-terminal phosphoramidate PEGylation leads to a significant 
concentration dependent increase of intracellular activity, while enlarging the 
molecular weight of the peptide only by a factor of 1.5 compared to the unPEGylated 
peptide. Moreover, medium-sized branched phosphoramidate PEG-chains retained 
the homogenous cytoplasmic distribution of the peptide. Taken together, these 
results demonstrate the potential of phosphoramidate-linked PEGylated 
biopolymers in the selective targeting of intracellular biological pathways of 
pharmaceutical and clinical importance. Further studies in combining the 
Staudinger-phosphite PEGylation strategy with direct cellular uptake is currently 
underway in our laboratories.
Figure 4.4   Activation of caspase-3 in electroporated Jurkat E6.1 cells after 6 h of 
incubation. 
For the individual experiments fold increase in caspase-3 activity was normalized to total activity and to respective 
protein content. Activity scale for Y-axis corresponds to value x 10-2. a) Caspase-3 activation by BH3 versus mBH3 
unPEGylated and PEG750 conjugated peptides. Results represent mean ± S.E. for three independent experiments. 
b) Comparative caspase-3 activity for BH3 unPEGylated versus BH3 PEG750 and BH3 PEG2000 of two independent 
experiments. Results represent mean ± S.E.
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S4 Supporting Information
S4.1 General information
Reagents and solvents, unless stated otherwise, were commercially available as 
reagent grade and did not require further purification. The resins as well as 
Fmoc-protected natural or unnatural Lamino acids were purchased from 
Novabiochem or IRIS BioTech. 
NMR 1H, 13C and 31P-NMR spectra were recorded on a Jeol ECX-400 400 MHz 
spectrometer (JEOL corporation, Akishima, Tokyo, Japan) at ambient temperature.
SPPS Peptides were synthesized with an ABI 433A Peptide Synthesizer (Applied 
Biosystems, Inc., Foster City, California, USA) via standard Fmoc-based conditions 
(Fast-moc protocol with HOBt/HBTU conditions) on a Rink Amide resin preloaded 
with fluorescein as described below.
Preparative HPLC purification of the peptides was performed on a JASCO LC-2000 
Plus system (JASCO, Inc., Easton, Maryland, USA) using a reversed phase C18 
column (Kromasil material) or reversed phase C4 column (Jupiter, Phenomenex 
Inc., Torrance, California, USA) at a constant flow of 16 mL/min) using water and 
acetonitrile with 0.1% TFA) applying an optimized gradient using a Smartline 
Manager 5000 with interface module, two Smartline Pump 1000 HPLC pumps, a 
6-port-3-channel injection valve with 1.0 mL loop, a UV detector (UV-2077) and a 
high pressure gradient mixer (All Knauer, Berlin, Germany).
Analytical HPLC Purity of the peptides was determined by LC/UV analysis. The 
system consisted of a Waters 600S controller, a Waters 616 pump, a Waters 717plus 
autosampler, a Waters 2489 UV/Visible detector (all Waters Corporation, Milford, 
Massachusetts, USA), a Jasco FP-2020Plus fluorescence detector (JASCO Inc., Easton, 
Maryland, USA) and a C18-column (Eclipse, Agilent Technologies, Santa Clara, 
California, USA). Data was processed by Empower Pro software (Waters 
Corporation). All runs were performed at constant flow of 1.0 mL/min: 5 min at 
10% acetonitrile in water (with 0.1% TFA), gradient 10 – 100% acetonitrile in water 
(with 0.1% TFA) over 30 min. UV/Vis absorbance spectra were collected at 220 nm, 
fluorescence of carboxyfluorescein was collected at 492 nm (excitation) and 517 
nm (emission).
High-resolution mass spectra (HRMS) were collected with an Agilent 6210 ToF LC/
MS system (Agilent Technologies, Santa Clara, California, USA) using as an eluent 
water and acetonitrile in a 1:1 mixture (with 0.1 % TFA) at a flow rate of 0.2 mL/min.
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Dynamic Light Scattering measurements were performed on a Malvern Instruments 
Zetasizer nano ZS (Malvern Instruments Ltd., Worcestershire, UK) with a 
backscatter detection angle of 173° at a temperature of 25°C using a 4 mW 632.8 
nm HeNe laser. Each measurement was conducted at a concentration of 1 mM of 
BH3 conjugate in PBS buffer at least three times. The size distribution by intensity 
was calculated by the software based on the correlation functions using the 
Multiple Narrow Modes algorithm consisting of a non-negative least squares fit 
[S1]. This size distribution by intensity was converted to a distribution by volume 
employing the Mie theory [S2].
S4.2 Synthesis of PEG-peptide conjugates
S4.2.1 Synthesis of azidopeptides
A Rink Amide resin (0.1 mmol) was modified with a carboxyfluorescein-moiety 
according to a procedure developed by us before. [S3]. For this, first a Rink Amide 
resin (0.1 mmol) was preloaded with Fmoc-Lys-(Dde). After Fmoc was deprotected, a 
carboxyfluorescein was coupled to the amine. To facilitate SPPS, the hydroxylgroups of 
the carboxyfluorescein were protected with trityl groups. Then the Dde-group was 
removed using hydrazine. Finally, a short PEG-linker (Fmoc-O2Oc-OH) was coupled 
to the amine.
 The modified resin was then applied to solid phase peptide synthesis on an 
Applied Biosystems peptide synthesizer using 10 equivalents of Fmoc-amino acid 
as well as HOBt/HBTU and DIPEA as coupling reagents in each step. Finally, para- 
azidophenylalanine was coupled manually (3.0 equivalents of Fmoc-protected 
amino acid, DIC and HOBt in DMF, 2 x 1 h). After deprotection, total cleavage was 
done (3 mL 95% TFA, 2% TIS, 2% DTT, 1% MeSPh, 3h), followed by precipitation of 
the peptide in cold ether.
azido-BH3-peptide was purified by semi-preparative HPLC (35 to 55% of acetonitrile 
in water containing 0.1% TFA on a RP-C18 column) to yield in a yellow trifluoroac-
etate: 30.84 mg; 7.91 μmol; yield = 7.9%; molar mass (peptide) = 3.33 kDa; molar 
mass (TFA5 salt) = 3.90 kDa. HRMS: m/z: 1109.8703 [M+3H]3+ (calcd. m/z: 1109.8708), 
see appendix for spectra.
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S4.2.2 Synthesis of PEG-phosphites
Trimethylphosphite was purchased from Sigma Aldrich and used without further 
purification.
 All PEG-phosphites were synthesized in a thermal in	substance reaction, based 
on a modified protocol of Skopek et. al [S4]. In order to avoid hydrolysis of the 
product, no purification was done. Due to the chemoselective character of the 
Staudinger-phosphite reaction, impurities do not interfere in the reaction and can 
be removed easily after the reaction.
Tris(tetraethylene glycolmethylether) phosphite (n = 4), tris(PEG200)phosphite 
Carefully dried tetraethylene glycolmethylether (3 eq., 3.0 mmol, 0.64 mL) and 
hexamethylphophortriamide (1 eq., 1.0 mmol, 0.18 mL) are stirred under argon 
stream at 70°C for 3 h. The product was recovered as clear oil (1.0 mmol, 0.67 g). 
1H-NMR (400 MHz, [D]-acetonitrile): d = 3.56-3.43 (m, 48.3, -OCH2CH2O-); 3.26 (s, 9.0, 
-OCH3). 31P-NMR (400 MHz, [D]-acetonitrile): d = 140.
Tris(polyethylene glycolmethylether) phosphite (n ≈ 15), tris(PEG750)phosphite 
The precise Molar Mass (number average molecular weight) of the polyethylene 
glycolmethylether was determined with 1H-NMR spectroscopy: Mn = 773 g/mol. 
Carefully dried polyethylene glycolmethylether (3 eq., 0.406 mmol, 0.314 g) and 
hexamethylphophortriamide (1 eq., 0.135 mmol, 24.5 μL) are stirred under argon 
stream at 110°C for 72 h. The product was recovered as white paraffinic solid (0.133 
mmol, 0.311 g). 1H-NMR (400 MHz, [D]-acetonitrile): d = 3.58-3.57 (m, 198.9, 
-OCH2CH2O-); 3.32 (s, 9, -OCH3). 31P-NMR (400 MHz, [D]-acetonitrile): d = 140.
Tris(polyethylene glycolmethylether) phosphite (n ≈ 45), tris(PEG2000)phosphite 
The precise Molar Mass (number average molecular weight) of the polyethylene 
glycolmethylether was determined with 1H-NMR spectroscopy:  Mn = 2208 g/mol. 
Carefully dried polyethylene glycolmethylether (3 eq., 0.389mmol, 0.859 g) and 
hexamethylphophortriamide (1 eq., 0.130 mmol, 23.5 μL) are stirred under argon 
stream at 110°C for 72 h. The product was recovered as white solid (0.131 mmol, 
0.876 g). 1H-NMR (400 MHz, [D]-acetonitrile): d = 3.52-3.51 (m, 565.8, -OCH2CH2O-); 
3.26 (s, 9.0, -OCH3). 31P-NMR (400 MHz, [D]-acetonitrile): d = 141.
before purification: LC-UV at 220 nm using an optimized gradient of 35 to 55% of 
acetonitrile in water containing 0.1% TFA on a RP-C18 column
after purification: LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 
0.1% TFA on a RP-C18 column
azido-mBH3-peptide 0.05 mmol of the batch was purified by semi-preparative 
HPLC (10 to 60% of acetonitrile in water containing 0.1% TFA on a RP-C18 column) 
to yield in a yellow trifluoroacetate: 12.24 mg; 3.26 μmol; yield = 6.5%; molar mass 
(peptide) = 3.18 kDa; molar mass (TFA5 salt) = 3.75 kDa. HRMS: m/z: 1061.1892 
[M+3H]3+ (calcd. m/z: 1061.1908), see appendix for spectra.
LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 0.1% TFA on a 
RP-C18 column
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containing 0.1% TFA on a RP-C18 column) yielded the peptide as yellow trifluoroac-
etate (0.71 mg; 0.16 μmol; yield 14.8 %; molar mass (peptide) = 3.76 kDa; molar mass 
(TFA5 salt) = 4.33 kDa) with very good purity. HRMS: m/z: 1254.6102 [M+3H]3+ 
(calcd. m/z: 1254.6098), see appendix for spectra.
LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 0.1% TFA on a 
RP-C18column
BH3 PEG750  BH3-azidopeptide (TFA5 salt; 4.08 mg; 1.05 μmol) was dissolved in 1.5 
mL of Tris buffer (100 mM; pH = 8.4) and tris(PEG750)phosphite (94 mg; 42 μmol; 
40 eq.) was added. The reaction mixture was incubated at 30°C for 16 h. The 
mixture was filtered over a C18-Sep-Pak column (Waters, 2 g) in order to remove 
buffer and some parts of PEG-alcohol, the resulting solution was lyophilized 
subsequently. Purification via semi-preparative HPLC (10 to 60% of acetonitrile in 
water containing 0.1% TFA on a RP-C4 column) yielded the peptide as yellow triflu-
oroacetate (1.15 mg; 0.21 μmol; yield 20.1%; molar mass (peptide) = 4.89 kDa; molar 
mass (TFA5 salt) = 5.46 kDa) with good purity. HRMS: polymeric distribution, one 
example: m/z: 1206.3645 [M+4H]4+ (calcd. m/z: 1206.3665), see appendix for spectra.
LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 0.1% TFA on a 
RP-C4 column
S4.2.3 Staudinger phosphite reaction
For the purification of the products it was found that first buffer and excess of 
PEG-alcohol should be removed via flash chromatography over a C18 Sep-Pac 
cartridge (short disposable C18 column, 2 g, by Waters), the resulting concentrated 
fraction was then subjected to reversed phase HPLC. It was found that for (m)BH3 
PEG0 and PEG4 conjugates, purification was readily possible using a C18 RP 
column. However, for (m)BH3 PEG15 and PEG45 conjugates it was more effective to 
apply a C4 RP column with bigger pore-size (300 Å) in order to remove left PEG 
alcohol. Purity of the products was confirmed using LC-UV analytical HPLC and 
High Resolution Mass spectrometry.
unpegylated BH3  BH3-azidopeptide (TFA5 salt; 4.49 mg; 1.15 μmol) was dissolved 
in 600 μL of Tris buffer (100 mM; pH = 8.4) and a solution of trimethoxyphosphite 
(1 mg; 8 mol; 7 eq.) in 100 μL of the same solvent was added. The reaction mixture 
was incubated at 27°C for 24 h. Then another solution of trimethoxyphosphite (1 
mg; 8 μmol; 7 eq.) in 100 μL was added and the mixture incubated for another 24 
h. Purification via semi-preparative HPLC (5 to 60% of acetonitrile in water 
containing 0.1% TFA on a RP-C18 column) yielded the peptide as yellow trifluoroac-
etate (0.95 mg; 0.24 μmol; yield 20.8%; molar mass (peptide) = 3.41 kDa; molar mass 
(TFA5 salt) = 3.98 kDa) with very good purity. HRMS: m/z: 1137.2061 [M+3H]3+ (calcd. 
m/z: 1137.2066), see appendix for spectra.
LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 0.1% TFA on a 
RP-C18 column
BH3 PEG200  BH3-azidopeptide (TFA5 salt; 4.32 mg; 1.11 μmol) was dissolved in 600 
μL of Tris buffer (100 mM; pH = 8.4) and a solution of tris(PEG200)phosphite (5 mg; 
8 μmol; 7 eq.) in 100 μL of the same solvent was added. The reaction mixture was 
incubated at 27°C for 24 h. Then another solution of the same phosphite (5 mg; 8 
μmol; 7 eq.) in 100 μL was added and the mixture incubated for another 24 h. 
Purification via semi-preparative HPLC (35 to 55% of acetonitrile in water 
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synthesis	in	solution
LC-fluorescence, 35 to 55% of acetonitrile in water containing 0.1% TFA on a RP-C4 
column (optimized gradient)
unPEGylated mBH3  mBH3-azidopeptide (TFA5 salt; 6.60 mg; 1.76 μmol) was 
dissolved in 600 μL Tris buffer (100 mM; pH = 8.4) and a solution of trimethoxy-
phosphite (25 μL; 26 mg, 208 μmol, 120 eq.) in 200 μL of the same Tris buffer was 
added. The mixture was incubated over night at 27°C to 30°C. The purification via 
semi-preparative C18 HPLC (10 - 60% of acetonitrile in water containing 0.1% TFA 
on a RP-C18 column) and subsequent lyophylization yielded in the product as 
yellow trifluoroacetate with good purity (1.38 mg; 0.36 μmol; yield 20.5%; molar 
mass (peptide) = 3.26 kDa; molar mass (TFA5 salt) = 3.83 kDa). HRMS: m/z: 1088.5205 
[M+3H]3+ (calcd. m/z: 1088.5265), see appendix for spectra.
LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 0.1% TFA on a 
RP-C18 column
mBH3 PEG200  mBH3-azidopeptide (TFA5 salt; 4.26 mg; 1.34 μmol) was dissolved in 
1.5 mL of Tris buffer (100 mM; pH = 8.4) and added to tris(PEG200)phosphite (22 mg; 
34.08 μmol; 30 eq.). The reaction mixture was incubated at 30°C for 48 h. Then the 
mixture was filtered over a C18-Sep-Pak column (Waters, 2 g) in order to remove 
BH3 PEG2000  BH3-azidopeptide (TFA5 salt; 4.28 mg; 1.10 μmol) was dissolved in 1.5 
mL of Tris buffer (100 mM; pH = 8.4) and tris(PEG2000)phosphite (67 mg; 11.0 μmol; 
10 eq.) was added. The reaction mixture was incubated at 30°C for 24 h. Then 
another portion of the same phosphite (67 mg; 11.0 μmol; 10 eq.) was added and the 
mixture incubated for another 16 h. The mixture was filtered over a C18-Sep-Pak 
column (waters, 2 g) in order to remove buffer, insoluble parts as well as some 
parts of PEG-alcohol. Subsequently, the resulting solution was lyophilized. 
Purification via semi-preparative HPLC (10 to 60% of acetonitrile in water 
containing 0.1% TFA on a RP-C4 column) yielded the peptide as yellow trifluoroac-
etate (1.97 mg; 0.24 μmol; yield 21.6%; molar mass (peptide) = 7.76 kDa; molar mass 
(TFA5 salt) = 8.33 kDa) with good purity. HRMS: polymeric distribution, one 
example: m/z: 1777.9307 [M+4H]4+ (calcd. m/z: 1777.7071), see appendix for spectra.
LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 0.1% TFA on a 
RP-C4 column
Comparison of conversion to BH3 PEG2000 conjugate either on the solid support 
or in solution.
synthesis	on	the	solid	support
LC-fluorescence, 35 to 55% of acetonitrile in water containing 0.1% TFA on a RP-C4 
column (optimized gradient)
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LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 0.1% TFA on a 
RP-C18 column
mBH3 PEG2000  mBH3-azidopeptide (TFA5 salt; 3.53 mg; 0.94 μmol) was dissolved 
in 1.5 mL of Tris buffer (100 mM; pH = 8.4) and tris(PEG2000)phosphite (114 mg; 
18.8 μmol; 20 eq.) was added. The reaction mixture was incubated at 30°C for 48 h. 
Then the mixture was filtered over a C18-Sep-Pak column (waters, 2 g) in order to 
remove buffer, insoluble parts as well as some parts of PEG-alcohol. The resulting 
solution was lyophilized. Purification via semi-preparative HPLC (10 to 60 % of 
acetonitrile in water containing 0.1% TFA on a RP-C4 column) yielded the peptide 
as yellow trifluoroacetate (1.00 mg; 0.12 μmol; yield 13.0%; molar mass (peptide) = 
7.64 kDa; molar mass (TFA5 salt) = 8.21 kDa) with good purity. HRMS: polymeric 
distribution, one example: m/z: 1433.8233 [M+4H]4+ (calcd. m/z: 1433.0137), see 
appendix for spectra.
LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 0.1% TFA on a 
RP-C18 column
buffer and some parts of PEG-alcohol. The resulting solution was lyophilized. 
Purification via semi-preparative HPLC (35 to 55% of acetonitrile in water 
containing 0.1% TFA on a RP-C18 column) yielded the peptide as yellow trifluoroac-
etate (0.83 mg; 0.20 μmol; yield 17.5%; molar mass (peptide) = 3.61 kDa; molar mass 
(TFA5 salt) = 4.18 kDa) with very good purity. HRMS: m/z: 1205.9264 [M+3H]3+ (calcd. 
m/z: 1205.9297), see appendix for spectra.
LC-UV at 220 nm, 10 to 100% of acetonitrile in water containing 0.1% TFA on a 
RP-C18 column
mBH3 PEG750  mBH3-azidopeptide (TFA5 salt; 6.01 mg; 1.60 μmol) was dissolved in 
1.0 mL of Tris buffer (100 mM; pH = 8.4) and tris(PEG750)phosphite (38 mg; 16 μmol; 
10 eq.) was added. The reaction mixture was incubated at 30°C for 24 h; then 
another portion of phosphite was added (38 mg; 16 μmol; 10 eq.) and the reaction 
was left for another 24 h. The mixture was filtered over a C18-Sep-Pak column 
(Waters, 2 g) in order to remove buffer and some parts of PEG-alcohol. The resulting 
solution was lyophilized subsequently. Purification via semi-preparative HPLC (10 
to 60% of acetonitrile in water containing 0.1% TFA on a RP-C4 column) yielded the 
peptide as yellow trifluoroacetate (2.43 mg; 0.46 μmol; yield 28.4%; molar mass 
(peptide) = 4.77 kDa; molar mass (TFA5 salt) = 5.34 kDa) with good purity. HRMS: 
polymeric distribution, one example: m/z: 1179.8586 [M+4H]4+ (calcd. m/z: 
1179.8630), see appendix for spectra.
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S4.3 DLS measurements
Dynamic Light Scattering measurements were performed on a Malvern Instruments 
Zetasizernano ZS (Malvern Instruments Ltd., Worcestershire, UK) with a backscatter 
detection angle of 173° at a temperature of 25°C using a 4 mW He–Ne laser operating 
at a wavelength of 632.8 nm. Each measurement was conducted at a concentration 
of 1 mM of BH3 conjugate in PBS buffer at least three times. The size distribution 
by intensity was calculated by the software based on the correlation functions 
using the Multiple Narrow Modes algorithm consisting of a non-negative least 
squares fit [S1]. This size distribution by intensity was converted to a distribution 
by volume employing the Mie theory [S2]. The distribution by volume represents 
the distribution by number. In the distribution by intensity big molecules are over-
represented due to much stronger scattering.
BH3 unPEGylated, hydrodynamic radius Z(r) = 1,660nm
BH3 PEG200, hydrodynamic radius Z(r) =1,755 nm
BH3 PEG750, hydrodynamic radius Z(r) = 2,028 nm
BH3 PEG2000, hydrodynamic radius Z(r) = 2,626 nm
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S4.4 Biological Experiments
S4.4.1 Cell culture 
Jurkat E6.1 cells were maintained in RPMI (Gibco, Invitrogen) supplemented with 
10% fetal bovine serum (PAN Biotech, Aidenbach, Germany) and 2 mM stable 
glutamine (PAA, Pasching, Austria). Cells were grown at 37°C in the presence of 5% 
CO2 and cultures were diluted every 2 days.
S4.4.2 Stability of PEGylated conjugates in cell lysate 
12 x 106 Jurkat E6.1 cells were lysed for 1 h on ice in a PBS lysis buffer containing 1 
% v/v Triton X-100 (United States Biochemicals, Cleveland, Ohio). Cells were then 
centrifuged at 20,000 x g for 20 min at 4°C to remove membrane debris. 
UnPEGylated or PEGylated BH3 conjugates were incubated at a concentration of 2 
μM at 37°C and 5 μL aliquots were collected at the indicated time points. Cell 
density was adjusted so that degradation could be followed over longer times (48 
h). To each aliquot, 95 μL of protease inhibitor cocktail (Roche, Manheim, Germany) 
was added and samples were frozen at -20°C. To assess the accessibility to proteolytic 
degradation 2 mg/mL proteinase K (recombinant, PCR grade, Roche, Manheim, 
Germany) was added to the 24 h samples followed by further incubation for 
additional 3-7 h. In order to perform FCS measurements, frozen samples were 
thawed and 900 μL of Tris buffer (100 mM Tris-HCl, pH 8.8) were added. 50 μL of this 
solution were transferred into a 384-well plate (175 μm, low-base design, MMI). 
Fluorescence autocorrelation measurements were performed using a TCS SP5 
confocal microscope (Leica Microsystems, Manheim, Germany) equipped with a 
dual channel fluorescence correlation spectroscopy unit and an HCX PL APO 63x 
N.A. 1.2 water immersion lens. The 488 nm line of an argon ion laser was used for 
excitation of the fluorophore and emission was collected from 500-550 nm. ISS 
Vista software, version 3.6 RC (ISS, Champaign, IL) was used to fit the autocorrela-
tion curves using a 3D Gaussian model with two diffusional components and a 
triplet term. The diffusional autocorrelation time (τD) of the high molecular weight 
component was fixed to the intact peptide while that of the low molecular weight 
component was fixed to the completely degraded sample and the fractions of the 
intact or degraded polymer-peptide conjugate were derived from the fits. Data 
represented here show relative half-life, i.e. half-life normalized to the total 
proteolytic activity in the lysate. Proteolytic activity is expressed by a summation 
of half-lifes of all the conjugates for the respective individual experiments.
S4.4.2.1  Diffusional autocorrelation time of the unPEGylated and the 
PEGylated peptides 
Fluorescence autocorrelation measurements were performed as mentioned above 
(S4.4.2). The diffusional autocorrelation time τD, which reflects the mean residence 
time of the molecules in the confocal detection volume and directly correlates 
with their hydrodynamic radius, showed an increase from 40 μs for unPEGylated 
BH3 to 47 μs for BH3 PEG200, 51 μs for BH3 PEG750 and to 74 μs for BH3 PEG2000. 
Figure S4.1 is a representative of these differences in τD. Autocorrelation functions 
 
 
 
 
 
 
 
 
 
S4.6 Appendix 
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Figure S4.1   Autocorrelation functions for the unPEGylated and PEGylated 
peptides. 
a) Increase in τD correlating with increase in PEG chain length represented by a right shift of the autocor-
relation curves; b)-e) Shifts in diffusional autocorrelation time between the intact conjugates (solid line) 
and proteinase K treated degraded peptides (broken line). b) BH3 unPEGylated; c) BH3 PEG200; d) BH3 
PEG750; e) BH3 PEG2000.
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were analyzed with a two-component model accounting for intact and fully 
degraded peptide conjugate. While this model is certainly a simplification, auto-
correlation measurements provide the advantage of a separation free determination of 
degradation in microliter sample volumes. In a representative experiment, τD for 
the fully degraded unPEGylated BH3 peptide was 26 μs while that for BH3 PEG200, 
BH3 PEG750 and BH3 PEG2000 were 25 μs, 26 μs and 27 μs, therefore showing 
identical diffusional autocorrelation times within experimental variation. Diffusional 
autocorrelation times were similar to the one of free fluorescein (about 25 μs).
S4.4.2.2  Statistical comparison of the stability of the PEGylated BH3/mBH3 
conjugates in cell lysate
Fluorescence correlation spectroscopy was used to determine the stability of the 
PEGylated BH3/mBH3 conjugates. Since the same PEGylation protocol was applied 
to both BH3 and the mBH3 peptides, the stabilities were expected to be similar for 
both the wild type and the mutant variant with the same PEG chain length or 
mass. FCS is a separation free technique that gives information about the 
concentration and the mean residence time (the diffusional autocorrelation time 
τD) of the particles resulting from diffusion of particles through a subfemtoliter 
confocal detection volume. Autocorrelation functions calculated from the 
measurements were fitted with a 3D Gaussian model including one triplet term 
and two diffusional components. The diffusional autocorrelation time (τD) of the 
high molecular weight component was fixed to the intact conjugate while that of 
the low molecular weight component was fixed to the completely degraded sample 
and the fractions of the intact and degraded conjugates were derived from the fits. 
The time-dependent decrease of the fraction of intact conjugate was then fitted 
with a first order exponential decay using GraphPad Prism (GraphPad Software 
Inc., San Diego, CA, version 4) and the half-life was obtained from the fit. Data 
represented here (Table S4.1) show relative half-lives (expressed as arbitrary units, 
a.u.), i.e. half-life normalized to the total proteolytic activity in the lysate. We 
performed such normalization for each experiment since the proteolytic activity 
of the lysate was different for every experiment. Total proteolytic activity is 
expressed by a summation of half-lives of all the conjugates for the respective 
individual experiments. A statistical comparison of the relative half-lives between 
each PEGylated BH3 and mBH3 data set was performed using unpaired two-tailed 
t-test with GraphPad Prism (GraphPad Software Inc., San Diego, CA, version 4). 
Variances of the two sets (each pair of PEGylated BH3 and PEGylated mBH3) were 
assumed to be equal due to the small sample size. p<0.05 was selected as the 
significance level.
 Indeed, stabilities (represented as relative half-life) of each PEG BH3/mBH3 
pair of same PEG chain length or mass did not show any significant difference Ta
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S4.4.3.2  Time dependent intracellular distribution of BH3 unPEGylated, BH3 
PEG750 and BH3 PEG2000
Next to the cell-associated fluorescence directly after electroporation, we were also 
interested in determining whether the larger PEG had an impact on the intra- 
cellular distribution and retention of fluorescence. Jurkat cells were electroporated 
as described above and confocal images were taken at the indicated time points for 
6.5 h. During this time cells were maintained at 37°C. BH3 PEG2000, BH3 PEG750 
and unPEGylated BH3 showed a homogenous distribution throughout the cytoplasm 
and nucleus for the indicated time points. Only for BH3 PEG2000 some contrast for 
nuclear structures was present. Also, at 6.5 h the major part of the fluorescence 
was still homogenously distributed (Figure S4.3). However, compared to both 
unPEGylated BH3 and BH3 PEG750, BH3 PEG2000 was retained over 6.5 h. 
Fluorescein was released from the cells in less than an hour.
(Table S4.2) indicating that the experimental variations of the relative half-lives 
observed between the wild type or mutated PEG conjugates were within the limits 
of significance.
S4.4.3 Electroporation
1 x 106 cells were electroporated using 100 μL Nucleofector solution V (Lonza, 
Cologne, Germany) containing the final concentration of the peptide/polymer- 
peptide conjugates with a pre-installed programme X-001 in a Nucleofector device 
(Amaxa Biosystems, Lonza, Cologne, Germany) according to the manufacturer’s 
information. After electroporation, 900 μL of medium was added; cells were incubated 
for 5 min and then washed twice.
S4.4.3.1 Electroporation efficiency of BH3 PEG750 compared to BH3 PEG2000
1 x 106 Jurkat cells were electroporated with 100 μM of fluorescein, BH3 
unPEGylated, BH3 PEG750 and BH3 PEG2000. Cells were washed twice and 5 x 105 
cells were suspended in 200 μL of phenol red free RPMI (supplemented with 10% 
fetal bovine serum and 2 mM glutamine) in an eight-well chambered coverglass 
(Nunc, Rochester, USA). Cells were imaged using a Leica SP5 confocal microscope 
with fluorescence excited using the 488 nm line of argon ion laser and emission 
collected at 500-550 nm. After the cells had settled down images were taken 
immediately which corresponded to 30 min after electroporation. Image J (version 
1.46j, freeware, NIH) was used to analyze the confocal microscopy images. Images 
were first smoothened and then converted to a binary mask using thresholds for 
fluorescence intensity and size that was used to extract cell-associated fluorescence 
in the original background-corrected images. To separate adjacent cells a watershed 
function was applied to the binary mask. Mean intensities were measured from all 
cells (at least 150 cells were counted). 
 Since BH3 PEG2000 displayed a larger hydrodynamic radius than BH3 PEG750, 
we hypothesized that the electroporation efficiency for BH3 PEG2000 would be 
less than for BH3 PEG750. To our surprise, cell-associated fluorescence intensity for 
BH3 PEG2000 in comparison to BH3 PEG750 was found to be similar indicating 
equivalent uptake efficiency of the larger BH3 PEG2000 conjugate. 
Figure S4.2   Electroporation efficiency of BH3 PEG750 versus BH3 PEG2000. 
Jurkat E6.1 cells were electroporated with 100 μM of BH3 PEG750 and BH3 PEG2000 and confocal 
microscopy images were recorded 30 min after electroporation. Data represent plots of normalized 
mean fluorescence intensities. To correct for differences in image acquisition, the data for the repetition 
of the experiment was normalized to the average of the data for the first experiment. Error bars represent 
S.D. for two independent experiments shown.
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S4.4.4 Image enhancement 
Image J (version 1.46, freeware, NIH) was used to modify brightness and contrast 
of the confocal microscopy images.
S4.4.5 Caspase-3 activity
1 x 106 Jurkat E6.1 cells were electroporated with 100 μM of the BH3 PEG2000, BH3 
PEG750 or the unPEGylated peptide and incubated for 6 h at 37°C. Cells were 
washed once with ice-cold PBS and were then lysed on ice in a lysis buffer 
containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 and 
protease inhibitor cocktail, pH 7.7. Protein content was determined using a 
commercially available Bradford Protein assay kit (Bio-Rad laboratories, Munich, 
Germany). Equivalents of 30 μg of protein were added in a caspase activity buffer 
containing 20 mM HEPES, 10 mM dithiothreitol, 10% glycerol and 100 mM NaCl, 
pH 7.5. A fluorogenic Caspase-3 substrate (N-acetyl-Asp-Glu-Val-Asp-amino-4-methyl-
coumarin; Calbiochem, Bad Soden, Germany) was added to a final concentration 
of 2 μM. Fluorescence was measured immediately after substrate addition and 
after 3 h incubation at 37°C using a Synergy 2 single channel microplate reader 
(BioTek Instruments, Winooski, USA). Caspase-3 activity was normalized to the 
total activity and to the individual protein content of the respective samples.
Figure S4.3   Time-dependent intracellular distribution of BH3 PEG2000 versus 
BH3 PEG750 and unPEGylated BH3. 
Jurkat E6.1 cells were electroporated with 100 μM of a) fluorescein or b) unPEGylated BH3 c) BH3 PEG750 
or d) BH3 PEG2000 and confocal microscopy images were recorded over 6.5 h at the indicated time 
points. Scale bar corresponds to 10 μm.
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S4.4.5.1  Statistical comparison of caspase-3 activation by (m)BH3 unPEGylated 
and (m)BH3 PEG750 conjugates
1 x 106 Jurkat E6.1 cells were electroporated with 100 μM and 300 μM of the (m)BH3 
PEG750 or the (m)BH3 unPEGylated peptides and incubated for 6 h at 37°C. 
Caspase-3 activity was determined as described above (S4.5). Caspase-3 activity was 
normalized to the total activity and to the individual protein content of the 
respective samples.
 A statistical comparison of the normalized caspase-3 activity was performed 
using one-way analysis of variance (ANOVA) with GraphPad Prism (GraphPad 
Software Inc., San Diego, CA, version 4). Tukey’s multiple comparison test was used 
as a post-hoc test. Variances of the data sets were assumed to be equal due to the 
small sample size. p<0.05 was selected as the significance level. 
BH3 PEG750 showed a significantly increase in activity in comparision to the BH3 
unPEGylated peptide both at 100μM and 300 μM. BH3 PEG750 also showed 
concentration dependent increase in activity. Wildtype PEG750 conjugate also 
showed significantly higher activity than the mutant conjugates. Activity for 
mBH3 PEG750 did not show any significant difference with mBH3 unPEGylated.
Table S4.4   P-values for the one-way analysis of variance for the BH3 PEG750 
conjugate versus the unPEGylated peptide and mBH3 counterpart 
One way analysis of variance (ANOVA) was performed with the normalized caspase-3 
activities. Three independent experiments (see Table S4.3) were performed for the 
BH3 PEG750 conjugate versus BH3 unPEGylated peptide and the mBH3 counterpart. 
Sample size was eight. Variances were assumed to be equal.
 
  P value P<0.0001
  P value summary ***
  Are means signif.different? (P < 0.05) Yes
  Number of groups 8
  F ratio 18.07
  R squared 0.8877
Table S4.5   P-values for Tukey’s multiple comparison post-hoc test with the BH3 
PEG750 conjugate versus the unPEGylated peptide and mBH3 
counterpart 
Tukey’s multiple comparison test was used as a post-hoc test to detect significant 
differences in caspase-3 activation. A p-value of < 0.05 was considered to be 
significant. Concentrations mentioned in parenthesis are in μM.
Tukey’s Multiple Comparison Test P value Significance
  PEG 750-BH3 (100) vs BH3 (100) P < 0.01 yes
  PEG 750-BH3 (100) vs PEG 750-mBH3 (100) P < 0.05 yes
  PEG 750-BH3 (100) vs mBH3 (100) P < 0.01 yes
  PEG 750-BH3 (100) vs PEG 750-BH3 (300) P < 0.05 yes
  PEG 750-BH3 (100) vs BH3 (300) P > 0.05 no
  PEG 750-BH3 (100) vs PEG 750-mBH3 (300) P > 0.05 no
  PEG 750-BH3 (100) vs mBH3 (300) P < 0.01 yes
  BH3 (100) vs PEG 750-mBH3 (100) P > 0.05 no
  BH3 (100) vs mBH3 (100) P > 0.05 no
  BH3 (100) vs PEG 750-BH3 (300) P < 0.001 yes
  BH3 (100) vs BH3 (300) P < 0.05 yes
  BH3 (100) vs PEG 750-mBH3 (300) P > 0.05 no
  BH3 (100) vs mBH3 (300) P > 0.05 no
  PEG 750-mBH3 (100) vs mBH3 (100) P > 0.05 no
  PEG 750-mBH3 (100) vs PEG 750-BH3 (300) P < 0.001 yes
  PEG 750-mBH3 (100) vs BH3 (300) P > 0.05 no
  PEG 750-mBH3 (100) vs PEG 750-mBH3 (300) P > 0.05 no
  PEG 750-mBH3 (100) vs mBH3 (300) P > 0.05 no
mBH3 (100) vs PEG 750-BH3 (300) P < 0.001 yes
mBH3 (100) vs BH3 (300) P > 0.05 no
mBH3 (100) vs PEG 750-mBH3 (300) P > 0.05 no
mBH3 (100) vs mBH3 (300) P > 0.05 no
  PEG 750-BH3 (300) vs BH3 (300) P < 0.01 yes
  PEG 750-BH3 (300) vs PEG 750-mBH3 (300) P < 0.001 yes
  PEG 750-BH3 (300) vs mBH3 (300) P < 0.001 yes
  BH3 (300) vs PEG 750-mBH3 (300) P > 0.05 no
  BH3 (300) vs mBH3 (300) P > 0.05 no
  PEG 750-mBH3 (300) vs mBH3 (300) P > 0.05 no
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Multivalent presentation of the 
cell-penetrating peptide 
nona-arginine on a linear scaffold 
strongly increases its 
 membrane-perturbing capacity
5
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Abbreviations
CPP, cell-penetrating peptide; R9, nona-arginine; Dex-(R9)5, pentavalent display of 
R9 on a linear dextran backbone; PI, propidium iodide; N.A., numerical aperture; 
FBS, fetal bovine serum; PBS, phosphate-buffered saline; BSA, bovine serum 
albumin.
Keywords
Cell-penetrating peptide, drug delivery, nona-arginine, multivalency, sphingomy-
elinase, protein-protein interactions.
5.1 Introduction 
Conjugation to cell-penetrating peptides (CPPs) is considered a highly promising 
strategy to mediate cellular delivery of molecules that otherwise poorly enter cells 
[1-3]. Natural and synthetic CPPs are continuously being (re-)designed to improve 
delivery [4, 5]. In contrast to the original concept of the CPP acting as a Trojan 
horse that passages passively through the plasma membrane by virtue of its 
structural characteristics it has become clear that with the exception of direct 
membrane permeation at low concentrations [6, 7] CPPs actively induce cellular 
uptake [8]. In particular for large molecular weight cargos, endocytosis is the route 
of uptake [9]. Furthermore, concentrations above about 10 mM, arginine-rich CPPs 
induce activation of acid sphingomyelinase, which leads to rapid cytoplasmic 
import via ceramide-rich membrane micro domains [10, 11].
 While the molecular mechanism underlying the activation of acid sphingo-
myelinase has not been resolved, for induction of endocytosis, it has been proposed 
that binding to negatively charged oligosaccharides of the glycocalyx leads to a 
clustering of syndecans [12], which activates Rac-dependent actin remodeling [13]. 
However, uptake is also observed for cells that are poor in glycosaminoglycans 
such as Jurkat T cell leukemia cells which calls for the involvement of additional 
processes [11]. 
 Strikingly, in spite of its activity as a CPP, for nona-arginine (R9) little to no 
enrichment at cellular membranes is observed. Only when internalization is 
compromised, a staining of the plasma membrane is visible which can be attributed 
to the interaction with glycosaminoglycans [14]. This indicates that in spite of a 
documented ability to interact with the head groups of the lipid bilayer and the 
capacity to partition into a hydrophobic environment in the presence of negatively 
charged chelating groups [15-17], on cells there is little enrichment at the level of 
the plasma membrane. Also, among a panel of nine tested CPPs R9 had the least 
membrane-disruptive potential [18], overall indicating that enrichment at the 
plasma membrane plays only a small role in the uptake of this CPP.
Abstract 
Arginine-rich cell-penetrating peptides (CPP) are widely employed as delivery 
vehicles for a large variety of macromolecular cargos. As a mechanism-of-action 
for induction of uptake cross-linking of heparan sulfates and interaction with 
lipid head groups have been proposed. Here, we employed a multivalent display of 
the CPP nona-arginine (R9) on a linear dextran scaffold to assess the impact of 
heparan sulfate and lipid interactions on uptake and membrane perturbation. 
Increased avidity through multivalency should potentiate molecular phenomena 
that may only play a minor role if only individual peptides are used. To this point, 
the impact of multivalency has only been explored for dendrimers, CPP-decorated 
proteins and nanoparticles. We reasoned that multivalency on a linear scaffold 
would more faithfully mimic the arrangement of peptides at the membrane at 
high local peptide concentrations. On average, five R9 were coupled to a linear 
dextran backbone. The conjugate displayed a direct cytoplasmic uptake similar to 
free R9 at concentrations higher than 10 mM. However, this uptake was accompanied 
by an increased membrane disturbance and cellular toxicity that was independent 
of the presence of heparan sulfates. In contrast, for erythrocytes, the multivalent 
conjugate induced aggregation, however, showed only limited membrane perturbation. 
Overall, the results demonstrate that multivalency of R9 on a linear scaffold 
strongly increases the capacity to interact with the plasma membrane. However, 
the induction of membrane perturbation is a function of the cellular response to 
peptide binding. 
Cellular sticky tape: Multivalent presentation of nona-arginine on a linear dextran 
scaffolds adds new functional characteristics to arginine-rich cell-penetrating 
peptides; unlike nona-arginine at the same peptide concentration this conjugate 
strongly engages with the plasma membrane and causes aggregation of red blood 
cells (RBC). 
RBCHeLa
multivalent R9 on a
linear dextran scaffold
monovalent
R9
RBCHeLa
R9 Dex-(R9)5
Graphical Abstract
142 | Chapter 5 Multivalent R9 induces membrane perturbation | 143
surface area of the plasma membrane or in a structurally adaptive binding due to 
the flexibility of the dextran backbone. In particular, we hoped that this 
configuration would shed further light into the structural requirements for 
triggering the rapid sphingomyelinase-dependent uptake mechanism. All data 
presented so far, indicated that this import route is restricted to free CPPs or CPPs 
conjugated to small molecular weight cargo [9, 10].
 Next to addressing uptake and toxicity for HeLa and Jurkat cells we also 
included human erythrocytes in our studies. These cells lack endocytosis and 
should therefore reveal to which degree a membrane-disruptive activity is a 
function of the conjugate-membrane interaction or the triggering of a cellular 
response. Since multivalency can generate strong interactions for low affinity 
binders, we also addressed whether inside the cell the multivalent display of R9 
leads to the disruption of protein-protein interactions. Our results demonstrate 
that the multivalent display strongly enhances interactions with the plasma 
membrane. The restriction of toxicity to cells that show uptake demonstrates that 
toxicity is a consequence of the reaction of the cells to these conjugates. Interactions 
of the conjugates with the plasma membrane alone are insufficient to evoke strong 
toxicity. 
5.2 Materials and Methods
5.2.1 Reagents
Nona-arginine (R9) with an amidated C-terminus and an N-terminal carboxyfluo-
rescein was purchased from EMC microcollections (Tübingen, Germany). Dex-(R9)5 
was synthesized using a 10 kDa dextran (Dex) backbone comprising on average of 
62 glucose monomers. Carboxyethyl groups were introduced using acrylamide 
followed by amide hydrolysis to form 2-carboxyethyl dextran (CED). N-(2-aminoeth-
yl)maleimide was synthesized and coupled to the modified polymer. Using ma-
leimide-thiol coupling, in a single step N-cysteinyl-lysinyl-5(6)-carboxyfluorescein 
and N-cysteinylnona-arginine amide were coupled to the modified dextran 
achieving an average loading of five nona-arginine peptides and one fluorophore 
per polymer as determined by quantitative amino acid analysis and NMR [22]. 
Dex-(R9)5 had a final molecular weight of 22 kDa (for details see S5, Figure S5.1.1 
and S5.1.2). Dex and CED were used as negative controls. Imipramine, resazurin 
and Tween-20 were from Sigma-Aldrich (Zwijndrecht, The Netherlands). Propidium 
iodide (PI) and Alexa-647-labeled Annexin-V were from Invitrogen (Eugene, USA) 
and Ficoll-Paque from GE Healthcare (Uppsala, Sweden). Complete Ringer (pH 7.4) 
solution was prepared using 32 mM HEPES, 125 mM NaCl, 5 mM glucose, 5 mM 
KCl, 1 mM MgSO4, 2.5 mM CaCl2.
 The geometry in which positive charge is presented greatly influences uptake 
efficiency. On one hand, it has been demonstrated that import can be enhanced 
through rigidifying the peptide backbone through cyclization [19]. On the other 
hand, multivalency is a well-established principle to potentiate molecular 
interactions through introduction of avidity [20-22]. Multivalent interactions in 
nature include binding of DNA at several sites by transcription factors, like the 
retinoid X receptor [20] or immunogenic recognition by multivalent antibodies 
such as IgM [23]. In the context of CPP, oligoarginines are an example for a 
multivalent display of the guanidino-group and up to a certain length, activity of 
oligoarginines increases with the number of residues [24, 25]. With respect to a 
multivalent display of CPP, multivalency has been investigated for TAT, oligolysine, 
HSV-1 VP22, oligoarginine, Antp, (reviewed in [26]), zinc coordinated oligotyrosine 
peptides [27] and recently for TP10, pVEC and polyproline helix SAP [28]. A 
tetravalent presentation of deca-arginine fused to the p53 protein was shown to 
improve delivery efficiency even at low concentrations without increasing toxicity 
[29]. In the latter study, this increased activity was associated with enhanced 
interactions with cell surface heparan sulfates. However, these multivalent 
arrangements were either based on globular scaffolds or branched dendrimers, 
geometries that confine the area of interaction with the membrane components of 
the cell. To be effective for promoting uptake, a stretch of arginines has to be 
present. A dispersed presentation of individual arginines on a polymer results in 
considerably reduced uptake also at higher charge density [30]. Overall, the 
multivalent geometries that have been investigated so far for CPPs are more 
restricted than those addressed for antimicrobial peptides for which presentation 
along linear scaffolds has also been investigated, already [31].
 In all these applications, the multivalent CPPs were well tolerated, showing 
little signs of toxicity. Also, individual oligoarginine peptides are generally well 
tolerated to concentrations in the mean micromolar range [11, 24].
 Beyond yielding a benefit in efficiency, so far, the multivalent display of CPPs 
has yielded little insights into the molecular mechanisms triggering import. Also, 
no functional characteristics were reported that differed greatly for those of the 
individual CPPs. As for individual CPPs, it has been proposed that the multivalent 
systems crosslink glycosaminoglycans followed by endocytosis [32]. This may be 
due to the globular nature of these structures that renders them very similar to 
CPPs linked to macromolecules. 
 Therefore, in the present study we compared a multivalent configuration of 
nona-arginine (R9) in which on average five copies of the CPP were coupled to a 
linear and flexible dextran backbone (Dex-(R9)5) to the monovalent R9 counterpart. 
We hypothesized that in comparison to multivalent displays on globular 
structures, this configuration would result in contact of the molecule with a larger 
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5.2.5 Image enhancement
Image J (version 1.46j, freeware, NIH) was used to modify brightness and contrast 
of the confocal microscopy images.
5.2.6 Image quantification
Image J (version 1.46j, freeware, NIH) was used to analyze the confocal microscopy 
images. Images were first smoothened and then converted to a binary mask using 
thresholds for fluorescence intensity and size that was used to extract cell-associ-
ated fluorescence in the original background-corrected images. To separate 
adjacent cells a watershed function was applied to the binary mask. Mean 
intensities (represented as intracellular fluorescence) were measured from all cells 
(at least 50 cells were counted). 
5.2.7 Cytotoxicity assay
HeLa cells (7.5 x 103 cells/well) were seeded in 96-well microtiter plates and grown 
overnight. The next day, cells were treated with varying concentrations of R9/
Dex-(R9)5/Dex/CED for 24 h at 37ºC. Cell viability was measured using the resazurin 
assay. Resazurin is a non-fluorescent dye that is reduced to the highly fluorescent 
resorufin by metabolically active cells [33, 34]. Cells were incubated with resazurin 
(100 μg/mL) for 4 h. Fluorescence was read with a Synergy 2 single-channel 
microplate reader (BioTek Instruments, Winooski, USA). Percentage cell viability 
was calculated as [(Ti–T0)/(C–T0)]ł100 for concentrations in which Ti ≥ T0 and 
[(Ti-T0)/T0]ł100 for concentrations in which Ti < T0. Ti is the fluorescence of the 
test-well after a 24-h period of exposure to the treatment, T0 is the fluorescence at 
time zero (i.e. before addition of compounds) and C is the fluorescence after 24 h of 
cell seeding. This parameter can have values from +100 to -100 [35]. 
5.2.8 Effect of Dex-(R9)5 on erythrocytes
Blood was drawn from healthy volunteers. The study was performed following the 
guidelines of the local medical ethical committee and in accordance with the 
declaration of Helsinki. Written informed consent was obtained from all blood 
donors participating in this study. To isolate erythrocytes, fresh blood was 
centrifuged at 1500 x g for 10 min. Erythrocyte pellets were washed twice with 
calcium-free Ringer to prevent complement activation and once with complete 
Ringer. Erythrocytes were resuspended in 100 μL Ringer and diluted to 1 million 
cells/well in chambered coverslips. R9 or Dex-(R9)5 were added to the cells in an 
equal volume of Ringer at the indicated concentrations and imaged by time lapse 
confocal microscopy. Alexa-647-labeled Annexin-V was also added at a dilution of 
1:25. Cells were manually counted to quantify exposure of phosphatidylserine, 
changes in morphology and lysis.
5.2.2 Tissue culture
Jurkat T cell leukemia cells (ACC-282, DSMZ, Braunschweig, Germany) and HeLa 
cells (CCL-2, ATCC, LGC Standards, Wessel, Germany) were cultured in RPMI1640 
with stable glutamine and 2.0 g/L NaHCO3 (PAN Biotech, Aidenbach, Germany) 
supplemented with 10% heat inactivated fetal bovine serum (FBS; PAN Biotech). 
Cells were maintained at 37°C in a humidified incubator containing 5% CO2. 
Jurkat cells were passaged every 2-3 days when the cells had grown to a density of 
approximately 4 x 105 cells/mL while HeLa cells were passaged every 2 days at 
around 80-90% confluency.
5.2.3 Confocal microscopy
Confocal laser scanning microscopy was performed on a TCS SP5 confocal 
microscope (Leica Microsystems, Mannheim, Germany) equipped with an HCX PL 
APO 63x 1.2 N.A. water immersion lens. Cells were maintained at 37°C on a tem-
perature-controlled microscope stage. For multichannel recordings with 
propidium iodide (PI) or Annexin-V in addition to the labeled R9 or Dex-(R9)5, 
images were recorded using the 488 nm line of an argon-ion laser and a HeNe 561 
or 633 nm laser. To avoid crosstalk, fluorescence was recorded sequentially where 
necessary.
5.2.4 Dex-(R9)5 uptake
HeLa cells (4 x 104/well) were seeded in 8-well microscopy chambers (Nalge Nunc 
International, New York, USA), 24 h prior to peptide addition. Cells were incubated 
with 4 μM Dex-(R9)5 or 20 μM R9 in RPMI 1640 supplemented with 10% FBS (heat 
inactivated) for 20 min. For assessing the effect of imipramine on peptide uptake, 
cells were pre-incubated for 45 min with 30 μM imipramine in RPMI 1640 without 
serum. For subsequent incubation with peptide, 30 μM imipramine was 
co-incubated with peptide in medium containing 10% FBS. Cells were washed 
twice with medium. To check for membrane-integrity as well as cell viability, cells 
were incubated with 5 μg/mL PI and immediately imaged by microscopy. For 
studies in Jurkat cells, 200 μL of a 5 x 105 cells/mL Jurkat cell suspension in RPMI 
1640 without phenol red and 10% FBS were transferred per well into 8-well 
microscopy chambers coated with a 20 μg/mL fibronectin solution in PBS for 30 
min at room temperature (RT). At time point t=0, 5 μM or 10 μM of R9 or 1 μM or 2 
μM of Dex-(R9)5 were added to the wells. Living cells were imaged using a TCS SP5 
confocal microscope (Leica Microsystems, Mannheim, Germany) equipped with 
an HCX PL APO 63x 1.2 N.A. water immersion lens. Cells were maintained at 37°C 
on a temperature-controlled microscope stage. Images were recorded using the 
488 nm line of an argon-ion laser.
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5.3 Results 
5.3.1  Dex-(R9)5 exhibits sphingomyelinase-dependent uptake and 
nucleolar staining
Previous work on multivalent cationic peptides and protein transduction domains 
elucidated that multivalency greatly improves cellular import of these conjugates 
[29]. Uptake occurred by endocytosis, consistent with the general assumption 
according to which macromolecular CPP-complexes and conjugates are taken up 
along this route and direct translocation and rapid cytoplasmic uptake are 
restricted to free CPP and CPP conjugated to small molecular weight cargo [9, 10]. 
However, so far, multivalent configurations were nanoparticulate, potentially 
restricting the ability of these molecules to engage with larger areas of the plasma 
membrane. Therefore, we here synthesized a highly flexible multivalent CPP 
conjugate by coupling on average five copies of nona-arginine to a 10-kDa dextran 
backbone. A fluorescein moiety was introduced to monitor the cellular distribution 
and uptake. 
 HeLa cells were incubated with 20 μM R9 or 4 μM Dex-(R9)5, corresponding to 
the same concentration of CPP and the distribution of fluorescence was observed 
by confocal microscopy in living cells. As reported before, at this concentration R9 
exhibited a uniform homogeneous staining of cells with only few endocytic 
vesicles [11] (Figure 5.1, also S5, Figure S5.2). This is the typical distribution of 
fluorescence observed for sphingomyelinase-dependent import through nucleation 
zones [10, 11]. Also for Dex-(R9)5 cells showed an intense cytoplasmic fluorescence, 
however, this fluorescence was distributed less homogenously than for R9 and also 
showed a distinct nucleolar staining as was observed for the D-amino acid analog 
of R9 [14]. Areas of more intense fluorescence were reminiscent of nucleation zones. 
Also, cell shapes were more irregular for Dex-(R9)5-treated cells than for cells 
incubated with free peptide, suggesting a stronger membrane-perturbing effect of 
the multivalent conjugate. Interestingly, cell-associated fluorescence for Dex-(R9)5 
was about the same as for R9 (Figure 5.1B). Considering, that one conjugate carried 
one fluorophore for five peptides, this indicates that on a per-peptide basis, uptake 
was in about the same range (maximum five fold higher per peptide) than for R9.
 Sensitivity to imipramine which acts as an inhibitor of acid sphingomyelinase 
was identified as a characteristic of nucleation zone-dependent uptake [10]. 
However, as detailed above this route of uptake was limited to free CPPs or CPPs 
conjugated to small cargos [9, 10]. A polymer-conjugate of similar size but with 
only 3 nona-arginines was unable to enter via this route [37, 38]. To investigate 
whether Dex-(R9)5 nevertheless exploited this mechanism or whether uptake 
occurred as a consequence of membrane disruption, uptake was assessed in the 
presence of imipramine. Imipramine abolished cytoplasmic fluorescence of both, 
5.2.9 Impact of Dex-(R9)5 on protein-protein interactions
In order to induce activation-dependent protein complex formation, Jurkat cells 
were treated with 0.5 mM of the broad-range phosphatase inhibitor pervanadate 
(PV) in HBS or as a control with HBS for 10 min at 37°C. Cell lysates were prepared 
by suspending 1 million cells per subarray in 50 μL lysis buffer (1% Triton X-100, 50 
mM n-octyl-D-glucopyranoside (Fluka, Taufkirchen, Germany), 20 mM Tris, 1 mM 
EDTA, 150 mM NaCl, 1 mM Na3VO4, pH 7.5, and complete protease inhibitor 
cocktail (Roche Applied Science, Mannheim, Germany)). N-octyl-D-glucopyrano-
side ensured the efficient extraction of signaling proteins from lipid rafts. After 
lysis on ice for 1 h, the crude lysates were cleared by centrifugation at 20,000 x g at 
4°C for 15 min. Afterwards, 5 μM R9 or 1 μM Dex-(R9)5 were added to cell lysate. 
Finally, lysates were incubated on microarrays as described below. Peptide 
microarrays presenting known interaction motifs for proteins involved in T cell 
signaling were prepared as described before [36]. One microarray substrate carried 
16 identical subarrays. For incubation of these subarrays with different samples a 
16-well clip-on frame (ProPlate Multiarray System, Grace Biolabs, Molecular 
Probes, Eugene, OR, USA) was mounted onto the microarray slides. Microarrays 
were incubated with 50 μL of lysate from 1 million cells per subarray for 1 h at 4°C 
and washed three times with washing buffer (PBS, 0.05% (w/v) BSA, 0.05% (w/v) 
Tween-20). For the detection of bound protein by indirect immunofluorescence, 
microarrays were incubated with 2 μg/mL primary antibody (α-PLCγ1, Santa Cruz 
Biotechnology, Heidelberg, Germany, sc-81; α-LAT, Millipore 05-770, Schwalbach, 
Germany) diluted in washing buffer for 15 min at RT and washed three times with 
washing buffer. Afterwards, microarrays were incubated with 1 μg/mL secondary 
goat-anti-rabbit antibody conjugated with Alexa-633 and goat-α-mouse secondary 
antibody conjugated with Alexa-546 (A21070, A11003, Invitrogen) for 10 min at RT 
followed by a final washing step with washing buffer. As a negative control, one 
subarray was immunostained without incubation with lysate. Finally, microarrays 
were dried with nitrogen and scanned (ProScanArray, PerkinElmer Life Sciences, 
Waltham, MA, USA). Processing of the signals occurred as described previously 
using ArrayPro Analyzer (Media Cybernetics, Silver Spring, MD, USA) [36]. Signals 
on microarrays were obtained by subtraction of the median signal of a local 
ring-shaped background from the mean of signal intensities on a peptide spot.
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multivalent conjugate there was a loss of membrane integrity for some cells (Figure 
5.2). Remarkably, the number of PI-positive cells was decreased by the presence of 
imipramine indicating that membrane damage is a consequence of uptake rather 
than the interaction of the conjugate with the plasma membrane (Figure 5.2). This 
increased membrane-disruptive potential was also reflected by a higher reduction 
in cell viability over a 24-h incubation (Figure 5.3). A strong reduction in cell 
viability was noticed for 1 μM Dex-(R9)5 (corresponding to a overall peptide 
concentration of 5 μM) compared to 11 μM R9 over 24 h. Dex and CED, which were 
used as negative controls, did not show any significant toxicity indicating that 
neither the native nor the carboxyethylated dextran backbone were responsible 
for the toxicity of Dex-(R9)5.
 HeLa cells have a high density of heparan sulfates and other negatively 
charged oligosaccharides [39] that serve as binding sites for arginine-rich peptides 
[40]. We were therefore interested to assess the impact of the linear, multivalent 
Dex-(R9)5 conjugate on Jurkat T cell leukemia cells that express significantly lower 
levels of heparan sulfates [39]. At 5 μM (Figure 5.4A) over the time course of the 
experiment R9 showed only internalization in a few cells with no signs of toxicity. 
At 10 μM (Figure 5.4B), R9 fluorescence rapidly entered the cytoplasm reminiscent 
R9 and Dex-(R9)5 in a major part of cells supporting a role of sphingomyelinase-de-
pendent uptake in both cases (Figure 5.1, S5, Figure S5.2). To exclude that the 
reducing effect was due to an interference of the imipramine with the peptides/
conjugate at the plasma membrane, we compared the effect of a pre-incubation 
with imipramine with the one of a pre- and co-incubation. Indeed, in the latter 
case the reduction was stronger demonstrating that some direct interference 
occurs (S5, Figure S5.3).
 Considering the more irregular cell shape for the Dex-(R9)5-treated cells we 
also probed for membrane damage which does not occur for sphingomyelinase- 
dependent uptake [11]. Cells were exposed to conjugates for 20 min and after 
washing PI was added to monitor changes in membrane integrity. For the 
Figure 5.1   Cellular distribution and imipramine-sensitive uptake of Dex-(R9)5. 
(A) Following a 45 min pretreatment with/without imipramine (imi) in serum-free RPMI, HeLa cells were 
incubated with 20 μM R9 or 4 μM Dex-(R9)5 for 20 min at 37°C in the presence or absence of 30 μM 
imipramine followed by washing and imaging with confocal microscopy. Microscopy settings for image 
acquisition of all samples were adjusted for R9 to avoid saturation. One confocal slice is shown for all the 
microscopy images. Scale bars correspond to 20 μm. One representative experiment of at least three 
experiments is shown. Homogenous staining of R9 is observed in 70% of cells (for whole field-of-view of 
images see S5, section S5.2, Figure S5.2). Brightness and contrast has been adjusted for visualization 
purposes using the same parameters for fluorescence images and parameters to yield the best possible 
result for transmission images. (B) Imipramine-sensitive uptake quantified from A (raw, unmodified 
images); at least 50 cells were counted. Error bars represent S.E.
Figure 5.2   Uptake of Dex-(R9)5 is associated with only partial loss of membrane 
integrity. 
HeLa cells were treated with 4 μM Dex-(R9)5 or 20 μM R9 for 20 min at 37°C in the presence or absence of 
30 μM imipramine (imi) as stated before. After washing, PI (5 μg/mL) was added and cells were imaged 
without any further washing step by confocal microscopy. 0.25% Tween-20 was used as a positive control 
for membrane disruption. Scale bars correspond to 20 μm. Brightness and contrast has been adjusted for 
visualization purposes using the same parameters for fluorescence images and parameters to yield the 
best possible result for transmission images.
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drugs [43] have been shown to cause shape changes and cell lysis in erythrocytes. 
For CPPs only few studies about the impact on erythrocytes exist. One study 
addressed the uptake of α- and β-oligoarginines in normal versus parasite-infected 
erythrocytes [44] demonstrating that both types of oligoarginines did not enter 
healthy erythrocytes but only the parasite-infected ones. TAT only showed activity 
of nucleation zone-dependent uptake [11]. For the free peptide, uptake occurred in 
the absence of visible membrane staining. In contrast, Dex-(R9)5 (Figures 5.4C, 
5.4D), already at a concentration of 1 μM with respect to backbone caused massive 
membrane staining and cell death accompanied by formation of membrane blebs. 
Control CED had no effect on cell viability (Figure 5.4E).
5.3.2  Dex-(R9)5 but not R9 binds to erythrocyte membranes and induces cell 
aggregation
Concomitant with increased toxicity, for Dex-(R9)5 we observed an increased 
membrane staining which was absent for R9. Two possible explanations were 
considered for this membrane staining. First, the multivalent display of guanidi-
no-groups could afford sufficient avidity for interaction with the plasma membrane 
also in the absence of a massive disturbance. Second, staining could be a 
consequence of the membrane-disruptive effect of the conjugate, leading to 
exposure of negatively charged phosphatidylserine that would then in turn lead to 
a membrane accumulation of the peptide. In this second case, it would be 
interesting to learn whether disruption was again a function of the peptide alone, 
or of the cellular response to the peptide. In order to distinguish these mechanisms, 
we employed erythrocytes as a model system. In contrast to nucleated cells, 
erythrocytes do not exhibit endocytosis. Cationic amphipathic, membrane-active 
peptides like mastoparan [41], gramicidinS [42], mellitin [42] and several other 
Figure 5.3   Multivalency of nona-arginine in Dex-(R9)5 increases toxicity. 
HeLa cells were treated with the indicated concentrations of Dex-(R9)5 (with respect to the polymer 
backbone) for 24 h and cell viability was determined using a resazurin assay in comparison to R9. CED 
(carboxyethyl dextran) and Dex (native dextran) were used as controls. Data represents average ± SEM of 
three independent experiments, each carried out in triplicate, which means N=9.
Figure 5.4   Time lapse microscopy of the membrane-disruptive behavior of 
Dex–(R9)5 in Jurkat cells. 
Jurkat cells were exposed to (A) 5 μM R9, (B) 10 μM R9, (C) 1 μM Dex-(R9)5 and (D) 2 μM Dex-(R9)5 at 37°C 
and fluorescence and transmission recorded with 2 images/min. Concentrations of Dex-(R9)5 were with 
respect to the polymer backbone. 2 μM CED (E) was used as control. Peptide/conjugate was added at the 
time of image acquisition by careful pipetting into the sample. The start of exposure of cells to peptide/
conjugate is visible from the increase in fluorescence outside the cells. Scale bars correspond to 25 μm.
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Dex-(R9)5. In contrast, addition of 6 μM R9 to erythrocytes in Ringer exhibited 
weaker membrane staining and did not show any aggregates (Figures 5.5, S5 Figure 
S5.4.2). No cell entry was observed. Moreover, only a minor percentage of cells 
(around 4% from 2 different experiments, 595 cells in total) showed shape changes 
and formed echinocytes (by 20 min) without exposure of phosphatidylserine (S5 
Figure S5.4.2). CED, the dextran backbone control, induced no changes in 
erythrocyte morphology (S5, Figure S5.5). To explore to which degree the 
membrane aggregating behavior of Dex-(R9)5 would extend to potential in vivo 
applications, erythrocytes were also exposed to the conjugate in the presence of 
human serum. Serum completely neutralized the effects of Dex-(R9)5 on 
erythrocytes observed in Ringer (S5, Figure S5.5). 
5.3.3  Both, Dex-(R9)5 and R9 interfere with protein-protein interactions 
involved in early T-cell signal transduction 
The observations for Jurkat cells and erythrocytes demonstrated that the 
multivalent display of R9 strongly potentiated the capacity to interact with lipid 
membranes independent of the presence of heparan sulfates. Clearly, on the linear 
backbone, multivalency yielded sufficient avidity to support interactions with the 
lipid head groups. Given a recent report of interactions of arginine-rich peptides 
with microfilaments [46], we were interested to learn whether multivalency also 
conferred an increased capacity to interfere with protein-protein interactions. To 
this end, we took advantage of a peptide-based microarray approach which we had 
used before to probe in parallel for signaling-dependent changes in the formation 
of protein complexes in Jurkat T cells [36] (also see section 5.2.9). The peptide arrays 
comprised a collection of phosphotyrosine-containing and proline-rich peptides 
which interact with SH2 and SH3 domains that play a major role in the organization 
of signaling pathways [47, 48]. Binding of proteins from cell lysates was probed by 
indirect immunofluorescence. We opted for PLCγ1 [49, 50] and the scaffold protein 
LAT [51, 52], two important players in early complex formation within T cell 
signaling, as indicators for a possible impact on protein-protein interactions. PLCγ1 
can bind to peptides on the microarray via its SH2 and SH3 domains. In contrast, 
LAT can only bind as part of a protein complex as it has no suitable domains to 
directly engage in interactions with peptides on the array. LAT should therefore be 
a sensitive indicator for changes in protein-protein interactions. In order to trigger 
signaling events and induce formation of protein complexes, Jurkat cells were 
stimulated with the broad-range phosphatase inhibitor pervanadate [53] or as a 
control for resting cells treated with HBS only. Pervanadate leads to the phosphor-
ylation of tyrosines and as a consequence to SH2 domain-mediated complex 
formation. Addition of R9 and Dex-(R9)5 caused the loss of several signals on 
proline-rich peptides but not on phosphotyrosine-containing peptides (Figure 5.6). 
in combination with a phototoxic effect [45].
 Erythrocytes were incubated with Dex-(R9)5 in the presence of fluorescently 
labeled Annexin-V and the impact on erythrocyte morphology and phosphati-
dylserine exposure was determined by time lapse confocal microscopy (Figures 
5.5A, S5 Figure S5.4.1). The multivalent conjugate bound to the membrane almost 
immediately after addition. For 37% of the cells (3 independent experiments with 
605 cells in total) this binding was followed by phosphatidylserine exposure 
(detected by binding of Annexin-V), indicating that disruption of membrane 
polarity was a potential consequence but not the cause of strong binding of the 
conjugates. Phosphatidylserine exposure was followed by disruption of membrane 
integrity as visible by entry of fluorescence into the cytoplasm. By 20 min, 9% of 
the cells were lysed. Interestingly, within the first 2 min erythrocytes also formed 
aggregates (Figure 5.5B, S5 Figure S5.4.1) that incorporated 50% of cells at 0.6 μM of 
Figure 5.5   Dex-(R9)5 induces erythrocyte aggregation and phosphatidylserine 
exposure. 
(A) 0.6 μM Dex-(R9)5 and 6 μM R9 were added to erythrocytes in Ringer and imaged by confocal microscopy 
at 37°C after 20 min. Annexin-V was also added to cells at a dilution of 1:25 to stain for phosphatidylser-
ine. Scale bars correspond to 50 μm. (B) Erythrocyte aggregates formed after addition of 0.6 μM Dex-(R9)5. 
The scale bar corresponds to 10 μm.
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intracellular trafficking of globular molecular geometries [26]. For example, the 
tetravalent display of the TAT CPP increased uptake efficiency by 1000-fold. 
Interestingly, to this point there were no indications that the multivalent 
configuration conferred qualitatively new characteristics to the interaction of 
these molecules with cells. 
 In this study, we linked on average five nona-arginine CPPs to a linear dextran 
backbone. With this linear geometry, in a fully stretched conformation this 
multivalent construct can engage plasma membrane over a length of at least 25 
nm (the dextran polymer backbone, Dex, exhibits this length in the extended 
conformation [22]) and a width of 7 nm (two fully extended R9), yielding a maximal 
contact area of 175 nm2. In comparison, a streptavidin molecule which has been 
used as a globular scaffold has a diameter of 5 nm which would be extended by 
fully stretched peptides to 12 nm and thus an equivalent contact area of 144 nm2. 
This similarity in size indicates that the observed differences must to a large 
extend be a consequence of the flexibility of the dextran backbone.
 Remarkably, as derived from quantitative image analysis, uptake of the 
conjugate, when related to peptide, was enhanced by a factor of five at most in 
comparison of the free peptide. Therefore, this linear arrangement of oligoarginines 
falls behind what was observed for the globular configurations. However, very 
interestingly, this construct showed the same imipramine-sensitive cytoplasmic 
uptake as the free peptide, in spite of a total molecular weight of 22 kDa (CED + 
peptides). So far, observations by us [37] and others [9] had shown that this uptake 
is restricted to small molecules only. In fact, elongation of nona-arginine by only a 
heptapeptide strongly reduced the efficiency of this uptake route. The molecular 
details of the nucleation zone dependent uptake still remain elusive. Based on the 
sphingomyelinase dependence and the formation of ceramide, a lipid that forms 
membrane micro domains [48], we proposed a model according to which peptides 
enter along domain boundaries in a non-disruptive manner. Even though still 
speculative in nature, the uptake that we observed here demonstrates that a 
continuous display of arginines along a flexible, linear scaffold enables passage 
through these domain boundaries also for larger molecules. It is tempting to 
assume that the peptides act like pearls on a string. The ability to also drive larger 
molecules across the membrane by this mechanism further supports a privileged 
role for arginines for partitioning into lipid bilayers. Furthermore, local arginine 
density instead of the absolute concentration of molecules is decisive in triggering 
this uptake route as in both cases the concentration of nona-arginine was 20 μM. 
 Nevertheless, the nucleation zone dependent entry was superimposed by a 
stronger membrane-perturbation, demonstrating that a covalent linkage to a 
linear scaffold is not equivalent to the addition as independent molecules. On 
HeLa cells, already at a peptide concentration of 1 μM the multivalent conjugate 
Also LAT was affected more strongly than PLCγ1 consistent with the indirect 
binding of LAT as part of a protein complex which provides several points for 
interference with the interaction. However, there was little difference between R9 
and Dex-(R9)5. 
5.4 Discussion  
Oligoarginines have gained ample attention as CPPs due to their high internaliza-
tion efficiency [24, 25, 54], [55]. An increase of the valency of the guanidino-group 
through a multivalent display of oligoarginines further increases uptake efficiency 
[29]. So far, investigations of multivalency have focused on uptake efficiency and 
Figure 5.6   Impact of R9 and Dex-(R9)5 on protein-protein interactions. 
Peptide microarrays were incubated with Jurkat cell lysates in the presence and absence of free R9 or the 
conjugate. Colored squares indicate ratios of signals of treated cell lysates over untreated lysates on 
respective peptides and respective coefficients of variation (CV). A cross relates to a signal that was lost 
in the presence of peptide or conjugate. Cells were either resting (HBS) or stimulated with the broad-range 
phosphatase inhibitor pervanadate (PV). All data are mean values of three independent experiments. 
Shown are those nine out of thirty one peptides on the arrays for which signals could be observed.
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concentration of 120 g/L corresponding to 6 mM [58]. For Dex-(R9)5 no cross-linking 
occurred in the presence of serum, indicating a strong serum binding of the 
conjugate that competed for membrane interactions [61]. Erythrocytes do not 
possess endocytosis and also lack sphingomyelinase demonstrating that the 
increased toxicity for HeLa and Jurkat cells is a consequence of the reaction of the 
nucleated cells towards the conjugate rather than a membrane disruption caused 
by the physicochemical characteristics of the conjugate. This is also supported by 
the reduced membrane disruption for HeLa cells in which the sphingomyelinase- 
dependent uptake had been abolished by imipramine treatment.
 Since arginine-rich CPPs have already been shown to interact with actin and 
stabilize stress fibers [46], we set out to test whether R9 and Dex-(R9)5 also had an 
impact on molecular interactions inside the cell. We opted for our peptide mi-
croarray-based approach as it provides a straightforward means to probe for the 
perturbation of several interactions in parallel and furthermore also captures an 
impact on the formation of signaling complexes. Both R9 and the Dex-(R9)5 
conjugate had a similar disturbing effect on interactions mediated by proline-rich 
peptides. It is difficult to predict to which degree this disruptive potential will be 
significant in vivo. However, given the fact that polyvalency did not increase the 
disrupting behavior, we consider it highly unlikely that also at significantly higher 
concentrations R9 will severely disturb protein interactions in cellular signaling. 
This is also in accordance with the fact that the massive cytosolic import that is 
observed for nucleation zone-dependent uptake does not cause any acute toxicity 
or perturbation of cell structure. 
5.5 Conclusions  
In summary, our analyses show that for arginine-rich CPPs multivalency on a 
linear scaffold affords a high avidity that critically affects the interaction with 
cellular membranes. As demonstrated for binding of R9 to erythrocytes, no 
binding is detected for the free peptide while strong binding and also cross-linking 
into erythrocyte stacks/aggregates occurs for the multivalent Dex-(R9)5 conjugate. 
For HeLa and Jurkat cells, this multivalency strongly increases toxicity. The 
observed toxicity for both cell lines demonstrates that this increase in avidity is 
also observed for Jurkat cells with low levels of glycocalyx, indicating that 
interactions with lipids play a more prominent role. In addition, the membrane 
disruptive behavior is a function of peptide uptake and not of the conjugate alone. 
These results clearly demonstrate that arginine-rich CPPs engage membrane 
structures just strong enough to trigger uptake while avoiding detrimental 
multivalent interactions that disturb membrane organization of larger areas. 
showed significant long-term toxicity over a period of 24 h. This membrane-disrup-
tive capacity was even enhanced on Jurkat cells. Jurkat cells possess only little 
glycocalyx [39]. While we cannot exclude that the glycocalyx present on Jurkat 
cells mediates the observed interaction, the strong membrane perturbation 
induced by the conjugate on the Jurkat cells and enrichment in the plasma 
membrane indicates that the peptide exerts a much stronger perturbating effect 
on the lipid bilayer. It is reasonable to assume that this is a consequence of the 
peptide gaining more readily access to the lipid bilayer and interacting with lipid 
head groups. Exposure of negatively charged phosphatidylserines further 
enhances this interaction. One may also envision that an initial local exposure of 
phosphatidylserine further promotes membrane association and thus membrane 
perturbation.
 It is notable that the massive membrane staining was restricted to Jurkat cells 
and also that for Jurkat cells, the conjugate did not gain access to the cytoplasm. In 
our opinion, the most likely way of reasoning is that in Hela cells the conjugate 
induces rapid uptake and that interactions with the glycocalyx shield the lipid 
bilayer, while for Jurkat cells, in the absence of a pronounced glycocalyx the 
perturbation of the lipid bilayer dominates and the peptide is sequestered by the 
plasma membrane and therefore not able to reach the cytosol.
 Our results differ from those of Kawamura et al. [29], who showed that the 
tetravalent display of deca-arginine at the N-terminus of the p53 tetramerization 
domain did not confer any toxicity to CHO cells at a peptide concentration of up to 
25 μM for 4 h. This discrepancy suggests that a conformationally constraint 
arrangement of oligoarginines as part of a macromolecule has a lower mem-
brane-disturbing potential, an observation in line with the absence of toxicity of 
CPP-functionalized quantum dots [56] and nanoparticles [57]. However, very 
interestingly, the capacity to engage in interactions with the lipid bilayer by itself 
was not sufficient for causing severe toxicity. The dextran conjugate also strongly 
bound to and even cross-linked erythrocytes. While this lead to exposure of phos-
phatidylserine in a considerable number of cells, there was no disruption of cells 
and massive lysis.
 In contrast, at a concentration of 6 μM, R9 was completely indifferent to erythro - 
cytes. These observations demonstrate that with a higher degree of multivalency, 
when linked to a linear scaffold, oligoarginine acquires fundamentally new 
 characteristics. Several articles have reported on such aggregation behavior of 
erythrocytes being dependent on the size and concentration of polymers such as 
dextran and also on the surface charges on the erythrocyte membrane [58, 59, 60]. 
However, the minimum size of dextran reported to cause erythrocyte aggregation 
is 40 kDa at concentrations of 30-40 g/L corresponding to 750 μM-1 mM [58]. A 
smaller dextran with 20 kDa was not able to induce any aggregation up to a 
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1H NMR (D2O, 300 MHz): δ= 2.65 (t, 2 H, CH2COOH), 3.25-4.1 (m, CH2CH2COOH, 
C(2-6)H (glucose units)), 4.93 - 5.30 (m, 1 H, C(1)H) ppm; 13C NMR (D2O, 75 MHz): δ= 
34.20 (CH2COOH), 65.03 (OCH2CH2COOH), 69.03 (C(4) glucose unit), 69.67 (C(2) 
glucose unit), 70.89 (C(4) glucose unit), 72.89(C(3) glucose unit), 97.18 (C(1) glucose 
unit, 175.39 (CH2COOH) ppm; 
S5.1.2 N-(tert-Butoxycarbonyl)-1,2-diaminoethane (5) 
A solution of 1,2-diaminoethane (27 mL, 400 mmol) in CHCl3 (400 mL) was cooled 
to a temperature of 0°C. Boc-anhydride (8.7 g, 40 mmol) dissolved in CHCl3 (200 
mL) was added drop wise over 3 h. That mixture was stirred for a further 30 min 
at 0°C and afterwards allowed to warm to room temperature overnight. After 
removing the solvent by evaporation, the remaining residue was dissolved in 3 N 
Na2CO3 (300 mL) and the mixture extracted with CHCl3 (3 x 200 mL). The organic 
phase was dried over Na2SO4 and evaporated to provide the product as a colorless 
oil (yield: 6.4 g, 98%).
1H NMR (300 MHz, CDCl3): δ = 1.35 (s, 9 H, CCH3), 2.69 (t, 2 H, CH2NHBoc), 3.07 (q, 2 
H, CH2CH2NHBoc), 5.11 (br s, 1 H, NHBoc) ppm; 13C NMR (75 MHz, CDCl3): δ = 27.87 
(CCH3), 41.36 (H2NCH2CH2), 42.93 (CH2NHBoc), 78.52 (CCH3), 155.73 (NHCOO) ppm;
HRMS (ESI-TOF): m/z calculated for C7H16N2O2: 161.1285 [M+H]+. Found 161.1285 g/
mol [M+H]+.
S5.1.3 N-(2-((tert-Butoxycarbonyl)aminoethyl)maleimide (6) 
To a solution of NEt3 (6.6 mL, 47.79 mmol) and 5 (5.1 g, 31.9 mmol) in Et2O (60 mL), 
a solution of maleic anhydride (3.1 g, 31.9 mmol) in Et2O (60 mL) was added drop 
wise at 0°C. After complete addition, the mixture was stirred for 4 h while being 
allowed to reach room temperature. The solvent was removed and the residue was 
dissolved in acetone (150 mL). Et3N (8.8 mL, 63.7 mmol) was added and the mixture 
was heated to reflux. After adding acetic anhydride (4.5 mL, 47.8 mmol), the 
solution was refluxed for 20 h. The solvent was removed under reduced pressure 
and the remaining dark brown oily residue worked up by chromatography of the 
over silica gel (EtOAc/hexane 1:1). After removing the solvent a white solid was 
obtained as product (yield: 3.7 g, 48.1%).
1H NMR (CDCl3, 300 MHz): δ = 1.4 (s, 9 H, CCH3), 3.34 (q, 2 H, J = 4.9 Hz, CH2CH2NHBoc), 
3.66 (t, 2 H, J = 5.1 Hz, CH2CH2NHBoc), 4.74 (br s, 1 H, NHBoc), 6.71 (s, 2 H, CHCHCON) 
ppm; 13C NMR (CDCl3, 75 MHz): δ = 27.83 (CCH3), 37.5 (CH2CH2NHBoc), 38.91 
(CH2CH2NHBoc) 79.07 (CCH3), 133.96 (CHCHCON), 155.46 (NHCOO), 170.34 (CONCO) 
ppm; HRMS (ESI-TOF): m/z calculated for C11H16N2O4: 241.1183 [M+H]+. Found 
241.1188 [M+H]+.
S5 Supporting Information
S5.1. Synthesis of Dex-(R9)5 using maleimide coupling
S5.1.1 2-Carboxyethyl dextran (CED) (2) 
In a 1 N NaOH solution (25 mL) dextran (5 g, 1 mmol, MW 10 kDa, PDI =1.58) was 
stirred. At a temperature of 30°C acryl amide (0.9 g, 12.5 mmol) was added and 
stirred. After 12 h the temperature was increased to 50°C and the solution was 
stirred for an additional 24 h. After neutralizing the solution, the oligosaccharide 
products were precipitated by drop wise addition of methanol under stirring. The 
solvent was removed by filtration, the residue washed with methanol and dried. 
The white solid was dissolved in water (25 mL) and dialyzed (benzoylated dialysis 
tubing, pore size: 2000 NMWCO (nominal molecular weight cut-off), Sigma 
Aldrich) twice with 0.1 N HCl (10 L) and water (2 x 10 L) over 24 h. After lyophilization, 
a white powder was obtained in a yield of 4 g (72%, 13 carboxyethyl groups per 
dextran). The average number of carboxyethyl groups per dextran was quantified 
by 1H NMR spectroscopy and confirmed by titration against 0.1 N NaOH.
Figure S5.1.1   Synthesis protocol for Dex-(R9)5. 
Native dextran was derivatized to an activated polymer, which could then be functionalized with 
cysteine- containing peptides including 8 and 9.
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S5.1.7 Synthesis of nona-arginine dextran conjugates (4) 
Polymer 3 (10 mg, 1 μmol) loaded with 13 maleimide groups (13 μmol) was dissolved in 
MES buffer (1 mL, pH 6.5). After degassing, and setting the flask under nitrogen 
atmosphere, N-terminal cysteine-extended nona-arginine (R9) 9 (11 mg, 7 eq.) and 
 cysteinyllysinyl fluorescein amide (CK(Fluo)) 8 (2 mg 3 eq.) were added. The pH value 
was checked and the mixture stirred for further 16 h. After concentrating the solution, 
the product was precipitated with MeOH. After several washing steps with MeOH and 
DMF the solid was dissolved in water (2.5 mL) and purified twice using PD-10 columns. 
After lyophilization the resulting conjugate was obtained as an orange powder. 
 The numbers of attached peptides per dextran molecule was determined by 
quantitative amino acid analysis (Genaxxon Bioscience, Ulm, Germany). A weighed 
sample of the peptide polymer was subjected to peptide hydrolysis (6 N HCl at 110 °C 
in a closed pressure vessel). Under these conditions all amide bonds are cleaved 
quantitatively. Subsequently, all free amino acids were functionalized with a 
chromophore and analzyed by HPLC using the integration of peaks for quantification. 
The results of quantitative amino acid analysis are summarized in Table S5.1. 
Compound 4 was found to contain 4.383 μmol of arginine per g, corresponding to 
a loading of 487 nmol of nona-arginine per g. Taking into account that the sample 
contained 95 nmol/g dextran this resulted in a loading of 487/95 = 5.12 nona- 
arginine copies per dextran molecule. Loading quantification was confirmed by 
1H-NMR analysis at 300 MHz in D2O (see Figure S5.1.2) and by measuring the 
absorption of carboxyfluorescein.
 With this synthesis procedure and based on previous analysis [S1, S2], it is 
expected that the nona-arginines are distributed randomly over the polymer. 
 Carboxyethylation was found to be selective for the 2-hydroxy position of the 
glucose monomers, probably due to the higher acidity of this position. Therefore, 
it can be excluded that more than one functional group is located at one glucose 
monomer and it can be assumed that carboxyethylation is randomly distributed 
on the glucose units. 
S5.2.  Dex-(R9)5 exhibits sphingomyelinase-dependent uptake and 
nucleolar staining
HeLa cells (4 x 104/well) were seeded in 8-well microscopy chambers (Nalge Nunc 
International, New York, USA), 24 h prior to peptide addition. Cells were incubated 
with 4 μM Dex-(R9)5 or 20 μM R9 in RPMI 1640 supplemented with 10% FBS (heat 
inactivated) for 20 min. For assessing the effect of imipramine on peptide uptake, 
cells were pre-incubated for 45 min with 30 μM imipramine in RPMI 1640 without 
serum. For subsequent incubation with peptide, 30 μM imipramine was 
co-incubated with peptide in medium containing 10% FBS. Cells were washed 
twice with medium and immediately imaged by microscopy.
S5.1.4 N-(2-Aminoethyl)maleimide (7) A 
solution of 6 (4.6 g, 19.2 mmol) in DCM (35 mL) was cooled to 0°C. TFA (27 mL) was 
added and the solution was stirred for 1 h while being allowed to reach room 
temperature. After concentrating, the mixture was precipitated with cold Et2O (50 
mL). Washing steps with cold Et2O (3 x 50 mL) followed by evaporation of remaining 
solvent provided a white solid as product (yield: 2.5 g, 93%).
1H NMR (CDCl3, 300 MHz): δ = 3.18 (t, 2 H, J = 5.8 Hz, NH3+CH2CH2), 3.79 (t, 2 H, J = 
5.8 Hz, NH3+CH2CH2N), 6.86 (s, 2 H, COCH2CH2CON) ppm; 13C NMR (CDCl3, 75 
MHz): δ = 34.92 (NH3+CH2CH2), 38.28 (NH3+CH2CH2), 134.6 (COCH2CH2CO), 172.53 
(COCH2CH2CO) ppm; HRMS (ESI-TOF): m/z calculated for C6H8N2O2: 141.0659 
[M+H]+. Found 141.0662 [M+H]+.
S5.1.5 Maleimidoethyl amidoethyl dextran (Maleimide dextran) (3) 
CED 1 (0.2 g, 0.02 mmol) bearing 13 carboxy groups (0.26 mmol) and maleimide 4 
(0.69 g, 2.69 mmol) were dissolved in water (1 mL). After adjusting a pH value of 
6.5-7, EDC (0.26 g, 1.35 mmol) was added. After 1 h further EDC (0.26 g, 1.35 mmol) 
was added and the solution was allowed to stir for 4 h. After precipitating the 
mixture with methanol, the remaining solid was separated and washed with 
methanol and DMF several times. For final cleaning, the solid was dissolved in 
water (2.5 mL) and purified over Sephadex G-25. Lyophilization led to a product as 
a white solid (yield: 0.19 g, 82%). The quantification of maleimide groups per 
dextran was performed using 1H NMR spectroscopy. It could be proven that under 
the used conditions all carboxy groups on the dextran reacted to the corresponding 
maleimidoethyl amide groups.
1H NMR (D2O, 300 MHz): δ = 2.48 (t, 2 H, J = 4.7, CH2CH2COOH), 3.3-4.1 (m, 
CH2CH2COOH, H (glucose units)), 4.98, -5.3 (m, anomeric H), 6.89 (s, 2 H, COCHCHCO) 
ppm; 13C NMR (D2O, 75 MHz): δ= 36.38 (CH2CONH), 37.12 (NHCH2CH2NH2), 39.97 
(NHCH2CH2N), 65.35 (C(6)H2), 65.58 (C(OCH2CH2CONH), 67.94 (C(4) Glucose), 71.41 
(C(5) Glucose), 72.57 (C(3)H Glucose), 74.68 (C(2) Glucose), 98.71 (C(1) Glucose), 179.29 
(CONH), 181.82 (CH2CONH) ppm.
S5.1.6 Peptide synthesis (8, 9) 
Peptides were synthesized manually or by automated Fmoc-SPPS on TentaGel S Ram 
amide (0.2 mmol/g) resins. Peptides were identified by LCMS, HRMS and Maldi TOF.
N-cysteinyl-lysinyl-5(6)-carboxyfluorescein (H2N-CK(Fluo)-CONH2) (8)
N-cysteinyl-nona-arginine amide (H2N-CRRRRRRRRR-CONH2) (9)
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S5.3. Effect of imipramine on peptide internalization
In order to investigate the direct interference of imipramine with peptide internal-
ization, uptake of R9 or Dex-(R9)5 was compared in cells either pre-incubated with 
imipramine or in cells pre-incubated and co-incubated with imipramine. Briefly, 
HeLa cells (4 x 104/well) were seeded in 8-well microscopy chambers (Nalge Nunc 
International, New York, USA) 24 h prior to peptide addition. Cells were pre-incubated 
for 45 min with 30 μM imipramine in RPMI 1640 without serum. Cells were washed 
thrice in RPMI 1640 supplemented with 10% FCS (fetal calf serum) and incubated 
with 4 μM Dex-(R9)5 or 20 μM R9 in RPMI 1640 supplemented with 10% FCS for 20 
min in presence or absence of 30 μM imipramine. Cells were washed twice with 
medium and imaged with microscopy. After microscopy, cells were washed twice 
with HBS (HEPES-buffered saline, HBS; 10 mM HEPES, 135 mM NaCl, 5 mM KCl, 1 
mM MgCl2, 1.8 mM CaCl2, pH 7.4), trypsinized, centrifuged and finally resuspended 
in 200 μL RPMI 1640 supplemented with 10% FCS. Fluorescence was measured with 
excitation at 488 nm using a BD FACSCalibur flow cytometer (BD Biosciences, 
Erembodegem, Belgium). 1 x 104 cells were gated using forward and sideward scatter 
and were analyzed with the Summit software (Fort Collins, USA).
Table S5.1   Results of amino acid analysis for the peptide-dextran. 
On the basis of the measured peptide concentrations, the numbers of the peptides 
per polymer could be determined.
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 # Name Concentration /  
mg peptide polymer [nmol]
Composition  
of peptide polymers
CK(Fluo)- 
peptide
R9  
peptide
dextran Fluo-groups 
per dextran
R9-groups  
per dextran
4 Dex-5R-CK(Fluo) 89 487 95 0.9 5.2
*dextran loaded with peptides and N-cysteinyl-lysinyl-5(6)-carboxyfluorescein (H2N-CK(Fluo)-CONH2)
Figure S5.1.2   1H-NMR-spectrum (300 MHz, D2O) of nona-arginine loaded, 
carboxyfluorescein-labeled peptide dextran 4. 
The anomeric protons of the dextran monomers (glucose units) are at 4.9-5.1 ppm, the beta- and gam-
ma-methylene groups of the arginine side chain at 1.2-1.9 ppm and the aromatic protons or the car-
boxy-fluorescein at 6.7-7.6 ppm. To quantitate the degree of substitution, the integrated peaks of the 
fluorescein and arginine-methylene protons were related to the signal intensity of the anomeric protons 
of the glucose. With on average 62 glucose units per dextran the degree of substitution could be 
determined and cross-validated against the amino acid analysis and UV/Vis-measurements (fluorescein).
Figure S5.2   Cellular distribution and imipramine-sensitive uptake of Dex-(R9)5. 
Following a 45 min pretreatment with/without imipramine (imi) in serum-free RPMI, HeLa cells were 
incubated with 20 μM R9 or 4 μM Dex-(R9)5 for 20 min at 37°C in the presence or absence of 30 μM 
imipramine followed by washing and imaging with confocal microscopy. Microscopy settings for image 
acquisition of all samples were adjusted for R9 to avoid saturation. One confocal slice is shown for all the 
microscopy images. Scale bars correspond to 50 μm. One representative experiment of at least three 
experiments is shown. Brightness and contrast has been adjusted in the transmission images for 
visualization purposes using parameters to yield the best possible result for transmission images.
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S5.4.  Time lapse microscopy to monitor cell aggregation and 
phosphatidylserine exposure in erythrocytes treated with 
Dex-(R9)5 or R9
Fresh blood was drawn from a healthy volunteer and centrifuged at 1500 x g for 10 
min. The erythrocyte pellet was washed twice with calcium-free Ringer to prevent 
complement activation and once with complete Ringer. Erythrocytes were 
resuspended to 1 million cells/well in 100 μL of Ringer. 0.6 μM Dex-(R9)5 or 6 μM R9 
and Annexin-V (1:25) were added in an equal volume of Ringer to the cells. Image 
acquisition was started immediately after addition and continued over a period of 
20 min with intervals of 10 seconds. 
S5.5.  Neutralizing effect of serum on the erythrocyte binding 
capacity of Dex-(R9)5
To investigate whether the membrane binding potential of Dex-(R9)5 would be 
maintained in full blood, erythrocytes were incubated with the multivalent 
conjugate in the presence of human serum. Fresh blood was drawn into coagulation 
tubes (BD Vacutainer SST gel tubes), kept undisturbed for 1 h in an upright position 
Figure S5.3   Effect of imipramine on peptide internalization. 
(A) Following a 45 min pretreatment with/without imipramine in serum-free RPMI, HeLa cells were 
incubated with 20 μM R9 or 4 μM Dex-(R9)5 for 20 min at 37°C in the presence or absence of 30 μM 
imipramine followed by washing and imaging with confocal microscopy. For the pretreatment samples 
(no co-incubation with imipramine), cells were washed thrice before incubation with R9 or Dex-(R9)5. 
One confocal slice is shown for all the microscopy images. Scale bars correspond to 20 μm. (B-C) Flow 
cytometric analysis of the same samples. Median fluorescence were normalized to R9 and Dex-(R9)5 
respectively and represented as percentage. (wo = without imipramine, pre = pre-incubation only, pre+co 
= pre-incubation and co-incubation).
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Figure S5.4.1   Time lapse confocal microscopy to monitor cell aggregation and 
phosphatidylserine exposure in erythrocytes induced by 
Dex-(R9)5. 
Washed erythrocytes were seeded in 8-well microscopy chambers in Ringer in the presence of Alexa- 647-
labeled Annexin-V and treated with 0.6 μM Dex-(R9)5. Images were taken immediately after addition for 
a period of 20 min. Each image shows one confocal slice. Scale bar corresponds to 20 μm. 
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and then centrifuged at 1300 x g for 10 min. Serum was transferred into a fresh 
tube and stored at 4°C until erythrocytes were ready for use. Erythrocytes were 
separated from plasma and white blood cells using the Ficoll-Paque reagent, 
washed in calcium-free Ringer and finally resuspended in isolated serum from the 
same volunteer. An 8-well chambered coverslip was used for confocal microscopy. 
Erythrocytes were diluted to 1 million cells/well in 100 μL of serum. R9/Dex-(R9)5/
CED were added in an equal volume of serum to the cells at the indicated 
concentrations and imaged by time lapse microscopy. 
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Figure S5.4.2   Incubation of erythrocytes with R9. 
The free peptide does not induce erythrocyte aggregation. Erythrocytes were treated as stated above 
with 6 μM R9. Images were taken immediately after addition over a period of 20 min with intervals of 10 
seconds. Each image shows one confocal slice. Scale bar corresponds to 20 μm.
Figure S5.5   Serum neutralizes the erythrocyte-binding capacity of Dex-(R9)5. 
Erythrocytes were suspended in either Ringer or in serum and seeded in an 8-well microscopy chamber. 
0.6 μM Dex-(R9)5, 6 μM R9 or 0.6 μM CED were added and samples were immediately imaged with confocal 
microscopy for 20 min. Scale bar corresponds to 20 μm.
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POG-488; bacterial sphingomyelinase, bSMase.
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6.1 Introduction
Since their discovery, cell-penetrating peptides (CPPs) have been utilized 
extensively as delivery vectors for the cellular import a range of different molecules 
into cells [1, 2]. Also in the development of novel cancer therapies, CPPs have been 
used as delivery vectors of chemotherapeutics [3-6]. According to the current 
understanding, apart from inducing cellular uptake, the CPP exerts no biological 
activity that could potentially interfere with the activity of the cargo. However, 
also CPPs may affect cellular physiology in more subtle ways than just cytotoxicity 
[7] thus revoking the original concept of CPPs acting as ‘Trojan horses’ without 
intrinsic biological activity. It has been shown for example that arginine-rich CPPs 
exert a stabilizing effect on filamentous actin in cancer cells [8]. Furthermore, 
induction of endocytosis can induce internalization of certain growth factor 
receptors, leading to a desensitization of cells to external stimuli [9]. 
 Recently, we have shown that the rapid cytoplasmic uptake of arginine-rich 
CPPs which occurs at peptide concentrations above 10 mM involves the formation 
of ceramide, a phenomenon that depends on a CPP-induced translocation of acid 
sphingomyelinase (ASMase) to the outer leaflet of the plasma membrane [10]. 
ASMase is a lysosomal enzyme that hydrolyzes sphingomyelin in the plasma 
membrane to ceramide and phosphorylcholine [11]. Activation of ASMase occurs as 
a response to extracellular stress stimuli such as chemotherapeutics [12, 13] and 
radiation [14]. Ceramide acts as a pro-apoptotic tumor-supressor lipid in the sphin-
golipid-signaling pathways that contribute to the control of cell death and survival 
[11, 15]. An impaired ceramide metabolism has been reported to induce malignancy, 
metastasis and drug resistance in cancer [16, 17]. Defects in the generation of ceramide 
by the sphingomyelinases [18, 19], abnormal distribution of sphingomyelin in the 
plasma membrane [20] and the rapid conversion of ceramide to complex 
sphingolipids [21, 22] are believed to be the general causes for these malfunctions. 
Hence, a multitude of strategies to interfere with ceramide metabolism have been 
Abstract
Cell-penetrating peptides (CPPs) are being used as delivery vectors for the cellular 
import of a wide range of molecules that otherwise do not cross the plasma 
membrane. Entry of arginine-rich CPPs activates acid sphingomyelinase (ASMase) 
leading to the formation of ceramide, a pro-apoptotic lipid, in the plasma 
membrane. Here, we demonstrate that those CPPs that induce ceramide formation 
enhance the activity of the cancer drug Paclitaxel. Importantly, this does not 
require a covalent coupling of CPP and drug and does not involve an enhancement 
of drug uptake. In particular, the proteolytically stable D-nona-arginine (r9) 
peptide sensitizes ovarian cancer cells to Paclitaxel. Downregulation of ASMase 
completely obliterated this potentiating effect. Moreover, the sensitizing effect is 
absent in both, proliferating and quiescent primary fibroblasts. Overall, these 
results demonstrate that CPP-induced ceramide formation constitutes a promising 
route to enhance the activity of chemotherapeutics. As CPPs show no toxicity to 
cells by themselves, this combination may lead to treatments with lower side 
effects.
Sensitization of cancer cells for chemotherapeutic drugs by arginine-rich CPPs. 
Instead of mediating import through covalent conjugation, CPP and chemothera-
peutic are added independently. Sensitization is based on the capacity of the CPP 
to induce ceramide formation that acts as a pro-apoptotic signaling lipid.
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HeLa cells were cultured in RPMI 1640 with stable glutamine and supplemented 
with 10% heat-inactivated FCS and subcultured every 2 days. IMR-90 human 
fibroblast cells were grown in ATCC-formulated Eagle’s Minimum Essential 
Medium (MEM; ATCC/LGC Standards) supplemented with 10% heat-inactivated FCS 
and passaged every 4 days. Cells were maintained at 37°C in a humidified incubator 
containing 5% CO2. To induce quiescence in fibroblasts, a modified protocol of Lu 
et	 al.	 [31] was used. Briefly, 1 x 104 IMR-90 fibroblasts were seeded in MEM 
supplemented with 10% FCS in a 96-well microtiter plate and grown to confluence 
for 4 days. On the 5th day, cells were washed with serum-free MEM and were 
cultured 3 additional days in MEM supplemented with 0.1% FCS. 
6.2.3 Confocal microscopy 
Confocal laser scanning microscopy was performed on a TCS SP5 confocal 
microscope (Leica Microsystems, Mannheim, Germany) equipped with an HCX PL 
APO 63x 1.2 N.A. water immersion lens. Cells were maintained at 37°C on a tem-
perature-controlled microscope stage. Fluorescence was excited using the 488 nm 
line of an argon-ion laser or a 633 nm helium-neon laser and detected at 500-550 
nm or 650-750 nm. For all microscopy images, one confocal slice is shown. For 
detection of peptide uptake Ovcar-3 cells (8 x 104/well) or HeLa cells (4 x 104/well) 
were seeded in 8-well microscopy chambers (Nalge Nunc International, New York, 
USA), 24 h prior to peptide addition. Cells were incubated with the indicated 
concentrations of the fluorescently labeled peptides in their respective tissue 
culture medium supplemented with FCS for 20 min. For assessing the effect of 
imipramine on peptide uptake, cells were pre-incubated for 45 min with 30 μM 
imipramine (Sigma-Aldrich) in RPMI 1640 without serum. For subsequent 
incubation with peptide, 30 μM imipramine was co-incubated with peptide in 
growth medium supplemented with FCS. Cells were washed twice after the 
incubation and were analyzed immediately by confocal microscopy.
6.2.4 Flow cytometry 
Ovcar-3 cells (1.2 x 105/well) or HeLa cells (8 x 104/well) were seeded in 24-well 
plates 24 h prior to peptide addition. Cells were incubated with fluorescently 
labeled peptides with or without imipramine as described above. After incubations, 
cells were washed twice, trypsinized, centrifuged and finally resuspended in 200 
μL HEPES-buffered saline (HBS; 10 mM HEPES, 135 mM NaCl, 5 mM KCl, 1 mM 
MgCl2, 1.8 mM CaCl2, pH 7.4). Fluorescence of 1 x 104 cells (gated using forward 
and sideward scatter) was measured with excitation at 488 nm using a BD FACScan 
flow cytometer (BD Biosciences, Erembodegem, Belgium). Results were analyzed 
with the Summit software (Fort Collins, USA).
conceived, and the results indicate that deregulated ceramide metabolism is a 
targetable characteristic to reverse malignancy or multidrug resistance in cancer 
[23-26].
 Ovarian cancer is one of the leading malignant gynecological cancers in 
women [27]. The most common current therapy is the intravenous application of a 
combination of a taxane, such as Paclitaxel, with a platinum-based compound 
together with intraperitoneal injection of the same therapeutics [28]. Nevertheless, 
recurrence and resistance are constant obstacles motivating the search for new 
treatment modalities [29]. 
 Here, we demonstrate that the capacity of arginine-rich CPPs to induce 
ceramide formation can be exploited to enhance the bioactivity of the chemother-
apeutic drug Paclitaxel in ovarian cancer cells. In contrast to the strategies 
explored so far, this increase is not achieved through covalent coupling of a CPP 
with a drug and enhanced delivery. Instead, both CPP and drug are added to the 
cells as independent molecular entities. 
 For a series of CPPs the capacity to enhance Paclitaxel activity correlated with 
the ability to induce ASMase-dependent uptake. Detailed functional studies to 
validate the involvement of ceramide formation focused on the proteolytically 
stable D-enantiomer of nona-arginine (r9). Importantly, the cytotoxicity enhancing 
effect is specific for cancer cells, as demonstrated for quiescent and proliferating 
primary IMR-90 fibroblasts. Hence, the application of CPP represents a new 
approach to modulate ceramide levels in order to increase the activity of chemo-
therapeutic drugs.
6.2 Materials and methods
6.2.1 Peptides 
Peptides (Table 6.1) were purchased from EMC microcollections (Tübingen, 
Germany). Purity was evaluated by high-performance liquid chromatography 
(HPLC) and identity was confirmed by mass spectrometry. For unlabeled peptides, 
concentrations were determined by peak-integration of 1H-NMR spectra (SI, Figure 
S6.1). The CPP hLF was oxidized before use as described, previously [30]. 
6.2.2 Tissue culture 
Ovcar-3 cells (HTB-161), HeLa cells (CCL-2) and IMR-90 primary fibroblasts (CCL-186) 
were from the ATCC (LGC Standards, Wesel, Germany). Ovcar-3 cells were cultured 
in RPMI 1640 with stable glutamine and supplemented with 20% heat-inactivated 
fetal calf serum (FCS; PAN Biotech, Aidenbach, Germany), 0.01mg/mL bovine insulin 
(Sigma-Aldrich, Zwijndrecht, The Netherlands) and subcultured every 3 days. 
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control, an Alexa-633-conjugated goat-anti mouse IgG (H + L) secondary antibody 
(Invitrogen, 1:100 dilution) was used.
6.2.8 Downregulation of ASMase 
Ovcar-3 and HeLa cells were seeded in 6-well plates to 30-50% confluency. Cells 
were transfected with 50 nM of siGENOME SMARTpool human SMPD-1 siRNA 
(si-SMPD; ThermoFischer/Fermentas) or siGENOME non-targeting siRNA pool 2 
(si-NT; ThermoFischer/Fermentas) using 2 μM of PepFect6 (a kind gift from Mattias 
Hällbrink, Dept. of Neurochemistry, Stockholm University) as a transfection agent 
[35]. Briefly, PepFect6 was mixed with siRNA (molar ratio of PepFect to siRNA, 40:1) 
in RNAse-free water (ThermoFischer/Fermentas) in one-tenth of the final treatment 
volume (150 μL) and incubated at room temperature for 1 h. The PepFect6-siRNA 
complexes were then added to the wells containing 1.35 mL of serum-free media. 
Cells were incubated for 4 h after which 3 mL of fresh medium (supplemented 
with FCS) was added to the wells. The next day, the old medium was exchanged 
with fresh medium (supplemented with FCS) and cells were cultivated with the 
siRNA for 2 days (total time of incubation was 72 h from transfection). 
Downregulation of acid spingomyelinase was validated using Western blot.
6.2.9 Western Blot 
Non-transfected and siRNA-transfected Ovcar-3 or HeLa cells were washed in 
HEPES-saline (20 mM HEPES, 0.132 mM NaCl, 1 mM CaCl2, 0.7 mM MgCl2, 0.8 mM 
MgSO4, 5.4 mM KCl, pH 7.3) and lysed in freshly prepared ice-cold lysis buffer (lysis 
solution (25 mM HEPES, 0.1% SDS, 0.5% deoxycholate, 1% TritonX-100, 10 mM EDTA, 
10 mM sodium pyrophosphate, 10 mM NaF, 125 mM NaCl) diluted in an equal 
amount of HEPES-saline, the final solution contained 1x protease inhibitor cocktail 
(Roche Diagnostics, Manheim, Germany), pH 7.3). Protein amounts were estimated 
in the whole-cell lysates using the Bradford assay (BioRad, Veenendaal, The 
Netherlands). Equal amounts of proteins were separated in a 10% SDS gel, 
transferred to a PVDF membrane and blocked for 30 min in blocking buffer 
(StartingBlock (TBS) Blocking Buffer, ThermoFischer/Fermentas). Blots were then 
incubated overnight at 4ºC in a solution containing 50% blocking buffer (diluted 
with HEPES-saline) with rabbit polyclonal anti acid sphinogomyelinase antibody 
(1:200, H-181, SantaCruz Biotechnology, Santa Cruz, USA) or anti β-actin 
monoclonal mouse antibody (1:10,000, clone AC-15, Sigma-Aldrich). Peroxidase-con-
jugated anti rabbit IgG (whole molecule; Sigma, St. Louis, Missouri, USA) or 
AffiniPure sheep anti mouse IgG (light chain; Jackson Immunoresearch 
Laboratories, PA, USA) were used as secondary antibodies (both diluted at 1:10,000). 
Signals from protein bands were detected using enhanced chemiluminescence 
(Super signal west pico chemiluminescent substrate, ThermoFischer/Fermentas). 
6.2.5 Cell viability assay 
Ovcar-3 cells (9 x 103 cells/well), HeLa cells (7.5 x 103 cells/well) and IMR-90 primary 
fibroblasts (5 x 103 cells/well) were seeded in 96-well microtiter plates and grown 
overnight. The next day, cells were treated with unlabeled or labeled peptides and 
Paclitaxel (Fresenius Kabi, Pharmacy of the Radboud University Medical Centre) in 
the indicated concentrations for 24 h at 37ºC. For testing toxicity in quiescent 
fibroblasts, IMR-90 cells were treated at the 8th day after seeding. Cell viability was 
measured using the resazurin (Sigma-Aldrich) assay. Resazurin is a non-fluores-
cent dye that is chemically reduced to the highly fluorescent resorufin by 
metabolically active cells [32, 33]. Cells were incubated with resazurin (100 μg/mL) 
for 4 h. Fluorescence was recorded with a Synergy 2 single channel microplate 
reader (BioTek Instruments, Winooski, USA). Samples were excited at 540 ± 25 nm 
and emission was collected at 620 ± 40 nm to avoid spectral overlap of resorufin 
with carboxyfluorescein. Percentage cell survival was calculated as [(Ti–T0)/(C–
T0)]ł100 for Ti ≥ T0 and [(Ti-T0)/T0]ł100 for Ti < T0, where Ti is the fluorescence of the 
test-well after a 24-h period of exposure to the treatment, T0 is the fluorescence at 
time zero (i.e. before addition of compounds) and C is the fluorescence after 24 h of 
cell seeding. This parameter can range from +100 to -100 [34]. 
6.2.6 Uptake of Paclitaxel Oregon Green-488 (POG-488) 
Ovcar-3 cells (1.1-1.2 x 105 cells/well) were seeded in 24-well plates, 24 h prior to 
addition of POG-488 (Invitrogen, Molecular Probes, Eugene, USA). 6 μM of unlabeled 
r9 or unlabeled D-Pen were co-incubated with 1 μM of POG-488 for 2 h. After 
incubation, cells were washed twice with HBS, trypsinized, centrifuged and finally 
resuspended in 200 μL HBS. Fluorescence of 1 x 104 cells (gated using forward and 
sideward scatter) was quantified by flow cytometry.
6.2.7 Ceramide immunostaining 
Ovcar-3 cells (8 x 104/well) or HeLa cells (4 x 104/well) were seeded in 8-well 
microscopy chambers (iBidi, Martinsried, Germany) and grown overnight. Cells 
were treated with 6 μM or 20 μM of Fluo-R9, Fluo-r9, R9 or r9 for 20 min. 1000 mU/
mL sphingomyelinase from Bacillus	cereus (bSMase; specific activity ≥ 100 units/mg 
protein (Lowry), Sigma-Aldrich, St. Louis, Missouri, USA) was used as a positive 
control. Both, for Ovcar-3 and HeLa cells, RPMI 1640 supplemented with 10% FCS 
was used for the incubation with the peptides or bSMase. Cells were stained for 
ceramide without membrane permeabilization as described previously [10]. 
Surface staining of ceramide was performed using a monoclonal mouse 
anti-ceramide IgM antibody 15B4 (Alexis Biochemicals, Lausen, Switzerland; 1:50 
dilution) including the isotope (Ab allotype, anti KLH mouse IgM antibody; BD 
Pharmingen, San Diego, U.S.A.) control. For detection of ceramide and isotype 
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6.2.10 Statistical analysis 
Results represent mean ± S.E.M. (if not mentioned otherwise). Unpaired (two-tailed) 
t-test and one-way analysis of variance (ANOVA) were used as statistical methods. 
Tukey’s Multiple Comparison was used as a posthoc test. A p-value of less than 0.05 
was considered to be significant. Due to small sample sizes, variances of the 
samples were considered equal. Data were analyzed using GraphPad Prism 
(GraphPad Software, San Diego, CA, USA, version 4).
6.3 Results
6.3.1 D-nona-arginine (r9) sensitizes Ovcar-3 cells to Paclitaxel
Recently, we showed that the rapid cytoplasmic uptake of nona-arginine (R9) 
involves the activation of acid sphingomyelinase which leads to the formation of 
ceramide in the plasma membrane. Ceramide is a pro-apoptotic lipid [11, 36] that 
has been shown to potentiate the activity of cytotoxic drugs and Paclitaxel in 
particular [37]. Given this property of R9, we hypothesized that arginine-rich CPPs 
can sensitize cancer cells to the activity of the chemotherapeutic drug Paclitaxel. 
As we aimed to enhance Paclitaxel toxicity at peptide concentrations that by 
themselves do not cause any toxicity, first, we determined viability of cells exposed 
to increasing concentrations of peptide over 24 h using the resazurin assay. 
However, R9, being an L-enantiomer, is prone to proteolytic degradation in the 
tissue culture medium and inside cells. Hence, for determination of long-term 
toxicity we used the D-enantiomer, r9. r9 shows the same ASMase-dependent rapid 
uptake as R9 [38]. r9 exerted a concentration-dependent cytotoxic effect with a 
reduction in viability of about 25% at 24 μM and only 4% cell survival at 96 μM. 
At 6 μM viability was reduced by only 15% (S6, Figure S6.2) which we considered to 
be acceptable. Therefore, this concentration was selected for co-incubations with 
Paclitaxel. 
 In combination with Paclitaxel, a potentiation of Paclitaxel activity was 
observed at all tested concentrations and the degree of potentiation increased 
with Paclitaxel concentration. For 0.5 nM, 5 nM, 50 nM and 500 nM Paclitaxel cell 
survival was reduced by 1.3 fold, 1.9 fold, 3.3 fold and 6.2 fold respectively (Figure 
6.1A). Thus, at a concentration that exhibits low cellular toxicity, r9 can nonetheless 
effectively sensitize Ovcar-3 cells to Paclitaxel. The L-enantiomer R9 caused only a 
modest enhancement of Paclitaxel activity (Figure 6.1B). 
 As a first experiment to delineate whether the observed sensitization was due 
to an induction of ceramide, we also tested the D-human Lactoferrin Peptide 
(D-hLF) and D-Penetratin (D-Pen) for activity-potentiating effects (Figure 6.1C-D). 
Uptake was determined in the absence and presence of imipramine. Imipramine 
Table 6.1   Amino acid sequences of used CPPs
Name Sequence
Labeled	peptidesa
Fluo-R9 Fluo-RRRRRRRRR-NH2
Fluo-r9 Fluo-rrrrrrrrr-NH2
Fluo-D-hLF Fluo-kcfqwqrnmrkvrgppvscikr-NH2
Fluo-D-Pen Fluo-rqikiwfqnrrmkwkk-NH2
Unlabeled	peptidesb
R9 Ac-RRRRRRRRR-NH2
r9 Ac-rrrrrrrrr-NH2
D-Pen Ac-rqikiwfqnrrmkwkk-NH2
a) Labeled peptides were N-terminally labeled with carboxyfluorescein (Fluo). b) Unlabeled peptides were 
N-terminally acetylated (Ac). All peptides were C-terminally amidated (-NH2).
Figure 6.1   CPP-mediated sensitization of Paclitaxel-induced cytotoxicity in 
Ovcar-3 cells.
Ovcar-3 cells were treated with Paclitaxel without or with 6 μM (A) r9 or (B) R9 (C) Fluo D-hLF or Fluo-r9 
and (D) Fluo D-Pen or Fluo-r9 for 24 h. Cell viability was evaluated using the resazurin assay. (A) Results 
represent mean ± S.E.M. from three independent experiments (N=9); (B) Results represent mean ± S.E.M. 
from two independent experiments (N=6). (C-D) Results represent mean ± S.E.M. from three independent 
experiments (N=9); significance was calculated using unpaired two-tailed t-test (for A and B) and one-way 
ANOVA (for C and D); * < p = 0.05.
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nucleolar staining was observed (Figure 6.3A). At 6 μM, some HeLa and few Ovcar-3 
cells still showed homogenous cytoplasmic and nucleolar fluorescence while for 
most cells only punctate fluorescence, indicative of endocytic uptake, and staining 
of the plasma membrane could be seen (Figure 6.3A). As expected, addition of 
imipramine completely abolished the cytoplasmic uptake at 20 μM. Also at 6 μM, 
imipramine reduced the nucleolar fluorescence, indicating that this staining was 
the consequence of peptide entering the cytoplasm in a ceramide-dependent 
manner. The membrane association of Fluo-r9 was in agreement with our previous 
observations [38]. 
 Next, we directly probed for ceramide formation using both the carboxyfluo-
rescein-labeled and the unlabeled versions of the peptides. We compared both 
analogs in order to exclude that the fluorophore has an impact on membrane 
interactions as demonstrated for an Alexa-488-labeled peptide, recently [41]. Im-
munofluorescence with unpermeabilized fixed Ovcar-3 and HeLa cells revealed 
the generation of ceramide-rich membrane regions at 20 and 6 μM for all tested 
peptides independent of the presence of the fluorophore (Figure 6.3B, S6, Figure 
S6.4). Cells treated with bSMase as a positive control, showed a similar membrane 
staining; untreated cells and the isotype controls for both Ovcar-3 and HeLa did 
not show any staining (Figure 6.3B, S6, Figure S6.5). Nucleolar staining by Fluo-R9 
in both, Ovcar-3 and HeLa cells was, as observed previously, an effect of fixation on 
acts as an inhibitor of ASMase by inducing the degradation of the enzyme [39]. Loss 
of cytoplasmic fluorescence is therefore a rapid test for an involvement of ASMase 
in the uptake mechanism. At higher concentrations L-hLF shows imipramine- 
sensitive uptake [10], while L-Pen enters cells only via endocytosis independent 
of concentrations [40]. A similar pattern was also observed with the D-peptides 
(S6, Figure S6.3). In accordance with the characteristics of the L-amino acid 
counterparts, for Fluo-D-hLF a modest sensitization was observed, while this effect 
was absent for Fluo-D-Pen (Figure 6.1C-D). It has been mentioned before, that rapid 
cytoplasmic uptake may be a function of the presence of a fluorophore [41]. 
However, for r9, the activity-enhancing effect was independent of the presence of 
the fluorophore (Figure 6.1A, C and D). 
6.3.2  Sensitization is not due to induction of enhanced uptake of 
Paclitaxel by r9
Given the evidence that CPPs can form non-covalent complexes [42, 43] and induce 
endocytosis [9, 44], we investigated whether the observed sensitization exerted by 
r9 could also be explained by an enhanced uptake of Paclitaxel. To visualize 
Paclitaxel uptake we employed an Oregon Green 488-labeled analog (POG-488) and 
assessed uptake after 2 h incubation with flow cytometry. R9 and D-Pen were also 
included in the experiment. R9 was used as this enantiomer was shown to induce 
endocytosis more effectively than the D-analog [38]. Penetratin was included as it 
is known to form non-covalent complexes with cargoes [45] and does not induce 
the imipramine-sensitive rapid cytoplasmic uptake [10]. R9 and r9 did not show 
any increase in uptake upon co-incubation with POG-488 (Figure 6.2). Instead a 
slight decrease in the median fluorescence was noticed. D-Pen caused a slight 
increase in uptake upon co-incubation (Figure 6.2). Overall the data exclude an 
increased uptake as the cause of the sensitization.
6.3.3 Imipramine-sensitive uptake and ceramide generation by r9
In HeLa cells the rapid cytoplasmic uptake is restricted to peptide concentrations 
above 10 μM. Therefore, our previous analyses had not addressed ceramide 
formation at lower peptide concentrations at which endocytosis is predominant. 
For this reason, we decided to evaluate the uptake of r9 and sensitivity of uptake to 
imipramine. In addition, we addressed the capacity of the peptide to generate 
ceramide in Ovcar-3 cells also at the peptide concentration of 6 μM. HeLa cells were 
used as a control cell line and 20 μM R9 and 1000 mU/mL bSMase (for generation of 
ceramide) acted as control conditions. In live-cell confocal microscopy nearly all 
Hela cells and the majority of Ovcar-3 cells incubated with 20 μM R9 exhibited 
intense cytoplasmic staining. For Ovcar-3 cells vesicles were still discernible, also 
in those cells that showed cytoplasmic fluorescence. For Fluo-r9 also an additional 
Figure 6.2   Effect of CPPs on uptake of Paclitaxel in Ovcar-3 cells. 
Ovcar-3 cells were co-incubated with 1 μM Paclitaxel Oregon Green 488 (POG-488) and 6 μM of R9 or r9 or 
D-Pen. Cellular fluorescence was quantified using flow cytometry. Error bars represent S.E.M of three 
independent experiments.
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the localization of the peptide [10]. A stronger nucleolar staining with 6 μM of 
Fluo-r9 was observed in fixed Ovcar-3 cells. Overall, these results provide strong 
evidence for a chirality- and fluorophore-independent activation of ASMase and 
generation of ceramide, also at low concentrations of nona-arginine.
6.3.4  Downregulation of ASMase reverses the sensitizing effect 
exerted by r9
Given the evidence that r9 does not enhance Paclitaxel uptake and induces the 
generation of ceramide in an imipramine-sensitive way, we next intended to probe 
directly for the role of ASMase in the sensitization effect using siRNA-mediated 
silencing of ASMase expression (si-SMPD) (Figure 6.4A). Treatment of cells with 
imipramine served as a positive control (Figure 6.4A). A non-targeting si-RNA pool 
(si-NT) was used as a negative control. si-SMPD was found to be as efficient as 
imipramine in reducing ASMase expression. We used the CPP PepFect6 for 
transfection of cells. This agent shows activity also for difficult-to-transfect cells 
[35]. The CPP is derived from the amphipathic CPP TP10 which does not induce 
rapid cytoplasmic uptake [46]. After ASMase silencing, cells were treated with 
increasing concentrations of Paclitaxel with or without 6 μM r9 and cell viability 
was measured using the resazurin assay. si-NT-treated cells (Figure 6.4C) showed a 
similar activity enhancement as untreated cells (Figure 6.4B). However, in si-
SMPD-treated cells the sensitizing effect was completely absent (Figure 6.4D). Cell 
survival even increased in spite of the presence of r9 (Figure 6.4E). In order to 
validate peptide uptake, confocal microscopy experiments were performed. For 
si-SMPD-treated cells only membrane staining of Fluo-r9 was observed (Figure 
6.4F), a distribution of fluorescence similar to the one of imipramine-treated cells 
(Figure 6.3A and 6.4F). Cytoplasmic fluorescence was completely absent. 
si-NT-treated cells showed endocytic and nucleolar fluorescence like the untreated 
cells and imipramine treatment reduced nucleolar fluorescence (Figure 6.4F). Flow 
cytometry with the same batch of cells also confirmed the reduction of peptide 
uptake in si-SMPD-treated cells compared to si-NT or untreated cells (Figure 6.4G).
 In order to exclude that the effect of silencing of ASMase expression was 
restricted to Ovcar-3 cells, the same experiment was repeated for HeLa cells. Also 
in HeLa cells, r9 showed a strong sensitizing effect (Figure 6.5A) which was 
unaffected by the si-NT treatment (Figure 6.5B) but strongly reduced in ASMase 
silenced cells (Figure 6.5C and 6.5D). However, we also observed a modest reduction 
in the cellular toxicity induced by Paclitaxel in ASMase-silenced HeLa cells (Figure 
6.5C), which was absent in Ovcar-3 cells (Figure 6.4D). Microscopy showed a lower 
uptake of Fluo-r9 in si-SMPD-treated cells compared to untreated or si-NT-treated 
cells. However, no membrane staining was observed (Figure 6.5E). The flow 
cytometry histogram for si-SMPD-treated cells showed a strong leftward shift and 
Figure 6.3   Chirality-independent sensitivity to imipramine (imi) and 
generation of ceramide in HeLa and Ovcar-3 cells. 
(A) Living cells were incubated with 20 μM or 6 μM Fluo-r9 for 20 min at 37ºC with or without imipramine. 
For imipramine treatments, cells were pretreated with 30 μM imipramine in serum-free medium for 30 
min at 37ºC followed by co-incubation with the peptides in complete growth medium. Fluo-R9 ± 
imipramine was used as a control. (B) Cells were treated with 20 μM or 6 μM of Fluo-R9, Fluo-r9 and r9 for 
20 min at 37ºC or left untreated. 1000 mU/mL bSMase was used as a control for the generation of 
ceramide. Surface staining of ceramide on cells that were fixed but not permeabilized was performed 
using anti-ceramide (IgM) antibodies including isotope controls (S6, Figure S6.5) and an appropriate Al-
exa-633-conjugated secondary antibody. Cells were imaged with confocal microscopy. Scale bars 
correspond to 10 μm. 
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Figure 6.4   Reversal of the potentiating effect of r9 on Paclitaxel in ASMase 
downregulated Ovcar-3 cells. 
(A) Efficiency of ASMase silencing by si-SMPD. Ovcar-3 cells were either left untreated or were treated 
with 50 nM of non-targeted siRNA (si-NT) or ASMase-directed siRNA (si-SMPD) for 72 h. Cells were lysed 
and protein expression was visualized using Western blotting. 30 μM imipramine (imi) was added to 
untreated cells in serum-free medium and incubated for 45 min at 37°C before lysis. (B, C) Effect of r9 on 
Ovcar-3 cells that were either left untreated (B) or were treated with 50 nM of non-targeted siRNA (si-NT) 
(C) or ASMase-directed siRNA (si-SMPD) (D) for 72 h. Paclitaxel was then co-incubated with or without 6 
μM r9 for 24 h and cell viability was assessed with the resazurin assay. (E) Direct comparison of all 
conditions, normalized to untreated controls. (B-E) Results represent mean ± S.E.M from four independent 
experiments (N=12). (F, G) Effect of si-SMPD on Fluo-r9 uptake. (F) Live-cell confocal microscopy images of 
untreated, si-SMPD and si-NT Ovcar-3 cells treated with 6 μM Fluo-r9 for 20 min at 37ºC. 30 μM imipramine 
was added to untreated and si-NT cells as control. Imipramine treatment was as stated before (same 
conditions as the microscopy experiments of Figure 6.3A). Scale bars correspond to 10 μm. (G) Flow 
cytometry after incubation of cells with of 6 μM Fluo-r9 (with or without imipramine) for 20 min.
Figure 6.5   Reversal of the potentiating effect of r9 on Paclitaxel in ASMase 
downregulated HeLa cells. 
HeLa cells were either left untreated or were treated with 50 nM of si-NT or si-SMPD for 72 h. Paclitaxel 
was then co-incubated with or without 6 μM r9 for 24 h and cell viability was assessed with the resazurin 
assay. Effect of r9 on Paclitaxel toxicity in untreated cells (A), si-NT-treated cells (B), and si-SMPD-treated 
cells (C); (D) direct comparison of all conditions, normalized to untreated controls. The inset shows the 
efficiency of ASMase silencing by si-SMPD (Lane 1: untreated, Lane 2: 50 nM si-SMPD, Lane 3: 30 μM 
imipramine, Lane 4: 50 nM si-NT; the upper arrow indicates ASMase band at 57 kDa, the lower arrow 
indicates the internal loading control β-actin at 42 kDa). (A-D) Results represent mean ± S.E.M from three 
independent experiments (N=9). Significance was calculated using unpaired two-tailed t-test (for A, B 
and C) and one-way ANOVA (using Tukey’s Multiple Comparison test as a posthoc test, for D); * < p = 0.05. 
(E) Live-cell confocal microscopy images of untreated, si-SMPD and si-NT HeLa cells, treated with 6 μM 
Fluo-r9 for 20 min at 37ºC. 30 μM imipramine was added to untreated cells as control. Imipramine 
treatment was as stated before. Scale bars correspond to 20 μm. (F) Quantification of cellular uptake 
using flow cytometry. Flow cytometry histograms of one representative experiment are shown. (G) 
Median fluorescence values derived from histograms were normalized to the sum of the fluorescence 
and represented in percentage. Error bars represent S.E.M. for three independent experiments. 
Significance was calculated using one-way ANOVA; * < p = 0.05.
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cells were in the G0 phase, 9% in the G1/M phase and only 1% in the S phase of the 
cell cycle (S6, Figure S6.6). In quiescent IMR-90 cells, Paclitaxel was without any 
effect as observed before [47] and with r9, no sensitizing effect was observed 
(Figure 6.6A). Interestingly, also in proliferating fibroblasts, r9 exhibited no 
sensitizing effect either (Figure 6.6B). These results suggest that the sensitization 
effect is specific for proliferating cancer cells and that the normal cells are spared 
from such an effect.
6.4 Discussion
Here, we demonstrate that the interaction of arginine-rich CPPs with cells induces 
ceramide formation and that this ceramide formation can be exploited to enhance 
the activity of a chemotherapeutic cancer drug. In contrast to CPP-based strategies 
so far, this increase in activity was not mediated by an enhancement of uptake. 
Both, CPP and chemotherapeutic were added as independent molecular entities 
eliminating problems in the synthesis and functional characterization of 
peptide-drug conjugates. Furthermore, sequestration in the endolysosomal 
compartment that may occur for CPP-conjugates will not be a concern [48]. 
 Interestingly, this potentiating activity was observed at a peptide concentration 
at which uptake occurs mostly by endocytosis and only few cells showed an 
 imipramine-sensitive cytoplasmic and nucleolar staining. However, as shown by 
immunofluorescence, also at this concentration ceramide-rich domains were 
formed at the plasma membrane. Our previous analyses had shown that rapid 
cytoplasmic uptake could be induced also at lower peptide concentrations through 
addition of bacterial sphingomyelinase, indicating that not the peptide 
concentration but formation of ceramide was a limiting factor in the induction of 
rapid uptake [10]. The ceramide-rich domains detected by immunofluorescence 
may therefore be insufficient to promote direct cytoplasmic entry but nevertheless 
sufficient to enhance cytotoxicity. In agreement with this concept, the sensitizing 
effect was a function of the capacity of the CPP to activate ASMase-dependent 
uptake. D-hLF had a reduced sensitizing activity and for D-Pen no sensitizing 
activity was observed. 
 Abolition of the sensitizing effect upon siRNA-mediated downregulation of 
ASMase provided conclusive evidence for the involvement of ceramide formation 
in this activity. ASMase inhibition by treatment with imipramine was not an 
option as impramine in combination with peptide caused significant cell toxicity 
over the 24 h time course of the experiment.
 Due to the capacity of arginine-rich CPP to induce endocytosis an increase in 
cellular Paclitaxel uptake could have contributed to this activity. However, using a 
overlapped completely with the one of imipramine-treated, and the one of 
si-NT+imipramine-treated cells. For si-SMPD-treated cells uptake was 56% lower 
than the one for untreated cells. These results confirm that downregulation of 
ASMase reduces the peptide translocation into cells and reverses the sensitizing 
effect due to lack of ceramide generation. 
6.3.5 Sensitization is absent in proliferating and quiescent fibroblasts
A prerequisite for the potential utilization of the toxicity-enhancing effect in the 
treatment of cancers is the absence of this effect in proliferating and quiescent 
non-transformed cells. In order to investigate whether the sensitizing effect is 
restricted to proliferating cancer cells, we co-incubated r9 and Paclitaxel in normal 
proliferating or quiescent IMR-90 fibroblasts. Quiescence was induced by contact 
inhibition followed by low serum incubations. DNA image cytometry measurements 
to quantify quiescence, confirmed that following this treatment around 90% of 
Figure 6.6   Lack of sensitizing activity in quiescent and proliferating IMR-90 
fibroblasts.
(A) Quiescent or (B) proliferating IMR-90 fibroblasts were treated with Paclitaxel ± 6 μM r9 for 24 h. Cell 
viability was evaluated using the resazurin assay. Results represent mean ± S.E.M. from three independent 
experiments (N=9).
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separate chemical entities overcomes major regulatory hurdles in clinical 
development. In all in vivo testing reported so far, arginine-rich CPP showed little 
toxicity [56-58]. Especially, for ovarian cancer patients, it would be possible to 
inject the peptide directly into the abdominal cavity while a combination of 
chemotherapy is administered. 
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S6 Supporting Information
S6.1 Determination of concentrations of unlabeled peptides
Unlabeled N-terminally acetylated and C-terminally amidated peptides were 
purchased from EMC microcollections (Tübingen, Germany). Purity was evaluated 
by high-performance liquid chromatography (HPLC) and identity confirmed by 
mass spectrometry. Concentrations were determined by peak integration using 
1H-NMR. A stock solution (1 mL) of peptide (~1 mM) in ultrapure water was 
flash-frozen in liquid nitrogen and lyophilized to dryness. It was then redissolved 
in an equal volume of D2O (99.9% D) and analyzed by 1H-NMR. The peak locations 
in the resulting spectrum were used to help select a spectrally non-overlapping, 
volatile and water-miscible solvent that would produce only a single peak in 
subsequent 1H-NMR. Methanol (CH3OH) fulfills all these requirements: its hydroxyl 
group exchanges with D2O, leaving only the singlet from its methyl group visible 
at ∂ = 3.34 [S1]. A known quantity of methanol (1.5 μL) was added to the sample, and 
it was measured again by 1H-NMR. Afterwards, all samples were flash-frozen in 
liquid nitrogen and lyophilized once more, after which they were redissolved in 
an equal volume of ultrapure water to recreate the original samples.
 Using this approach, the integrated CH3OH signal could be correlated to a 
physical quantity of methanol, allowing the same calculation for all other signals 
present. We used the aliphatic part of the arginine side chains (36H from 9 x Arg 
(4H)) in nona-arginine, and the aromatic protons in penetratin (15H from 2 x Trp 
(5H) and 1x Phe (5H)) to determine their concentration. The following calculation 
was used to obtain a signal-to-μmol ratio:
Methanol density 0.7918 g mL-1
Methanol Fg 32.04 g mol-1
#H per molecule 3
Amount per sample 1.5 μL
Methanol per mL 0.0247 mol (density / Fg)
Methanol per sample 37.07 μmol (above x amount x 1000)
Example signal 94.90 (represents 3H, see figure 1)
Signal per sample 31.63 (signal / #H)
Signal per μmol 0.85 μmol-1 (above/methanol per sample)
 Heavy water (D2O, 99.9%) was purchased from Aldrich and methanol (technical 
grade) was purchased from Baker (VWR International, Amsterdam, The 
Netherlands); both were used as received. Ultrapure water was purified using a 
WaterPro PS polisher (Labconco, Kansas City, MO) set to 18.2 MΩ cm-1. 1H-NMR 
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spectra were recorded on a Varian inova400 instrument at room temperature. 1H 
NMR spectra are reported in ppm (∂) relative to tetramethylsilane (∂= 0.00) and 
measured in D2O.
S6.2 Titration of r9 in Ovcar-3 cells
We aimed to potentiate Paclitaxel toxicity at peptide concentrations that by themselves 
did not cause any toxicity. For this reason, we determined the concentration- 
dependence of the toxicity of the proteolytically stable D-enantiomer of R9, r9.
 Ovcar-3 cells (9 x 103 cells/well) were seeded in 96-well microtiter plates and 
grown overnight. The next day, cells were treated with increasing peptide 
concentrations for 24 h at 37ºC. Cell viability was measured using the resazurin 
assay.
S6.3 Imipramine sensitivity of D-hLF and D-Penetratin uptake
Our previous findings indicated imipramine-sensitive activation of ASMase by 
arginine-rich CPPs at high concentrations of the L-enantiomer (R9/hLF). In 
contrast, penetratin only exhibits endocytosis. Here, we decided to evaluate the 
uptake and sensitivity of the D-peptides to imipramine at low concentrations in 
Ovcar-3 cells using live-cell confocal microscopy [S2]. 
 Ovcar-3 cells (8 x 104/well) were seeded in 8-well microscopy chambers (Nalge 
Nunc International, New York, USA), 24 h prior to peptide addition. Cells were 
incubated with the indicated concentrations of the fluorescently labeled peptides 
in RPMI supplemented with 20% FCS for 20 min. For assessing the effect of 
imipramine on peptide uptake, cells were pre-incubated for 45 min with 30 μM 
imipramine (Sigma-Aldrich, Zwijndrecht, The Netherlands) in RPMI 1640 without 
serum. For the subsequent incubation with peptide, 30 μM imipramine was 
co-incubated with peptide in FCS-supplemented tissue culture medium. Cells were 
washed twice after the incubation and were analyzed immediately by confocal 
microscopy. Confocal laser scanning microscopy was performed on a TCS SP5 
confocal microscope (Leica Microsystems, Mannheim, Germany) equipped with 
an HCX PL APO 63x 1.2 N.A. water immersion lens. Cells were maintained at 37°C 
on a temperature-controlled microscope stage. Fluorescence was excited using the 
488 nm line of an argon-ion laser and detected at 500-550 nm. For all microscopy 
images, one confocal slice is shown.
Figure S6.1   Representative 1H-NMR spectra for r9 with or without methanol 
added. 
(A) Spectrum without methanol (1 mM peptide) and (B) Spectrum containing 37.07 mM methanol. The 
chemical shifts are assigned as indicated.
Figure S6.2   Concentration-dependent cytotoxicity of r9. 
Ovcar-3 cells were treated with increasing concentrations of r9 for 24 h. Cell viability was evaluated 
using the resazurin assay. Results represent mean ± S.E.M. from three independent experiments (N=9).
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S6.4 Ceramide generation by unlabeled R9
We had shown previously the formation of ceramide platforms in HeLa cells using 
the carboxyfluorescein-labeled L-enantiomer of nona-arginine (Fluo-R9) at 20 μM. 
To probe for a potential fluorophore dependence of this phenomenon, we assessed 
ceramide formation for the unlabeled counterpart (R9). 
 Ovcar-3 cells (8 x 104/well) were seeded in 8-well microscopy chambers (iBidi, 
Martinsried, Germany) and grown overnight. Cells were treated with 20 μM and 6 
μM R9 for 20 min in RPMI 1640 supplemented with 10% FCS. Cells were stained for 
ceramide without membrane permeabilization as stated previously [S2]. 
S6.5  Isotype controls show no staining of ceramide in HeLa and 
Ovcar-3 cells
To further validate the specificity of the anti-ceramide immunofluorescence, 
isotype controls were also performed for cells treated with peptide or bacterial 
sphingomyelinase. In this way it should be excluded that antibodies nonspecifical-
ly bind to the plasma membrane as a consequence of peptide association or 
ceramide formation. Cells were treated with 20 μM of r9 or Fluo-R9 and 1000 mU/
mL sphingomyelinase from Bacillus	cereus (bSMase; specific activity ≥ 100 units/mg 
protein (Lowry), Sigma-Aldrich, St. Louis, Missouri, U.S.A) for 20 min. Both for 
Ovcar-3 and HeLa cells, RPMI 1640 supplemented with 10% FCS was used for the 
incubation of the peptides or bSMase. HeLa cells were used as a control cell line, 
while 20 μM Fluo-R9 and 1000 mU/mL bSMase acted as control conditions. Cells 
were stained for ceramide without membrane permeabilization as stated 
previously [S2]. Briefly, surface staining of ceramide was performed using 
monoclonal mouse anti-ceramide IgM antibody 15B4 (Alexis Biochemicals, Lausen, 
Switzerland; 1:50 dilution) including the isotope (Ab allotype, anti KLH mouse IgM 
antibody; BD Pharmingen, San Diego, U.S.A.) control. For detection of ceramide 
and isotype control, an Alexa-633-conjugated goat-anti mouse IgG (H + L) antibody 
(Invitrogen, 1:100 dilution) was used.
Figure S6.3   Fluo-D-hLF exhibits imipramine sensitive uptake while Fluo-D-Pen 
does not. 
Cells were incubated with 20 μM or 6 μM Fluo-D-hLF/Fluo-D-Pen for 20 min at 37ºC with or without 
imipramine. For imipramine treatments, cells were pretreated with 30 μM imipramine in serum-free 
medium for 30 min at 37ºC followed by co-incubation with the peptides in complete growth medium. 
Scale bars correspond to 10 μm.
Figure S6.4   Generation of ceramide platforms in Ovcar-3 cells by R9. 
Cells were treated with 20 μM or 6 μM of R9 for 20 min at 37ºC. Surface staining of ceramide was 
performed using anti-ceramide (IgM) antibodies including isotope controls and an Alexa-633-conjugated 
secondary antibody. Images show one confocal slice. Scale bars correspond to 10 μm.
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S6.6  Detection of quiescence of IMR-90 fibroblasts by DNA image 
cytometry
To induce quiescence in fibroblasts, a modified protocol of Lu et	al.	[S3] was used. 
Briefly, 1 x 104 IMR-90 fibroblasts were seeded in MEM supplemented with 10% FCS 
in a 96-well microtiter plate and grown to confluence for 4 days. On the 5th day, 
cells were washed with serum-free MEM and were cultured 3 additional days in 
MEM supplemented with 0.1% FCS. For analysis of quiescence, cells were 
trypsinized, washed in PBS using a centrifugation step, fixed with 4% formalin 
and kept overnight at 4ºC. Next, cells were resuspended in PBS and counted using 
a Coulter counter (Beckman Coulter, Woerden, The Netherlands). A cytospin (cells 
in suspension centrifuged on a glass slide) was prepared using 4 x 104 cells. Cells 
were then fixed in Böhm fixative (4% formaldehyde, 5% acetic acid in absolute 
methanol) for 1 h at room temperature followed by rinsing twice in ethanol, 
air-drying and incubation at 25ºC for 1 h in 5 M HCl (Merck, Darmstadt, Germany). 
After a washing step in Aqua Dest cell nuclei were stained with Feulgen’s stain and 
periodic acid Schiff (Merck, Darmstadt, Germany) for 1 h, rinsed in tap water for 
20 min, incubated in increasing concentrations (70%, 96%, 100%) of ethanol and in 
xylol. Cells were finally mounted in permount and analyzed using a cytometric 
image analysis system (QPATH; Leica Imaging Systems, Cambridge, UK), which 
consists of an automated microscope with a digital camera connected to a 
computer that runs the DNA analysis software. At least 5000 cell nuclei were 
screened and a minimum of 2000 images of cell nuclei displaying integrated 
optical density (IOD) values between 15 to 25 were selected manually excluding 
debris, necrotic cells, cut cells and cell clusters [S4]. A histogram was generated 
based on the IOD values showing the percentages of cells in 2C (diploid peak, G0/
G1), 4C (tetraploid peak, G2/M) and 8C (abnormality in DNA ploidy). A difference 
between 2C and 4C represented the S phase of the cell cycle. As a quality check for 
the histogram, a coefficient of variation less than 5% was considered acceptable. 
Figure S6.5   Specificity of anti-ceramide antibody using isotype control. 
Cells were treated with 20 μM of r9 or Fluo-R9 for 20 min at 37ºC. 1000 mU/mL bSMase was used as a 
control for generation of ceramide. Surface staining of ceramide was performed using anti-ceramide 
(IgM) antibodies including isotope controls and an Alexa-633-conjugated secondary antibody. Images 
show one confocal slice. Scale bars correspond to 10 μm.
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Figure S6.6   Quiescence in IMR-90 fibroblasts measured with DNA image 
cytometry. 
(A) A representative DNA ploidy histogram indicating the number of cell nuclei in diploid (2C) or 
tetraploid (4C) state. The x-axis corresponds to the integrated optical density (IOD) of the cell nuclei while 
the y-axis refers to the number of nuclei in the specific population. (B) Percentage of cells in different cell 
cycle phases as derived from (A).
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7.1. Summary
With the advent of genomic sequencing and ‘omics’ tools, the ‘druggable genome’ 
[1] has undergone an expansion [2]. Nevertheless, the fact also remains that many 
of the potential new targets relate to proteins involved in protein-protein 
interactions that are difficult to address specifically with high nanomolar affinities 
using synthetic molecules [3]. Thus, the focus of the pharmaceutical industry has 
remained primarily on the development of small molecules addressing the same 
targets as before with a consequence of still confining the pharmaceutical genome. 
In spite of considerable efforts to expand the target space, also in cancer, the 
golden standards for therapy are still the conventional therapy regimes of 
chemotherapy, surgery and radiation. As a consequence, undesired toxicity, 
resistance and recurrence have not been resolved yet. Hence, there is still a need 
for innovative therapies to specifically target cancer cells with low systemic 
toxicity and few side effects.
 Especially in cancer, peptides can offer an advantage over small molecule 
drugs by being non-toxic and active in chemotherapy-resistant cancers. Synthetic 
accessibility and the freedom to combine them with other therapeutics as in 
peptide-drug conjugates have triggered promising research in peptide-based 
therapies for cancer. Use of computer-based algorithms to design peptides or 
mimics has also aided in the identification of peptidic starting structures for 
further drug design to address protein-protein interaction interfaces critical to 
cancer [4]. However, though there are numerous peptide drugs available in the 
market, the main challenges of stability and bioavailability limit their intracellular 
applications. Nevertheless, several chemical strategies to improve both, the phar-
macokinetic and the pharmacodynamics properties of peptide drugs are currently 
under investigation, also in clinical trials, to resolve the fundamental problems 
associated with peptide drugs.
 This thesis particularly aimed to contribute to the above-mentioned area of 
peptide drug development by addressing new strategies to use peptides as 
anticancer drugs. Specifically, the thesis explored chemical modifications as new 
avenues to enhance the activity of known bioactive peptides and investigated a 
new bioactive principle of arginine-rich CPPs to enhance the cytotoxicity of a che-
motherapeutic drug. 
7.1.1.  Stabilization by polymeric scaffolds enhances activity of 
bioactive peptides
Chapters 2, 3 and 4 deal with functionalization of polymeric scaffolds with 
bioactive peptides. While in chapter 2 and 3 the peptides are coupled to linear 
polymers, chapter 4 presents the effects of site-specific coupling to a branched 
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concentration as the monovalent CPP but exhibited higher toxicity. In erythrocytes, 
this conjugate caused aggregation, flipping of membrane lipids as evidenced by 
exposure of phosphatidylserine and lysis which were absent for the monovalent 
CPP. This study indicated that an increase in the number of peptides on a flexible 
linear scaffold can qualitatively change the properties of a CPP and also influence 
the cellular response towards the CPP. 
7.1.4.  Ceramide-inducing arginine-rich CPPs enhance the activity of 
a chemotherapeutic drug specifically in cancer cells
Chapter 6 presents the application of a novel bioactive principle of arginine-rich 
CPPs to increase the activity of an anticancer drug. The capacity of these CPPs to 
activate acid sphingomyelinase and generate the proapoptotic lipid ceramide led 
to the hypothesis that this activity could be utilized to enhance drug activity in 
cancer cells. Since no dependence on chirality had been observed for induction of 
ceramide formation, both, the L- and D-isomers of nona-arginine were utilized to 
test this principle. The proteolytically stable D-nona-arginine showed the strongest 
effect in enhancing the cytotoxicity of Paclitaxel. However, the sensitizing effect 
was not due to induction of enhanced cellular uptake of the drug by the CPP. 
Moreover, the abolition of the enhancement by siRNA-mediated downregulation 
of acid sphingomyelinase indicated the specificity of this pathway in triggering 
the effect. The lack of the sensitization in proliferating and quiescent fibroblast 
indicated that this effect is specific to cancer cells. A biological function of a CPP 
was thus translated into an application that represents a promising approach for 
peptide therapeutics.
7.2. Outlook
Peptides hold great promise as novel therapeutics for cancer. The last 2 years have 
seen the approval of a significant number of peptide drugs by the Food and Drug 
Administration, however, retractions have also been reported [5]. Also, in peptide 
drug development safety and side effects are major concerns. Allergic or 
anaphylactic responses can be life-threatening risks and such reactions in human 
after administration of the peptide can evoke an immediate recall of the drug. 
 The clinical pipeline in CPP-based peptide drug development is limited. Until 
today no CPP-based peptide drug has been approved in oncology. However, some 
are being tested in clinical trials. Previously, some studies have reported on the 
application of CPPs in enhancing antitumor immunity by intracellular delivery of 
peptide vaccines in dendritic cells [6]. Intracellular delivery of antigenic peptides 
(for example TRP2 peptide) to dendritic cells by CPPs (for example TAT) allowed a 
polymer. For each of the individual polymers different chemical coupling strategies 
were applied. Coupling to a polymeric scaffold increased the half-life of the peptide 
as is described in chapter 2 for HPMA and chapter 3 for dextran. With the peptide 
coupled to a branched PEG, in chapter 4, an increase in half-life was observed that 
depended on the chain length of the polymer. In all cases, only the polymer-cou-
pled peptide showed apoptosis-inducing activity but not the free peptide. This 
indicated that stabilization of the peptide achieved by coupling to a polymeric 
scaffold is the underlying mechanism that enhanced the bioactivity of the peptide. 
7.1.2.  Modular design to cofunctionalize a polymeric scaffold  
with a bioactive peptide and a CPP maintains the intracellular 
activity of the bioactive peptide
Both in chapters 2 and 3, the polymer-peptide conjugates were cofunctionalized 
with a CPP in a modular design and their intracellular activity were investigated 
after CPP-mediated uptake. Both HPMA- and dextran-coupled multivalent 
conjugates efficiently entered cells and displayed high apoptotic activity (measured 
by caspase-3 activation) similar to the electroporated conjugates lacking the 
cell-penetrating moiety. Moreover, the activity was specific for the polymer-pep-
tide-CPP conjugates since the free peptide-CPP conjugates or the mutant 
counterparts did not exhibit any significant activity. Thus, the enhanced bioactivity 
conferred by stabilization was specific and was independent of the mode of import. 
Most importantly, the modular design retained the bioactivity of the peptide 
indicating that such a design can be implemented also for other peptides to 
enhance both stability and activity.
7.1.3.  Multivalent presentation on a linear scaffold increases the 
bioactivity of the peptides and CPPs
Chapters 3 and 5 describe the multivalent presentation of peptides on a linear 
dextran scaffold. In chapter 3, a bioactive peptide was presented in different copy 
numbers and tested for apoptosis induction in comparison to the free monovalent 
counterpart. The increase in apoptosis induction as measured with caspase-3 
activation was found to be dependent on the number of peptides being displayed. 
With the increase in peptide number there was an increase in caspase-3 activation. 
In chapter 5, the cationic CPP nona-arginine was presented in a multivalent 
fashion on a linear dextran backbone and compared to the free peptide. The study 
aimed at understanding the interaction of CPPs with the plasma membrane when 
presented in a multivalent arrangement on a linear scaffold. Interestingly, the 
data suggested that the increased uptake and membrane perturbation was mainly 
based on interactions with lipids rather than proteoglycans. The multivalent CPP 
conjugate exhibited acid sphingomyelinase dependent uptake at the same 
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address tissue-specific targeting and controlled release of the bioactive entity from 
the conjugate. In this context, tumor-homing peptides [24] (http://www.arrow-
headresearch.com/technology/homing-peptides) and cleavable linkers are 
receiving considerable attention. However, the applicability of the latter strategy 
in peptide therapeutics still might be limited by the release kinetics offered by the 
linkers in vivo. Hence, the success of such modern approaches ultimately depends 
on the results of in vivo animal testing and clinical trials. 
7.3. Conclusions
Peptide therapeutics is a fast growing area in drug development. Owing to the ease 
with which combinatorial peptide libraries can be produced and screened, low 
immunogenicity compared to larger proteins, the potential for delivery by 
less-invasive methods than intravenous injection [25, 26] and the ease of chemical 
manipulations, it is realistic to assume that peptides will play an important role in 
the next generation of anticancer therapies. 
 This thesis hopes to have contributed a minor portion in the field by giving 
insights into the potential of polymer conjugates for intracellular applications and 
the exploration of a new biological property of CPPs for the development of a new 
therapeutic approach. Additionally, it aimed to provide further fundamental 
understanding of the underlying mechanisms of the activity of peptide-polymer 
conjugates and multivalent CPPs.
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continuous and prolonged presentation of the peptides to antigen-specific T-cells 
over an extended period of time [7, 8]. Based on this principle, a phase I clinical 
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Twee klassen van therapeutica overheersen de huidige farmaceutische markt, te 
weten ‘small molecules’ en ‘biologics’ zoals eiwitten. De zogenaamde ‘small 
molecules’ hebben een gemiddeld molecuulgewicht van minder dan 500 Da, 
terwijl eiwitten molecuulgewichten van meer dan 10,000 Da hebben. Er bestaat 
dus ruimte voor het ontwikkelen van therapeutica in het gebied tussen de 500 en 
10,000 Da.
 Peptiden vormen een klasse van bioactieve moleculen die steeds meer 
aandacht krijgt. Deze peptiden bestaan uit 2 tot 100 aminozuren en variëren in 
molecuulgewicht tussen 220 Da en 12,000 Da. Door hun grootte en chemische 
kenmerken is het betrekkelijk eenvoudig zeer verschillende peptiden te produceren 
om zo tot een snelle optimalisatie van biologische activiteit te komen. Vooral in 
geval van kanker is het gebruik van peptiden voordelig ten opzichte van ‘small 
molecules’, aangezien peptiden niet toxisch zijn en activiteit vertonen in kankers 
die resistent zijn voor chemotherapie. De mogelijkheden tot synthese en combinatie 
met andere therapeutica (zoals peptide-medicijn conjugaten) hebben geleid tot 
veelbelovend onderzoek naar kankertherapieën gebaseerd op peptiden. Het 
gebruik van computer algoritmes bij het ontwerpen van peptiden of peptidomi-
metics heeft ook geholpen bij de identificatie van basis structuren en de verdere 
ontwikkeling van peptiden ten behoeve van beïnvloeding van eiwit-eiwit 
interacties. Echter, ook al zijn er verschillende peptide medicijnen op de markt, 
issues betreffende stabiliteit en biobeschikbaarheid limiteren momenteel hun 
toepassing binnen cellen. De meeste peptide medicijnen worden tot op heden 
geproduceerd ter injectie. Peptide medicijnen geschikt voor orale inname worden 
nog onderzocht. Peptiden laten een snelle klaring zien en zijn gevoelig voor 
afbraak door proteases. Beide feiten leiden tot een korte levensduur in plasma. De 
meeste peptiden zijn niet membraan-permeabel en kunnen dus alleen op extracel-
lulaire targets aangrijpen. Desalniettemin worden verschillende chemische 
strategieën om farmacokinetische en –dynamische kenmerken van peptide 
medicijnen te verbeteren onderzocht, waarvan enkele in klinische trials. Deze 
chemische strategieën bestaan o.a. uit het inbouwen van onnatuurlijke of 
D-aminozuren, peptide conformatie fixatie, cyclisatie en chemische koppeling 
aan polymeren met een groot molecuulgewicht. Een toename in cellulaire opname 
wordt bereikt door conjugatie van cel-penetrerende peptiden (CPP) en het 
aanbieden van peptiden in liposomale of nanosomale bereidingen moet leiden tot 
een verbetering in distributie en gecontroleerde afgifte in levende organismen.
 Dit proefschrift heeft als doel een bijdrage te leveren aan het verbeteren van 
de potentie van peptiden als anti-kanker medicijnen door (i) het verhogen van de 
activiteit van bekende bioactieve peptiden door chemische modificatie en (ii) het 
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inductie in vergelijking met het monovalente peptide. De toename in apoptose 
bleek afhankelijk van het aantal peptiden gekoppeld aan een polymeer, waarbij 
een toename in peptide aantal leidde tot een toename in caspase-3 activatie.
 Om te komen tot een beter begrip van de functionele impact van de koppeling 
van CPP aan flexibele polymeren zijn de cellulaire import en toxiciteit van een 
dextran polymeer met daaraan gekoppeld R9 peptiden onderzocht in Hoofdstuk 
5. Deze studie had als doel te begrijpen hoe CPP een interactie aangaan met het 
plasma membraan indien ze multivalent gepresenteerd worden aan een lineaire 
scaffold. De gegenereerde data suggereren dat de waargenomen toename in 
opname en membraan verstoring veroorzaakt wordt door interacties met lipiden 
en niet zozeer met proteoglycanen. Het multivalente CPP conjugaat vertoonde acid 
sphingomyelinase-afhankelijke opname bij dezelfde concentratie als de monovalente 
CPP, maar veroorzaakte wel een hogere toxiciteit. In rode bloedcellen leidde dit 
conjugaat tot aggregatie, het verschijnen van phosphatidylserine aan de buitenkant 
van de cel en lysis, hetgeen niet werd waargenomen voor de monovalente CPP. 
Deze studie heeft aangetoond dat een toename in het aantal peptiden aan een 
flexibele lineaire scaffold kan leiden tot kwalitatieve verschillen in het gedrag van 
de CPP en de respons van de cel daarop.
 Tot slot is de potentie van arginine-rijke CPP om ceramide formatie te induceren 
gebruikt om de activiteit van cytostatica te verhogen in Hoofdstuk 6. De capaciteit 
van deze CPP om acid sphingomyelinase te activeren en aldus het proapoptotische 
lipide ceramide te produceren heeft geleid tot de hypothese dat deze activiteit kan 
worden gebruikt om de activiteit van de huidige therapeutica in kankercellen te 
verbeteren. Aangezien de inductie van ceramide formatie niet afhankelijk is van 
chiraliteit zijn zowel L- als D-aminozuren gebruikt om de hypothese te testen. De 
proteolytisch stabiele D-vorm van R9 vertoonde het sterkste effect wat betreft het 
verhogen van de cytotoxiciteit van Paclitaxel. Dit effect was niet het gevolg van een 
toename in cellulaire opname van Paclitaxel door de CPP, maar van acid sphingo-
myelinase activiteit, aangezien het verlagen van de expressie van dit enzym leidde 
tot een gebrek aan verhoogde cytotoxiciteit. Delende fibroblasten en fibroblasten 
in rust vertoonden geen verhoging in cytotoxiciteit, hetgeen aangeeft dat het 
effect specifiek is voor kankercellen. Aldus is een biologische functie van een CPP 
omgezet in een veelbelovende toepassing voor peptide therapeutica.
 Dit proefschrift sluit af met Hoofdstuk 7 waarin conclusies van alle hoofdstukken 
(Hoofdstukken 2 t/m 6) worden samengevat en een vooruitblik wordt gepresenteerd 
betreffende toepassingen gebaseerd op polymeren en CPP.
 Peptide therapeutica vormen een groeiend gebied in medicijn ontwikkeling. 
Bibliotheken met peptiden kunnen betrekkelijk eenvoudig worden geproduceerd 
en gescreend, peptiden veroorzaken een minder heftige immuunrespons in vergelijking 
met grotere eiwitten, ze kunnen gemakkelijk chemisch worden gemanipuleerd en 
uitbuiten van een nieuw bioactief principe van arginine-rijke CPP. Om dit doel 
te bereiken is een apoptose-inducerend peptide geselecteerd en gekoppeld aan 
verschillende polymeren zoals HPMA, dextran en PEG om zodoende de proteolytische 
stabiliteit te verbeteren. Tevens is het peptide, om de cellulaire opname te 
stimuleren, geconjugeerd aan de CPP nona-arginine (R9) (Hoofdstuk 2 en 4).
 Hoofdstuk 2 laat zien dat co-functionalisatie van een HPMA polymeer met R9 
en een apoptose-inducerend Bid-BH3 peptide de apoptose inducerende activiteit 
significant verbeterd. In Hoofdstuk 3 is deze studie uitgebreid met een onderzoek 
naar de effectiviteit in de inductie van apoptose door het multivalent aanbieden 
van het Bid-BH3 peptide. Deze toepassing betrof een modulair ontwerp van HPMA 
en dextran-peptide-CPP conjugaten en multivalentie. In Hoofdstuk 4, is de impact 
getest van phosphoramidate-gekoppelde oligo- en polyethyleen glycol modificaties 
op de proteolytische stabiliteit van het BH3-peptide in cel-lysaten en op de intracel-
lulaire activiteit van dit peptide. In tegenstelling tot Hoofdstuk 2 en 3 waarin de 
beschreven peptiden gekoppeld zijn aan lineaire polymeren worden in Hoofdstuk 
4 de effecten beschreven van koppeling aan vertakte polymeren. Voor elk van de 
polymeren werden verschillende chemische koppeling strategieën gebruikt. 
Koppeling aan een polymeer leidde tot een toename in halfwaardetijd van het 
peptide zoals beschreven in Hoofdstuk 2 voor HPMA en Hoofdstuk 3 voor dextran. 
Koppeling aan een vertakte PEG, in Hoofdstuk 4, leidde tot een toename in 
halfwaardetijd die afhankelijk was van de ketenlengte van het polymeer. In alle 
gevallen leidde slechts het peptide dat gekoppeld was aan een polymeer tot 
inductie van apoptose, niet het vrije peptide. Dit gaf aan dat stabilisatie van het 
peptide, bewerkstelligd door koppeling aan een polymeer, het mechanisme is dat 
ten grondslag ligt aan de verbeterde bioactiviteit van het peptide.
 In Hoofdstuk 2 en 3 werden de polymeer-peptide conjugaten tevens gefunc-
tionaliseerd met een CPP (R9) in een modulair ontwerp. Hun intracellulaire 
activiteit werd onderzocht na CPP-gemedieerde opname. Zowel HPMA- als dex-
tran-gekoppelde multivalente conjugaten werden effectief opgenomen in cellen 
en lieten een hoge apoptose activiteit zien (middels het bepalen van caspase-3 
activiteit). Deze activiteit was vergelijkbaar met de activiteit van conjugaten zonder 
CPP die in de cel waren gebracht middels electroporatie. Bovendien was de 
activiteit specifiek voor de polymeer-peptide-CPP conjugaten, aangezien 
peptide-CPP conjugaten noch gemuteerde versies significante activiteit lieten zien 
t.o.v. het modulaire conjugaat. De toename in bioactiviteit werd dus veroorzaakt 
door de stabilisatie en was onafhankelijk van de wijze van import. Belangrijk is 
dat het modulaire ontwerp de activiteit van het peptide niet in de weg stond. Dit 
geeft aan dat een dergelijk ontwerp ook voor andere peptiden gebruikt kan worden 
om stabiliteit en activiteit te verbeteren. In Hoofdstuk 3 is ook onderzocht welk 
effect het multivalent aanbieden van het Bid-BH3 peptide heeft op apoptose 
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ze kunnen op de juiste plaats in het lichaam gebracht worden met methoden die 
minder invasief zijn dan intraveneuze injectie. Aldus lijkt er een belangrijke rol 
weggelegd voor peptiden in de nieuwste generatie anti-kanker therapieën. Dit 
proefschrift hoopt een kleine bijdrage geleverd te hebben aan het veld door het 
geven van inzicht in de potentie van polymeer conjugaten voor intracellulaire 
toepassingen en door het uitbuiten van een biologisch effect van een CPP in de 
ontwikkeling van een nieuwe therapeutische toepassing. Tevens heeft dit 
proefschrift tot doel gehad dieper fundamenteel inzicht te verwerven betreffende 
de mechanismen die ten grondslag liggen aan de activiteit van peptide-polymeer 
conjugaten en multivalente CPP.
Translated by Dr. Ir. Merel Adjobo-Hermans
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